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CELL TYPE SPECIFIC ROLES OF SEROTONIN RECEPTOR 4
IN THE HIPPOCAMPUS AND NEOCORTEX IN EMOTION AND COGNITION

Remzi Karayol, Ph.D.
The Rockefeller University 2018

Anxiety and mood disorders are the most prevalent classes of mental
disorders. However, current treatments for these debilitating diseases are limited
due to their delayed onset of action and numerous side effects, emphasizing the
need for faster acting and more efficacious therapies. Preclinical studies indicate
a critical role for Serotonin Receptor 4 (5-HT4R, product of the Htr4 gene) in this
direction as drugs that activate this receptor show fast-acting antidepressant-like
properties. Unfortunately, 5-HT4R is widely expressed in the periphery, limiting its
use as a direct therapeutic target due to various side effects. Understanding the
cell type specific mechanisms of 5-HT4R function in the brain will facilitate the
development of novel therapies.
To dissect the function of 5-HT4R in genetically defined cell types of the
hippocampus and neocortex, two regions highly implicated in emotive and
cognitive function, I generated a novel Cre-dependent Htr4 knockout mouse line.
Intriguingly, the loss of functional 5-HT4R specifically in the mature excitatory
neurons of the hippocampus led to robust antidepressant-like behavioral, cellular
and molecular responses. These phenotypes were accompanied by elevated

innate anxiety levels and deficits in hippocampus-dependent memories. By slice
electrophysiology, we showed that 5-HT4R was necessary for the proper
excitability of dentate gyrus granule cells. To identify molecular adaptations
underlying the observed changes in behavior and neuronal activity, I used the
translating ribosome affinity purification (TRAP) approach combined with nextgeneration RNA sequencing to measure hippocampal region- and cell typespecific differential gene expression in the presence and absence of 5-HT4R.
Analysis of these datasets revealed that the ventral and dorsal hippocampus
underwent distinct molecular adaptations, and identified functionally relevant
genes that may underlie these phenotypes and be potential therapeutic targets.
My graduate work identified unique roles for hippocampal 5-HT4R in
modulating mood, anxiety and memory. By regulating the excitability of individual
neurons and relevant intracellular pathways, 5-HT4R mediates functionally
distinct hippocampal circuits. Our findings suggest divergent molecular and
functional roles for 5-HT4R along the dorsoventral axis of the hippocampus, and
that specific cell type- or circuit-based strategies that target the 5-HT4R pathway
may yield more effective antidepressant therapies.

For my wife and my parents

iii

ACKNOWLEDGEMENTS

There are a number of people without whom this journey would not be
complete and as fun.
First of all, I would like to thank my thesis supervisor Dr. Nathaniel Heintz,
for his guidance and continuous support. I am really grateful to Nat for allowing
me to be a part his lab and giving me the freedom to pursue the project and
experiments I wanted. He always provided me with great insights to see the
bigger picture and ask the right scientific questions.
I would especially like to express my sincere gratitude to my thesis advisor
Dr. Eric Schmidt. He truly has been a great mentor with his everyday support,
guidance and discussions in my times of need. He personally guided me to
develop as a scientist in the making. His door was always open for my neverending questions, experimental and personal troubles. Without his patience and
knowledge, this work would not be possible. I am especially honored to be the
first PhD student to graduate under his guidance.
A special thanks to Dr. Winrich Freiwald who is the chair of my faculty
advisory committee. From the beginning of my time at Rockefeller, he has been a
genuine inspiration and motivation. His contagious passion for neuroscience and
his sincere advice for my PhD work and my personal development have been
truly invaluable and much appreciated. I would also like to thank Dr. Paul
Greengard, for being a member of my committee, providing his expertise that I
cherish deeply, and always challenging me with the right questions to guide me

iv

to become a better scientist. He also provided his resources for a collaboration
that filled an important gap in my research. I also thank Dr. Scott Russo, my
external examiner, for bringing his expertise and support and helping me to
understand my results further. In addition, I would like to thank Dr. Leslie
Vosshall for her influential support when I was an undergraduate student from
Turkey at the beginning of his scientific journey. I would also like to thank
everyone in the Dean’s Office for accommodating our every need, making us
PhD students’ lives easier, and assuring our success and comfort.
I would also like to thank my colleagues that have supported me and my
research and provided constructive criticism and feedback: Lucian Medrihan for
our collaboration and discussions, and providing his expertise in
electrophysiology; Jodi Gresack for teaching me practically everything I know
about mouse behavior; Erika Andrade, my bench neighbor, for her experimental
help and scientific discussions; Eva Holzner for technical support; Jennifer
Warner-Schmidt, for her constructive feedback; and The Rockefeller University
Transgenic Lab Services staff and Collaborative Research Center staff, for their
hard work and providing their indispensable expertise. I would also like to thank
each and every one of the Heinz Lab members, for all their help and good
company.
I would not have been able to accomplish any of these without the truly
unconditional support of my mother Zehra Karayol and my father Celalettin
Karayol. No matter how hard it was for them or me, they never failed to

v

encourage me to follow after what I wanted to do. I am very grateful to them for
providing me with the best education ever since I was a kid who wanted to
become a scientist and teaching me the values which I hold the dearest. I also
would like to thank my brother Emre and my friend Furkan, who have been with
me through every important part of my life, for their everlasting friendship and
support.
Finally, I would like to thank my wife, my other half, Nesibe, for her
boundless love and being my best friend. Her company helps me grow as a
person and as a scientist every day. As a student of neuroscience herself, she
also shared invaluable discussions with me for my research and this dissertation.
Further, her curiosity, intelligence and passion drive me to continuously learn
about life and science. I am very thankful for her irreplaceable support.

vi

TABLE OF CONTENTS
Dedication
Acknowledgements
Table of Contents
List of Figures
List of Tables

iii
iv
vii
xii
xv

CHAPTER 1. Introduction

1

1.1. Anxiety and mood disorders

2

1.1.1. Burden of the disease ..............................................................................2
1.1.2. Basic neural circuitry of emotion ..............................................................3
1.1.2.a. Hippocampus .......................................................................................... 4
1.1.2.b. Neocortex ............................................................................................... 5

1.1.3. Neurobiology and neurochemistry of emotion ..........................................6
1.1.3.a. Neurotransmitters and neuropeptides .................................................... 6
1.1.3.b. Neurotropic factors and neurogenesis .................................................... 8

1.1.4. Rodent models of anxiety and mood disorders ......................................10
1.1.4.a. Assessment of anxiety and mood related behaviors in rodents ........... 12

1.2. Serotonergic system in anxiety and mood regulation

14

1.2.2. Serotonin receptors ................................................................................16
1.2.2.a. Serotonin receptors in selective serotonin reuptake inhibitor action..... 18

1.3. Serotonin receptor 4 (5-HT4 receptor, 5-HT4R)

20

1.3.1. Molecular biology, signal transduction and central expression ..............20
1.3.2. 5-HT4 receptor in anxiety and mood regulation ......................................22
1.3.2.a. Evidence from pharmacological studies ............................................... 22
1.3.2.b. 5-HT4 receptor and p11 in antidepressant response ............................ 24

1.4. Cell type specific experimental approaches in mouse

26

1.4.1. Cre/loxP system .....................................................................................26
1.4.2. BAC Recombineering and transgenic targeting .....................................27
1.4.3. TRAP-Seq: genome-wide cell-type specific trascriptomics ....................27

1.5. Rationale

29

CHAPTER 2. The Role of 5-HT4 Receptor In Excitatory Neurons of Pallial
Origin in Anxiety and Depression
30
2.1. Introduction

31

2.2. Genetic targeting of Htr4 gene

33

2.2.1. Conditional knockout strategy: generation of Htr4-floxed mouse line ....33
2.2.2. RNAi knockdown strategy: screening for shRNA’s against Htr4. ...........37

vii

2.3. Conditional loss of 5-HT4 R from excitatory neurons of pallial origin

41

2.3.1. Emx1-Cre driver line ...............................................................................42
2.3.2. qRT-PCR confirmation of the deletion of Htr4 exon 5 ............................44
2.3.3. Confirmation of the loss of function of 5-HT4R .......................................46
2.3.4. Antibody screening against mouse 5-HT4R............................................49
2.3.5. Generation of a novel custom antibody against mouse 5-HT4R.............52

2.4. Anxiety and depression related behaviors and behavioral
antidepressant responses

56

2.4.1. Thigmotaxis and locomotor activity in the open field test .......................56
2.4.2. Elevated-plus maze test .........................................................................59
2.4.3. Novelty suppressed feeding test ............................................................62
2.4.4. Tail suspension test ................................................................................64
2.4.5. Forced swim test ....................................................................................66
2.4.6. Splash test ..............................................................................................69
2.4.7. Sucrose preference test .........................................................................71
2.4.8. Marble burying test .................................................................................73
2.4.9. Acoustic startle response and pre-pulse inhibition .................................75
2.4.10. Social Interaction ..................................................................................78
2.4.11. Summary of the behavior analysis of Emx1/Htr4 cKO mice .................80

2.5. Discussion

81

2.5.1. Generation of new tools to study 5-HT4R function in the brain...............81
2.5.2. 5-HT4R in the excitatory neurons of pallial origin mediates anxiety-like
behaviors ..........................................................................................................83
2.5.3. Pallial 5-HT4R is not necessary for behavioral responses to chronic SSRI
treatment ..........................................................................................................84
2.5.5. Caveats and future directions .................................................................86
2.5.6. Conclusion ..............................................................................................87

CHAPTER 3. Dissection of Cell Type Specific 5-HT4 Receptor Function in
the Hippocampus and Neocortex in Anxiety and Depression
89
3.1. Introduction

90

3.1.1. Hippocampus in anxiety and depression ................................................90
3.1.1.a. Hippocampal circuitry in the rodent brain ............................................. 90
3.1.1.b. The neural circuitry of anxiety and mood along the dorsoventral axis of
the hippocampus ............................................................................................... 94
3.1.1.c. Serotonergic modulation of the hippocampus....................................... 96

3.1.2. Neocortex in anxiety and depression .....................................................98
3.1.2.a. Cortical circuitry in the rodent brain ...................................................... 99
3.1.2.b. Serotonergic modulation of the neocortex .......................................... 100

viii

3.2. Cell type specific dissection of the role of 5-HT4R in the hippocampus
and neocortex in anxiety and depression related behaviors
103
3.2.1. Drd3-Cre driver line to target the hippocampus ...................................103
3.2.2. Tlx3-Cre line to target CStr p11 pyramidal cells ...................................106
3.2.3. Hippocampus specific roles of 5-HT4R in anxiety and depression related
behaviors ........................................................................................................108
3.2.3.a. Anxiety related behaviors in hippocampus specific Htr4 conditional
knockout mice .................................................................................................. 109
3.2.3.b. Depression related behaviors in hippocampus specific Htr4 conditional
knockout mice .................................................................................................. 117

3.2.4. CStr layer 5a cell specific roles of 5-HT4R in anxiety and depression..120

3.3. Spatial dissection of the role of 5-HT4R in the hippocampus and
neocortex in anxiety and depression related behaviors

128

3.3.1. The role of 5-HT4R along the dorsoventral axis of the hippocampus ...128

3.4. Discussion

132

3.4.1. Hippocampal 5-HT4R mediates anxiety and depression related behaviors
.......................................................................................................................132
3.4.2. 5-HT4R in corticostriatal circuit mediates some anxiety and depression
related behaviors ............................................................................................134
3.4.3. 5-HT4R in corticostriatal circuit may regulate hedonic effects of SSRIs
.......................................................................................................................135
3.4.4. Conclusion ............................................................................................136

CHAPTER 4. Cellular And Molecular Functions of 5-HT4 Receptor
in the Hippocampus

138

4.1. Introduction

139

4.1.1. Neuron types and the intrinsic connections of the hippocampus .........139
4.1.1.a. Granule cells of the dentate gyrus ...................................................... 140
4.1.1.b. Mossy cells of the hilus ....................................................................... 142
4.1.1.c. Interneurons of the dentate gyrus ....................................................... 143
4.1.1.d. Neurons of the CA fields ..................................................................... 144

4.1.2. Serotonergic modulation of hippocampal neurons ...............................145
4.1.3. Differential gene expression along the dorsoventral axis of the
hippocampus ..................................................................................................147

4.2. Drd3-Cre and Htr4 expression in the hippocampus

149

4.2.1. Cell type specific Drd3-Cre expression ................................................149
4.2.2. Cell type specific expression of Htr4-EGFP-L10a ................................153

4.3. Cellular and molecular adaptations in hippocampus specific Htr4
knockout mice

ix

157

4.3.1. The effect of hippocampus specific loss of 5-HT4R on neurogenesis ..157
4.3.1.a. Changes in the number of young adult born granule cells ................. 157
4.3.1.b. Changes in the expression of neurotrophic factors ............................ 160

4.3.2. Neuroadaptations in the serotonergic system in the hippocampus upon
the loss of hippocampal 5-HT4R .....................................................................162
4.3.3. The role of 5-HT4R in mediating the electrophysiological properties of
dentate gyrus granule cells ............................................................................165

4.4. Cell type specific genome-wide differential gene expression analysis
along the dorsoventral axis of the hippocampus
168
4.4.1. Differential gene expression between the dorsal and ventral dentate
gyrus of the hippocampus ..............................................................................174
4.4.2. Genome-wide molecular neuroadaptations along the dorsoventral axis of
the dentate gyrus upon the loss of 5-HT4R ....................................................177
4.4.3. Gene expression changes in mature excitatory neurons in the dentate
gyrus upon Htr4 deletion ................................................................................184

4.5. Discussion

189

4.5.1. The loss of 5-HT4R from mature excitatory neurons of the hippocampus
led to enhanced neurogenesis .......................................................................189
4.5.2. The loss of 5-HT4R from mature excitatory neurons of the hippocampus
resulted in adaptations in 5-HT receptor expression ......................................190
4.5.3. 5-HT4R was necessary to maintain proper excitability of dentate gyrus
granule cells ...................................................................................................191
4.5.4. TRAP-Seq may identify novel genes involved in 5-HT4R signaling,
anxiety and depression ..................................................................................193
4.5.5. Conclusion ............................................................................................196

CHAPTER 5. The Role of 5-HT4 Receptor in Learning and Memory

197

5.1. Introduction

198

5.1.1. Assessment of learning and memory in laboratory mice ......................198
5.1.1.a. Fear memory ...................................................................................... 199
5.1.1.b. Object memory ................................................................................... 201
5.1.1.c. Social recognition memory.................................................................. 202

5.1.2. Molecular basis of learning and memory ..............................................204
5.1.3. Serotonergic modulation of learning and memory ................................204

5.2. Hippocampus specific 5-HT4R function in in learning and memory. 207
5.2.1. The role of 5-HT4R in behavioral fear responses and fear memory .....208
5.2.2. The role of 5-HT4R in object memory ...................................................212
5.2.3. The role of 5-HT4R in social recognition memory .................................214

5.3. Discussion

217

5.3.1. Hippocampal 5-HT4R mediates fear responses and memories. ..........217

x

5.3.2. Hippocampal 5-HT4R mediates object memory. ..................................218
5.3.3. Pallial 5-HT4R mediates social recognition memory.............................219
5.3.4. Molecular signatures underlying the role of 5-HT4R in memory ...........219
5.4.5. Conclusion ............................................................................................220

CONCLUSIONS

222

MATERIALS AND METHODS

229

M.1. Generation of Htr4-floxed mouse line .....................................................230
M.2. Animals ...................................................................................................231
M.3. Breeding and Genotyping .......................................................................232
M.4. Drug treatments and behavioral assays .................................................233
M.5. shRNA construct generation and screening ...........................................244
M.6. Total RNA isolation and quantitative RT-PCR ........................................247
M.7. Generation of Htr4 cKO and WT expression vectors .............................249
M.8. cAMP induction assay ............................................................................250
M.9. Generation of AAV-DIO-Htr4-Myc ..........................................................251
M.10. Stereotactic surgeries ...........................................................................252
M.11. Electrophysiological recordings ............................................................253
M.12. Histology ...............................................................................................255
M.13. Translating ribosome affinity purification and RNA isolation ................257
M.14. RNA sequencing (RNA-Seq) ................................................................258
M.15. RNA-Seq read mapping, analysis, and visualization ............................260
M.16. Statistical Analysis ................................................................................262

APPENDIX

263

REFERENCES

269

xi

LIST OF FIGURES

CHAPTER 1
Figure 1.1.

Htr4 expression in the mouse brain.

21

Gene targeting strategy of Htr4-floxed mouse line.
Analysis of the generation of Htr4-floxed line.
Screening for shRNAs against Htr4.
Emx1-Cre expression is restricted to pallial structures.
Exon 5 was deleted from Htr4 mRNA in the hippocampus
and neocortex in Emx1/Htr4 cKO mice.
5-HT4R was non-functional after the deletion of Htr4 exon 5.
Custom antibody generation against mouse 5-HT4R.
Custom rb1 x 5-HT4R antibody showed specific
immunostaining on mouse brain tissue.
The loss of pallial 5-HT4R resulted in slightly elevated
anxiety-like behaviors in the open field.
The loss of pallial 5-HT4R led to increased anxiety-like
behaviors in the elevated plus maze.
Emx1/Htr4 cKO mice did not show a difference in anxiety-like
behaviors in the novelty suppressed feeding (NSF) test and
responded to chronic fluoxetine treatment.
Emx1/Htr4 cKO mice did not display a difference in
depression-like behaviors in the tail suspension test (TST)
and responded to chronic fluoxetine treatment.
Emx1/Htr4 cKO mice did not show a difference in
depression-related behaviors in the forced swim test (FST).
Emx1/Htr4 cKO mice showed slightly higher grooming in the
splash test.
Emx1/Htr4 cKO mice did not exhibit a difference in hedonic
behaviors in the sucrose preference test.
Emx1/Htr4 cKO mice did not show a difference in digging
behavior and responded to chronic fluoxetine treatment in
the marble burying test.

34
36
40
43
45

CHAPTER 2
Figure 2.1.
Figure 2.2.
Figure 2.3.
Figure 2.4.
Figure 2.5.
Figure 2.6.
Figure 2.7.
Figure 2.8.
Figure 2.9.
Figure 2.10.
Figure 2.11.

Figure 2.12.

Figure 2.13.
Figure 2.14.
Figure 2.15.
Figure 2.16.

xii

48
53
55
58
61
63

65

68
70
72
74

Figure 2.17. The loss of pallial 5-HT4R led to increased acoustic startle
responses.
Figure 2.18. Emx1/Htr4 cKO mice showed normal social interaction.

77
79

CHAPTER 3
Figure 3.1.

Hippocampal circuit and its role in anxiety and mood
regulation.
Figure 3.2. Corticostriatal circuit and its role in mood regulation.
Figure 3.3. Drd3-Cre reporter line specifically targets the hippocampus.
Figure 3.4. Tlx3-Cre reporter line targets corticostriatal (CStr) layer 5a
pyramidal neurons.
Figure 3.5. Hippocampus specific loss of 5-HT4R led to increased
anxiety-like behaviors in the open field and elevated plus
maze.
Figure 3.6. The loss of hippocampal 5-HT4R resulted in elevated
anxiety-like behaviors in the novelty suppressed feeding and
social interaction tests.
Figure 3.7. Drd3/Htr4 cKO mice exhibited increased anxiety-like
behaviors as elevated acoustic startle responses.
Figure 3.8. The loss of hippocampal 5-HT4R led to antidepressant-like
behavioral responses in the tail suspension, forced swim,
splash and sucrose consumption tests.
Figure 3.9. The loss of 5-HT4R specifically from CStr layer 5a neurons
led to slightly decreased anxiety-like behaviors in the EPM.
Figure 3.10. The loss of CStr 5-HT4R led to slightly decreased anxiety-like
behaviors in the NSF and anti-depressant-like behavioral
responses in the FST.
Figure 3.11. AAV-mediated Cre-dependent overexpression of 5-HT4R in
the hippocampus of Drd3-Cre mice led to neurotoxicity.

93
101
105
107
110

112

116
119

122
124

130

CHAPTER 4
Figure 4.1.
Figure 4.2.
Figure 4.3.
Figure 4.4.

Hippocampal regions and intrinsic circuitry.
Drd3-Cre targets excitatory neurons of the hippocampus.
Drd3-Cre targets mature excitatory neurons in the dentate
gyrus.
Htr4-EGFP-L10a is expressed in excitatory neurons of the
hippocampus.
xiii

141
151
152
154

Figure 4.5.
Figure 4.6.
Figure 4.7.
Figure 4.8.

Figure 4.9.
Figure 4.10.
Figure 4.11.
Figure 4.12.

Figure 4.13.

Figure 4.14.

Figure 4.15.

Figure 4.16.

Htr4-EGFP-L10a is expressed in mature excitatory neurons
in the dentate gyrus.
Drd3/Htr4 cKO mice showed increased neurogenesis
specifically in the ventral dentate gyrus.
Drd3/Htr4 cKO mice showed elevated expression of
neurotrophic factors in the hippocampus.
Region- and subtype specific-serotonin receptor expression
changes in the hippocampus were observed in Drd3/Htr4
cKO mice.
DG granule cells showed reduced firing in Drd3-Cre/Htr4
cKO mice.
Quality control of genome aligned TRAP-Seq replicates.
Visualization of TRAP-Seq reads mapped to cell type and
region marker genes for each sample.
Genome-wide gene expression analysis between the dDG
and vDG identified differentially expressed genes along the
dorsoventral axis of the DG.
Genome-wide differential gene expression analysis in the
dDG and vDG revealed region-specific molecular
adaptations in Drd3/Htr4 cKO mice.
Gene set enrichment analysis (GSEA) of significantly
regulated genes in Drd3/Htr4 cKO indicated both common
and region specific gene sets were altered in the cKO
between the dDG and vDG.
TRAP-Seq and differential gene expression analysis reveals
a robust molecular change in mature excitatory neurons of
the vDG in Drd3/Htr4 cKO mice.
Functional interpretation of the gene regulations in Drd3/Htr4
cKO.

156

Hippocampal 5-HT4R is necessary for proper retrieval of fear
memories.
Hippocampal 5-HT4R is necessary for object recognition
memory.
Cortical, but not hippocampal, 5-HT4R may mediate social
recognition.

210

159
161
164

166
171
172
175

178

182

185

187

CHAPTER 5
Figure 5.1.
Figure 5.2.
Figure 5.3.

xiv

213
216

LIST OF TABLES

CHAPTER 2
Table 2.1.

Summary of the antibody screening against mouse 5-HT4R.

51

MATERIALS AND METHODS
Table M.1.

Genotyping primers.

233

Table M.2.

shRNA oligonucleotide sequences.

246

Table M.3.

TaqMan Gene Expression Assays used for qRT-PCR.

248

Table M.4.

Primary antibodies used in this study.

256

Table M.5.

Overview of RNA-Seq datasets.

259

Table M.6.

Quality control of RNA-Seq alignments.

261

xv

CHAPTER 1.
INTRODUCTION

1

1.1. Anxiety and mood disorders

1.1.1. Burden of the disease
Mental disorders are commonly occurring and they are the leading cause
of years lived with disability worldwide, presenting an enormous global burden
from a societal perspective. Anxiety and mood disorders are two of the most
prevalent classes of mental disorders in the general population, anxiety disorders
with estimated lifetime prevalence averaging 16% and mood disorders with 11%
(Kessler et al., 2009). In addition, the most recent World Health Organization
(WHO) survey presents that, globally, depressive disorders are the first and
anxiety disorders are the sixth largest contributor to the non-fatal health loss as
of 2015. Yet, only a small minority of people with even seriously impairing mental
disorders receives treatment in most countries (Wang et al., 2007). Moreover, the
success in treating anxiety and mood disorders has been limited as current
therapies are neither consistently ameliorating nor precise enough. Although the
first-line pharmacological and psychological interventions are highly efficacious
for some individuals, many experience significant residual symptoms or various
side effects.
Mood disorders include major depressive disorder (MDD) and bipolar
disorder (BD), while disorders that have anxiety as a central aspect of
phenomenology are generalized anxiety disorder (GAD), obsessive compulsive
disorder (OCD), panic disorder, posttraumatic stress disorder (PTSD), specific
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phobia, and social anxiety disorder (SAD) (Ressler et al., 2015). Despite the wide
range in nosology, the comorbidity in psychiatric disorders is common. For
instance, the prevalence of comorbid anxiety with MDD is as frequent as % 60 in
patients (Kessler et al., 2005). Notably, comorbid symptoms generally worsen or
improve simultaneously with the severity of depressive symptoms. Comorbid
symptoms include irritability, restlessness, fatigue, trouble sleeping and difficulty
in concentrating. Depression symptoms also include anhedonia, loss of interest,
change in appetite, psychomotor retardation and suicidality, while patients with
anxiety also exhibit excessive worry, autonomic hyperactivity, increased startle
response and muscle tension. Although the combinations of depressive and
anxiety syndromes are classified as mood disorders with comorbid anxiety,
functional imaging studies in patients and postmortem analyses suggest that they
reflect dysfunction from a single etiology, which alters emotion regulation (Price
and Drevets, 2012). Consistent with this, antidepressant drugs are the first-line
treatments for both depressive and anxiety disorders (Gorman, 1996).

1.1.2. Basic neural circuitry of emotion
A variety of neuroanatomical, neurotransmitter and neuroendocrine
disruptions have been linked to anxiety and mood disorders. Functional imaging
studies that allow the characterization of anatomy, physiology and
neurochemistry in patients, and postmortem neuropathological analyses indicate
abnormalities in the brain regions that support emotive behavior (Drevets et al.,
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2008). The neural network controlling emotion involves mainly the limbic system
– including the hippocampus, amygdala, limbic cortices, basal ganglia, thalamus
and hypothalamus, and also higher cognitive centers in the frontal lobe that
extensively modulates the limbic system such as the subdivisions of prefrontal
cortex (PFC). These brain regions together form an extended ‘visceromotor’
network, and the abnormalities in the anatomy and function in this network
putatively account for the dysregulation of visceral, behavioral and cognitive
responses to emotional or stressful stimuli, reward learning and certain emotional
memory in anxiety and mood disorders (Price and Drevets, 2009). Notably,
patients with mood disorders show various abnormalities of morphology or
morphometry in the visceromotor network structures.

1.1.2.a. Hippocampus
The hippocampus is one of the most widely studied brain structure in
relation to anxiety and depression, both in humans and animals (Campbell and
Macqueen, 2004). First, it plays a central role in learning and memory, therefore,
hippocampal dysfunction possibly leads to improper context-dependent
emotional responses. Second, the hippocampus has modulatory effect on the
hypothalamic stress-response system hypothalamic-pituitary-adrenal (HPA) axis
(Herman et al., 2003; Rubin et al., 1966) and the amygdala (Phelps, 2004), a
brain region that is central in the encoding and expression of fear. Moreover, it is
one of the two brain areas where neurogenesis occurs in the adult mammalian
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brain, posing high capacity for neuroplasticity (Doetsch, 2003). Notably,
hippocampal volume has been observed to decrease in depressed patients
(Videbech and Ravnkilde, 2004), and changes in adult hippocampal
neurogenesis have been strongly implicated in anxiety and mood disorders and
antidepressant treatments (Sahay and Hen, 2007).

1.1.2.b. Neocortex
The hippocampus has also direct connections to the prefrontal cortex
(PFC) as wells as other limbic cortices (Ongür and Price, 2000). The PFC
consists of many subcortical regions involving in its heteromodal functions. It is
responsible for higher executive tasks involved in planning, decision making,
impulse control, reward processing, visceral response to emotions and mood
regulation (Price and Drevets, 2012). Although the frontal cortical regions, such
as the medial prefrontal cortex (mPFC) and orbitofrontal cortex (OFC), mediate
different aspects of emotionality and the extent of their link to anxiety and mood
disorders differs, they essentially modulate limbic structures responsible for
emotional processing. The limbic cortices include the cingulate and insular
cortices and these regions integrate the external and internal sensory information
regarding the environmental and emotional state of the organism. Abnormal
activity and decreased volume in the PFC and other cortical regions have also
been strongly associated with mood disorders in patients (Coryell et al., 2005;
Treadway et al., 2009).
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1.1.3. Neurobiology and neurochemistry of emotion

1.1.3.a. Neurotransmitters and neuropeptides
Although the precise mechanisms of how interconnected limbic regions
mediate emotion, and generate various symptoms of anxiety and depression
remain to be elucidated in more detail, data from human and animal studies
implicate the neurotransmitters providing communication between these regions
– such as glutamate (Glu) (Auer et al., 2000; Hashimoto et al., 2007), γ-aminobutyric-acid (GABA) (Sanacora et al., 2004), serotonin (5-hydroxytryptamine, 5HT) (Mann, 1999), norepinephrine (NE) (Delgado and Moreno, 2000), and
dopamine (DA) (Dunlop and Nemeroff, 2007) –; as well as the neuropeptides –
such as cholecystokinin (CCK) (Bradwejn et al., 1991), oxytocin (OXT)
(Neumann and Slattery, 2016), and corticotropin-releasing factor (CRF) (Laryea
et al., 2012). The involvement of numerous neurotransmitter and
neuromodulatory systems in emotive regulation emphasizes the complexity and
diversity of the factors that may constitute the etiology of affective disorders, and
strongly suggests their synergistic actions on different elements of the emotive
circuitry that mediate the homeostasis of the activity. On the other hand,
neurotransmitter systems provide an enormous range of targets for
pharmacological agents by which discreet therapeutic manipulations have been
attempted to ameliorate the pathophysiology and symptoms of affective
disorders.
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Anxiolytic and antidepressant drugs that act primarily on monoaminergic
systems are major examples at this direction. The efficacy of these drugs has
implicated serotonin (5-hydroxytryptamine, 5-HT), norepinephrine (NE), and
dopamine (DA) in the pathogenesis of anxiety and mood disorders, giving rise to
‘the monoamine hypothesis’ of mood disorders (Hirschfeld, 2000). These
monoamines significantly modulate the limbic system via monoamine projections
from the midbrain and brainstem nuclei (5-HT from the dorsal raphe nuclei
(DRN), NE from the locus coeruleus (LC), and dopamine from the ventral
tegmental area (VTA)), and significant evidence from human and animal studies
has shown the dysregulation of these systems in anxiety and depression
(Cowen, 2008; Ruhé et al., 2007).
The regulators of the monoaminergic signaling have been given more
attention because they are critical for the mechanisms of action of the
antidepressant drugs. For example, the most prescribed drugs for anxiety and
depression, selective serotonin reuptake inhibitors (SSRI) and serotoninnorepinephrine reuptake inhibitors (SNRI), inhibit the reuptake of these
monoamines by blocking the serotonin transporter (SERT) and/or the
norepinephrine transporter (NET). However, the delayed onset of antidepressant
effects in patients about three to four weeks strongly suggests that secondary
mechanisms involving changes in gene expression and synaptic plasticity may
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underlie the therapeutic mechanisms of these drugs (Krishnan and Nestler,
2008).
Neurotransmitters are usually co-released with neuropeptides, many of
which are expressed in limbic regions where they can influence stress and
emotion circuitry. Among many, corticotropin-releasing factor (CRF) is the
primary secretagogue of the hypothalamic-pituitary-adrenal (HPA) axis in
response to stress. Inappropriate stress responses and chronic exposure to
stress have been associated with anxiety and depression; for example, the HPA
axis is overactive in some patients with anxiety and depression with increased
CRF and glucocorticoid levels such as cortisol being the main stress steroid in
humans (Pariante and Lightman, 2008). Notably, HPA activity is under extensive
control of limbic structures including the amygdala (excitatory) (Gray et al., 1989;
Jankord and Herman, 2008) and the hippocampus (inhibitory) (Radley and
Sawchenko, 2011).

1.1.3.b. Neurotropic factors and neurogenesis
The observations of decreased volume in the hippocampus and cortical
structures in anxiety and depression patients have also led to the study of
neurotrophic factors that regulate neurogenesis and neuroplasticity in the brain,
mainly brain derived neurotrophic factor (BDNF) (Duman, 1997). Limbic regions,
especially the hippocampus, is rich in BDNF, which regulates neuronal growth
and survival as well as dendritic arborization and synaptic plasticity. In depressed

8

patients, BDNF levels were low (Karege et al., 2002; Shimizu et al., 2003) and it
increased with successful treatments (Chen et al., 2001). Rodent studies
recapitulate that BDNF signaling is involved in the changes in neuroplasticity in
response to stress and antidepressants (Sairanen et al., 2005); however, the
effects are both region and antidepressant specific (Dias et al., 2003).
A pronounced effect of several but not all antidepressant treatments is the
enhanced adult hippocampal neurogenesis (Santarelli et al., 2003). In the
hippocampus, new born cells in the subgranular zone of dentate gyrus (DG)
migrate into granule cell (GC) layer to become new mature GCs through a
mechanism involving proliferation, differentiation, migration and maturation.
Chronic antidepressant treatments increase the rate of neurogenesis, possibly
via several neurotropic factors, while several types of stress reduce it (Duman,
2004; Warner-Schmidt and Duman, 2006). Intriguingly, the ablation of
hippocampal neurogenesis inhibits some therapeutic-like effects of
antidepressant treatments in rodent models; however, it does not produce
increased anxiety or depression-related behaviors (David et al., 2009).
Comparably, while analysis of postmortem samples from depressed patients
indicate a decrease in the number of DG GCs, the number of progenitor cells
remains intact (Boldrini et al., 2013). Therefore, while increasing adult
hippocampal neurogenesis may be necessary for the antidepressant response, it
may not be sufficient to produce an antidepressant-like response (Sahay et al.,
2011). Currently, the data is not sufficient to suggest that a decrease in adult
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hippocampal neurogenesis may underlie the pathophysiology of depression. The
exact mechanisms of antidepressant induced neurogenesis and how it may
contribute to restore mood are yet to be detailed.
In summary, anxiety and mood disorders have a multifactorial
etiopathogenesis, including genetic predisposition and stress, resulting in a
number of pathophysiological changes. These possibly involve abnormalities in
the monoaminergic transmission, the hyperactivity in HPA axis and the reduction
in brain neurotropic signaling. Moreover, these pathologies are associated with
functional dysregulation of the extended visceromotor network. While
monoamine-based antidepressants remain the first line of therapy for anxiety and
depression, their limited efficacy emphasizes the need for faster acting
therapeutics with fewer side effects. Nevertheless, they have beneficial
modulatory effects on limbic circuit by increasing monoaminergic
neurotransmission and reversing some of the structural and physiological
abnormalities in the limbic circuit, which may underlie the improvement in some
of the debilitating symptoms of anxiety and depression in patients.

1.1.4. Rodent models of anxiety and mood disorders
Animal models have been crucial tools for understanding the etiology of
anxiety and mood disorders as well as the progress towards the development of
new therapeutic targets with improved efficacy and fewer side effects for their
treatment. However, it is impossible to precisely recreate these diseases in
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animal models due to the heterogeneous and unique nature of the symptoms in
humans, and the weakness in our understanding of the underlying complex
mechanisms. An acceptable animal model should have causative conditions,
behavioral symptom profiles (face validity), neuropathological changes (construct
validity) and treatment responses (predictive validity) that are similar to the
human disease. Most current models do not express all the abnormalities of
anxiety and depression related pathology, just as the symptoms in patients are
highly heterogeneous.
Since stress is a major factor in anxiety and mood disorders, various
rodent stress models have been used to induce anxiety and depression-like
symptoms and to investigate the underlying neural and molecular mechanism
(Krishnan and Nestler, 2011). Similar to the comorbidity of symptoms in anxiety
and depression in humans, all stress models in rodents exhibit some of
abnormalities related to both anxiety and depression. Thanks to these disease
models and advances in transgenic strategies the effects of a genetic,
pharmacological, or environmental manipulations can be studied mechanistically.
Genetically engineered mice also represent a powerful tool to study
candidate genes as the manipulation of a specific gene (loss or gain of function)
can result in anxiety and depression related pathology. These models have been
used to study the roles of candidate proteins in the progression of these
disorders and in the actions of classic and potential antidepressants as well as to
understand the neural mechanisms underlying the pathophysiology. Although the
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function of any gene in any part of the region or cell type in the brain can be
investigated through targeted genetic approaches, most studies have focused on
the models based on; 1) monoamine hypothesis, such as various monoamine
transporters, receptors and their modulators; 2) neurotrophic factor-related
hypothesis, such as BDNF the respective receptors, 3) HPA axis related
alterations, such as CRF, glucocorticoids and respective receptors.

1.1.4.a. Assessment of anxiety and mood related behaviors in rodents
It is important to distinguish between animal models and behavioral tests.
Behavioral tests are only the assays that are employed to assess the relevant
phenotypes on established or candidate models as well as behavioral responses
to antidepressant treatment. These tests use the animal’s response to potentially
threatening situations in the case of anxiety based assays, to stressful situations
in the case of despair based assays and to reward in the case of anhedonia
based assays.
Anxiety is normally inherent, protective and most of the time necessary for
animals to survive, however, abnormal and excessive anxiety is the hallmark of
the anxiety disorders and comorbid depression. Assays assessing anxiety-like
phenotypes in mice are based on mice’s exploratory tendencies towards novel
environments versus the aversion of exposed and/or well-lit areas (Ramos,
2008). Other ethologically relevant measures such as social interaction (File and
Hyde, 1979) and startle responses (Lee and Davis, 1997) have also been used.
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Mice displaying excessive anxiety-like behaviors in these paradigms have often
shown to successfully respond to acute or chronic administration of
antidepressants (or anxiolytics with non-antidepressant properties).
It is a harder challenge to understand mood related behaviors in mice due
to the uniqueness of the most depression phenotypes in human. However,
despair based models gauge the animal’s response to acute inescapable stress
as the lack of active coping (despair-like) behavior. These tests still retain their
popularity and utility since they are consistently responsive to acute
antidepressant treatment, and can be easily used to screen potential drugs.
Reward based assays assessing anhedonia like states in mice are regarded
more relevant because of the lack of the desire or experience of pleasure in
patients as well.
Since there is a lot of factors that may affect a rodent’s behavior during
testing, it is important to use multiple assays and internal controls, and to
interpret the results with caution and based on their nature. These tests, in the
end, are indispensable tools to understand the neurobiology of anxiety and mood
disorders, and to find new antidepressant treatments with better therapeutic
efficacy.
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1.2. Serotonergic system in anxiety and mood regulation

Serotonin (5-HT) is a monoamine, acting as a neurotransmitter, a
hormone and a mitogen, and is ubiquitous in all animals (Smythies, 2005). The
study of serotonergic system has provided biological insights into virtually all
brain functions, and the abnormalities in the serotonergic function have found to
be a common factor in numerous psychiatric and neurological diseases (Berger
et al., 2009). Serotonin modulates plethora of behaviors and neurophysiological
processes, including anxiety and mood as well as aggression, sleep, appetite,
memory and attention, even though less than one in a million of central nervous
system (CNS) neurons are serotonergic in the human brain, and immense
majority of serotonin in the body is outside the CNS. Nevertheless, brain stem
serotonin neurons, mainly in the dorsal and medial raphe nuclei of midbrain,
send ascending axonal projections throughout the brain. Where released, 5-HT
targets 14 different serotonin receptor subtypes (5-HTRs) of 7 families (5-HT1-7
receptors) that are expressed in many distinct combinations in different neuronal
types throughout the brain (Hannon and Hoyer, 2008).

1.2.1. Serotonin and its modulation in brain
In the CNS, upon neuronal depolarization of the 5-HT cells, serotonin is
released into the synaptic cleft where it can bind to the postsynaptic 5-HT
receptors or to the presynaptic 5-HT autoreceptors (somatodentridic 5HT1A and
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5HT1B receptors at axon terminals) (Hannon and Hoyer, 2008). As a modulatory
neurotransmitter, the strength and duration of 5-HT action on the postsynaptic 5HT receptor is crucial, and primarily dependent on the abundance of serotonin in
the synaptic cleft. The amount of extracellular serotonin is determined by its
binding to the autoreceptors and the activity of the selective serotonin transporter
(SERT). The autoreceptors provide a negative feedback against further release
of serotonin (Blier et al., 1998; Gardier et al., 2001) while SERT located on the
presynaptic and soma membrane of serotonergic neurons is responsible for
removing serotonin from the synaptic cleft into the presynaptic neuron (Rudnick
and Clark, 1993). The activity of serotonergic neurons is also tightly controlled via
glutamatergic inputs from forebrain areas (Zhou et al., 2017), inhibitory
GABAergic inputs from local interneurons (Challis et al., 2013) and dopaminergic
input from the midbrain dopaminergic nuclei (Ogawa et al., 2014).
One of the most clinically relevant functions of serotonin has been its role
in mood and anxiety disorders. The serendipitous discovery of the antidepressant
properties of tricyclics that elevate extracellular 5-HT levels, and later of selective
serotonin reuptake inhibitors (SSRIs), has prompted scientists to investigate the
role of the serotonergic system in anxiety and mood disorders and
antidepressant medication. SSRIs are still the first line treatment for anxiety and
mood disorders although they exert therapeutic effects only after chronic
treatment in clinical settings along with considerable side effects (Nestler et al.,
2002; Quitkin, 1984; Rush et al., 2006).
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Consistent with the action of serotonergic antidepressants, numerous
clinical and preclinical studies indicate that a disturbance in central serotonin
activity is a key factor in the pathophysiology of anxiety and mood disorders. For
example, abnormal levels of cerebrospinal fluid 5-HIAA, the main metabolite of 5HT, has been indicated in some anxiety and mood disorders (Åsberg, 1976;
Sullivan et al., 2006). Low levels of tryptophan, 5-HT precursor, have also been
consistently linked to depression (Lindseth et al., 2015). Notably, a polymorphism
in SERT causing low levels of the transporter in humans has been associated
with the susceptibility to anxiety and depression (Katsuragi et al., 1999). Many
recent studies have focused on studying the impact of SERT (mostly by blocking
with SSRI’s) and the serotonin receptors by using human brain imaging,
pharmacological manipulations and genetic mouse models.

1.2.2. Serotonin receptors
In addition to the serotonin transporter, the majority of the serotonin
receptors have been implicated in the neurobiology of anxiety, depression,
and/or antidepressant treatments. Except the ionotropic 5-HT3 receptor, all 5-HT
receptors are metabotropic G-protein coupled receptors (GPCRs), and have
either excitatory or inhibitory actions in distinct cell types (Bockaert et al., 2004).
5HT3 receptor is a ligand-gated Na+/K+ ion channel similar to GABA receptors
and expressed in a subtype of interneurons. 5-HT1 and 5-HT5 receptors are
negatively coupled to the adenylyl cyclase (Gi/o-coupled), meaning that the
activation of these receptors downregulates intracellular cAMP. 5-HT2 receptors,
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Gq/11-coupled, upregulate the inositol triphosphate and diacylglycerol pathways
increasing intracellular Ca2+ release and mediating excitatory transmission. 5HT4, 5-HT6, and 5-HT7 receptors are Gs-coupled increasing intracellular cAMP
upon activation. Additional G-protein independent signal transduction pathways
have also been described for some 5-HT receptors (Bockaert et al., 2010). The
functions of 5-HTRs have been mostly studied using pharmacological and
genetic manipulations in rodents to target each receptor subtype exclusively.
This allowed to understand the specific roles of each receptor in various parts
and cell types of the brain in anxiety and depression related behaviors as well as
behavioral and cellular actions of antidepressants.
Widespread expression of 5-HTRs in limbic and cortical regions that
mediates emotion justifies their involvement in anxiety and mood related
behaviors. Indeed, analyses of 5-HT receptor binding and expression in patients
and suicide victims from imaging and post mortem studies have revealed altered
levels of 5-HTRs indicating their possible involvement in the etiology of anxiety
and depression (Yohn et al., 2017). Pharmacological agents used in patients also
showed the link between these receptors and mood; for example, a partial 5HT1AR agonist has been used for generalized anxiety disorder (Huang et al.,
2017), and multimodal drugs targeting several 5-HTRs are used for major
depression (Sanchez et al., 2015). However, several factors including the wide
expression of serotonin receptors in CNS and periphery, and the presence of 5HT1AR and 5-HT1BR receptors as both autoreceptors and heteroreceptors
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complicates the use of these drugs. Hence, the discovery of new drugs that could
target subpopulations of these receptors may be necessary.
More evidence for 5-HTRs role in mood disorders comes from preclinical
studies. Pharmacological manipulation of most of the 5-HTRs via agonists or
antagonists leads to changes in anxiety and depression related behaviors in
mice, while these effects may not always be ideal. In this context, one of the
most recent promising findings is that a 5-HT4R partial agonist (RS67333)
produces rapid anxiolytic and antidepressant effects in rodents (Lucas et al.,
2007). Considering that the enhanced serotonergic tone after SSRI treatment
acts practically on 5-HTRs, recent studies have aimed to decipher the role of
these receptors in antidepressant responses to identify specific mechanisms that
may harness better antidepressant targets (Medrihan et al., 2017; Samuels et al.,
2015).

1.2.2.a. Serotonin receptors in selective serotonin reuptake inhibitor action
Our current understanding of SSRI action is limited; however, one of the
main goals of the field is to understand, and ultimately, bypass the delayed onset
of actions of SSRIs by three to four weeks. This delay may stem from the limiting
actions of 5-HT1A and 5-HT1B autoreceptors on the serotonin release from the
serotonergic cells in the raphe nuclei; among other possibilities such as
establishment of gene expression changes and synaptic plasticity (Krishnan and
Nestler, 2008). After chronic treatment, the negative feedback mechanism
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ultimately inactivates, at least in part, due to the desensitization of the 5-HT1A
autoreceptors in the raphe nuclei, consequently, resulting in a greater 5-HT
availability in the synapses (Artigas et al., 1996). Therefore, the identification of
serotonin receptors and cell types that drive the actions of elevated 5-HT levels
may present new targets that can be directly manipulated to mimic this process
and provide more efficacy.
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1.3. Serotonin receptor 4 (5-HT4 receptor, 5-HT4R)

1.3.1. Molecular biology, signal transduction and central expression
5-HT4 receptor is an excitatory 5-HT receptor type that is coupled to Gs
proteins. In humans, the Htr4 gene is around 700kb with 38 exons in
chromosome 5; in mice, it is in chromosome 18 with 7 exons. The receptor has
several different isoforms, generated through alternative splicing of the gene,
with distinct C-terminus sequences and functional properties. The longest
isoform in mouse is 388 amino acids long and around 42 kD. In brain and
peripheral tissues, humans have nine distinct variants of 5-HT4R (a-i, n), whereas
mice are currently thought to have only four (a, b, e, and f) (Bockaert et al.,
2004). The exact functional roles of these distinct isoforms remain unresolved;
however, numerous studies suggest that isoform-specific differences in 5-HT4Rs
and their distribution impact the overall coupling and regulation of the receptor
(Claeysen et al., 1999; Mnie-Filali et al., 2010). 5-HT4R is expressed in the heart,
gastrointestinal tract, adrenal gland, urinary bladder and lung as well as in the
CNS (Hegde and Eglen, 1996).
In situ hybridization, radioligand binding assays and transgenic Htr4
reporter mice revealed that, in the CNS, 5-HT4R is expressed in many limbic
structures and more: the hippocampus, neocortex, amygdala, hypothalamus and
many regions of the basal ganglia, although poorly expressed in the raphe nuclei
(Figure 1.1).
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Figure 1.1. Htr4 expression in the mouse brain
A. In situ hybridization (ISH) images showing Htr4 mRNA expression in the mouse brain.
Modified from BGEM ISH database (Magdaleno et al., 2006)
B. Anti-EGFP immunolabeling in Htr4-EGFP-L10a (bacTRAP) reporter mouse brain
showing EGFP-L10a expression under Htr4 regulatory elements.
C. Anti-EGFP immunolabeling in Htr4-EGFP reporter mouse brain showing EGFP
expression under Htr4 regulatory elements.
Images produced under GENSAT project (gensat.org).
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In the hippocampus, it is expressed in the pyramidal cells of CA fields and
the granule cells of dentate gyrus. In the neocortex, it is expressed in
glutamatergic pyramidal neurons, mostly in deeper layers in a relatively laminar
pattern.

1.3.2. 5-HT4 receptor in anxiety and mood regulation
Postmortem analyses of the brains from depressed subjects and suicide
victims showed changes in 5-HT4R binding in several brain regions (Rosel et al.,
2004). Moreover, imaging studies in humans demonstrated that an alteration in
5-HT4R binding in the striatum is associated with major depression. (Marner et
al., 2010). Moreover, some polymorphisms in Htr4 were associated with the
susceptibility to unipolar depression (Ohtsuki et al., 2002). Together these results
indicate a role for 5-HT4R in mood disorders in humans.
More understanding of the roles that 5-HT4R plays in anxiety and mood
disorders comes from the animal models of anxiety and depression. For
example, the Flinders sensitive line of rats, olfactory bulbectomy model,
glucocorticoid receptor heterozygous mice (GR+/−), and maternal prenatal stress
model in mice, showed changes in 5-HT4R receptor density in the limbic areas
such as the hippocampus (Chen et al., 2012; Licht et al., 2010; 2009).

1.3.2.a. Evidence from pharmacological studies
Further studies investigated whether 5-HT4R ligands can directly exert
anxiolytic and antidepressant-like effects or modify the effects of monoaminergic
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antidepressants. The most promising results have been achieved by an agonist
of this receptor. In rats, continuous systemic administration of a 5-HT4R agonist
(RS67333) rapidly increased the firing of 5-HT neurons, reaching a maximum
only after 3 days compared to similar effects of SSRIs that take up to several
weeks (Lucas et al., 2005). Intriguingly, subchronic administration of 5-HT4R
agonists (3-7 days) has consistently shown fast acting anxiolytic and
antidepressant-like properties, both in rats and mice (Lucas et al., 2007; WarnerSchmidt et al., 2009). In chronic mild stress (CMS) models, the 5-HT4R agonist
also reversed prolonged anxiety and depression-like behaviors in three days,
much faster than SSRIs (two weeks) (Lucas et al., 2007). Intriguingly, subchronic
5-HT4R activation also recapitulated the molecular and cellular effects of chronic
SSRI treatment in the hippocampus, including desensitization of 5-HT1A
autoreceptors, enhanced hippocampal neurogenesis and neurotrophic factor
expression. These evidences suggested that 5-HT4R agonists represent the first
putative fast-acting serotonergic antidepressants.
To study the loss of function of 5-HT4R, an Htr4 germline knockout mouse
line was generated (Compan, 2004). Although these mice did not display a
depressed-like phenotype, they showed an anxiety-like response to stress and
novelty. Similarly, chronic inhibition of 5-HT4R with an antagonist (GR125487)
does not affect the anxiety- and depression-like phenotypes induced by chronic
corticosterone treatment in mice (Mendez-David et al., 2014). However, inhibition
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of 5-HT4R attenuated the effects of an SSRI in this model, although there is
conflicting evidence by other groups (Cryan and Lucki, 2000).

1.3.2.b. 5-HT4 receptor and p11 in antidepressant response
Our lab also previously reported some evidence to support 5-HT4R
involvement in SSRI responses in the neocortex. In this study, p11-expressing
cortical neurons that projects to striatum were identified as the cortical neurons
that mediate the response to chronic SSRI treatment (Schmidt et al., 2012). This
population was targeted because p11 was shown to be increased in the
neocortex following chronic antidepressant treatment, and decreased in the
neocortex of depressed patients, suicide victims, and a mouse model of
depression. Moreover, p11 acts as an anchoring protein that binds to 5-HT1DR
and 5-HT4R and stabilizes their localization at the cell surface. Notably, the fast
acting anxiolytic and antidepressant-like effects of the 5-HT4R agonist were
dependent on p11 expression (Warner-Schmidt et al., 2009).
After chronic SSRI treatment, corticostriatal (CStr) p11 neurons showed a
robust molecular response, compared to neighboring corticopontene (CPn) layer
5 population, including a striking 16-fold upregulation of Htr4 expression in p11
neurons. Furthermore, the deletion of p11 specifically from the cortex resulted in
abolished behavioral response to chronic SSRI treatment, while the upregulation
of Htr4 was significantly blunted. Whether 5-HT4R in p11 cells is mediating the
effects of SSRIs remains to be an intriguing question.
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Accumulating evidence strongly suggests a role for 5-HT4R in the
modulation of anxiety and mood disorders both in the hippocampus and
neocortex. However, the expression of 5-HT4R in periphery and especially in the
gastrointestinal track and heart complicates the use of 5-HT4R agonists as an
antidepressant in humans due to the possibility of major side effects. In fact, 5HT4R ligands are clinically used in the treatment of irritable bowel syndrome
although there are some concerns over cardiovascular side effects as well
(Tonini and Pace, 2006). Therefore, specific approaches targeting 5-HT4R
pathway in specific cell populations or circuits that are mediating its fast acting
antidepressant properties will facilitate our understanding of its mechanism of
action and may lead to more efficacious therapies.
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1.4. Cell type specific experimental approaches in mouse

In order to investigate the mechanisms regulating 5-HT4R function and for
the discovery of new paths toward treatment of anxiety and mood disorders, it is
essential to target experimental manipulations to specific CNS cell types of
functional relevance. The Cre-recombinase approach and the intersectional
strategy using Cre-dependent mutant mice or viral vectors allow for the
investigation of the distinct contribution of each cell type and gene to anxiety and
depression-related phenotypes and responses to antidepressant drugs.

1.4.1. Cre/loxP system
The development of the Cre/loxP system for mouse genetics expanded
the possibilities for cell type specific manipulation of gene expression and
function. Cre recombinase is a DNA recombinase enzyme that carries out ‘Credependent’ site specific recombination between specific DNA target sequences,
loxP sites (Kühn and Torres, 2002). In the presence of Cre recombinase, this
recombination approach allows either for excision or reversal of the genomic
sequence in between loxP sites depending on the orientation and the number of
the loxP sequences. The Cre gene and loxP sites are typically integrated into the
genome via genome targeting techniques during embryonic stage to generate
transgenic lines. Cre and loxP transgenic mouse lines are generated separately
and crossed to produce a specific Cre-loxP line. Alternatively, the Cre
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recombinase coding sequence or the transgenes carrying loxP sites can be
delivered via carrier viruses into the brain region of interest of the reciprocal
transgenic line.

1.4.2. BAC Recombineering and transgenic targeting
The ability to genetically target specific cell types to understand their
properties in the context of an intact organism is essential to biological research.
The most efficient methodology devised for this purpose is the generation of BAC
transgenic mice, which was invented in our lab (Schmidt et al., 2013). The use of
modified BAC (bacterial artificial chromosome) vectors containing a specific
reporter (Cre, GFP, etc.) under a cell type specific promoter has been
systematically developed in our lab under GENSAT Project (gensat.org), which
generated an extensive library of transgenic reporter mouse lines expressing the
specific reporter (bacTRAP, Cre or EGFP) in distinct cell types in the CNS.

1.4.3. TRAP-Seq: genome-wide cell-type specific transcriptomics
The TRAP-Seq (Translating Ribosome Affinity Purification followed by
next-gen RNA sequencing) strategy allows the identification of all proteins being
translated in any genetically targeted cell population, and the alterations of this
translational profile in response to pharmacological or genetic perturbations
(Heiman et al., 2014). The basis of this technique is expressing EGFP-tagged
ribosomal protein L10a (EGFP-RPL10a) in the cell type of interest by employing
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abovementioned cell-type specific transgenic lines; followed by pulling down the
polysomes with the mRNAs being translated and sequencing these mRNA to
analyze changes in the gene expression upon genetic or pharmacological
perturbations. TRAP combines coincident detection of all translated mRNAs with
cell-type specificity and can be repeated easily for any experimental condition.
The use of bacTRAP transgenic lines or Cre-mediated EGFP-RPL10a
expression in Cre transgenic mice ensures that mRNA translational profiles can
be reproducibly obtained and directly compared from the same cell population
across experimental conditions. The extreme sensitivity of the technique is
demonstrated by its ability to distinguish very subtle gene expression changes in
response to drug administration between highly similar cell types, such as two
populations of layer 5 projection neurons in the cortex (Schmidt et al., 2012).
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1.5. Rationale

In the introduction, current understanding towards the etiology and the
extensive involvement of the serotonergic system in anxiety and mood disorders
is discussed. Strong evidence suggests that 5-HT4 receptors in the hippocampus
and neocortex are involved in the pathophysiology of these diseases, and may
provide faster and more effective routes towards the enhancement of their
symptoms. In this thesis, I investigate the role of 5-HT4R in genetically defined
cell populations in the hippocampus and neocortex to decipher its role in anxiety
and mood related behaviors and antidepressant responses. Later, I use
molecular, cellular and physiological approaches to discover underlying
mechanisms through which 5-HT4R mediates emotive behaviors. The
identification of novel targets by studying cell type and circuit specific
mechanisms of 5-HT4R function will facilitate the development of efficacious
therapies for affective disorders with fewer side effects.
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CHAPTER 2.
THE ROLE OF 5-HT4 RECEPTOR IN EXCITATORY NEURONS OF
PALLIAL ORIGIN IN ANXIETY AND DEPRESSION
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2.1. Introduction

The identification and targeting of the specific cell types and proteins
underlying the pathophysiology of disease present a powerful approach for
developing novel, more efficacious therapies with fewer side effects. There is a
body of work suggesting that 5-HT4 receptor (5-HT4R) may be involved in the
modulation of anxiety and mood, and the activation of this receptor may be a
faster route to an antidepressant response. Recently, data from our lab
suggested that 5-HT4R in the cerebral cortex may be involved in the mechanism
of chronic SSRI action (Schmidt et al., 2012). Therefore, we sought to investigate
the role of 5-HT4R in more defined brain regions and cell types. Teasing apart
the function of 5-HT4R in distinct elements of the anxiety and mood circuitry in
the brain is essential to have a better understanding of its function and the
disease due to the complexity of the emotion circuitry. Finding relevant cell types
and molecular mechanisms may yield novel therapeutic candidates.
We sought to study the role of 5-HT4R in the hippocampus and neocortex
because of a variety of strong reasons. First, the hippocampus is one of the most
implicated brain region in the modulation of anxiety, mood and antidepressant
responses. Most of the pathophysiology in the disease and the plasticity upon
treatment occur in the hippocampus. Second, our lab’s finding has led to the
hypothesis that an enhanced serotonergic tone acts on an upregulated pool of 5HT4R in p11 expressing cortical layer 5 neurons, thereby increasing the outflow
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from the neocortex to the striatum and contributing to the efficacy of
antidepressants. Third, the expression of Htr4 in hippocampal neurons is high
and almost ubiquitous especially in the dentate gyrus; and in the neocortex, it is
relatively laminar and mostly in layer 5 neurons similar to p11. Finally, the partial
5-HT4R agonist, RS67333, increases the DRN neuronal firing possibly via
feedback from 5-HT4R expressing neurons in the mPFC (Lucas et al., 2005), and
it has antidepressant-like effects in the hippocampus either due to a direct
activation or via indirect mechanisms (Lucas et al., 2007).
In Chapter 2, we achieved a conditional knockout strategy using our newly
generated transgenic Htr4 conditional knockout mice. We functionally ablated 5HT4R receptor from the excitatory neurons of the hippocampus and neocortex,
including p11 neurons. This approach allowed us to investigate the role of 5HT4R in these neurons in mediating emotional behaviors and antidepressant
efficacy.

32

2.2. Genetic targeting of Htr4 gene

2.2.1. Conditional knockout strategy: generation of Htr4-floxed mouse line
To study cell type specific functions of 5-HT4R, we targeted the Htr4 gene
to generate Htr4 conditional KO (cKO) mouse line to drive deletion in genetically
defined cell populations using the Cre/loxP system. Figure 2.1 shows the gene
targeting strategy. The exon 5 of Htr4 wildtype (WT) allele in the mouse
chr18qE1 locus was targeted (Figure 2.1A). Targeting vector design is shown in
Figure 2.1B, which includes: Htr4 exon 5 (black bar); middle arm (MA, black),
the intronic sequence surrounding exon 5; a 5’ long arm (LA, green) and a 3’
short arm (SA, blue), intronic sequences for homologous recombination; a
Neomycin resistance cassette (Neo, yellow rectangle), between MA and SA; FRT
(flippase recognition target) sites (grey half circle) flanking the Neo cassette, an
analogous system to Cre/loxP; and loxP sites (red triangle), flanking exon 5 and
Neo cassette.
After the introduction of the targeting vector into mouse embryonic stem
(ES) cells, the homologous arms drove the homologous recombination inserting
the targeting construct into the genome. Neo cassette was used to select for the
ES cells with the recombination via the antibiotic neomycin. FRT sites were
designed to excise the Neo cassette when the Htr4-floxed mice were generated
and crossed with flippase (FLP, the recombinase for FRT site) expressing mouse
line Rosa26::FLPe (R26FLP).
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Figure 2.1. Gene targeting strategy of Htr4-floxed mouse line.
(A) Schematic of Htr4 gene in mouse chr18qE1 locus.
(B) Gene targeting vector designed to drive the homologous recombination via LA and
SA to insert the loxP-flanked exon 5 and Neo cassette. Targeting vector includes: Htr4
exon 5 (black bar); middle arm (MA, black); 5’ long arm (LA, green) and short arm (SA,
blue); Neomycin resistance cassette (Neo, yellow rectangle); FRT (flippase recognition
target) sites (grey half circle); loxP sites (red triangle).
(C) Neo cassette and FRT sites were designed to be excised by crossing the Htr4-floxed
mice with Rosa26::FLP (R26FLP) mice. FLP-mediated recombination would lead to
Htr4-floxed allele.
(D) Schematic of Htr4 gene with exon 5 flanked with loxP sites (Htr4-floxed).
gP, genotyping primers (purple arrows). Scale bar for magnified schematics, 1kb.
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In Htr4-floxed line, loxP sites were inserted to flank exon 5 of the mouse
Htr4 gene, which encodes for the fourth transmembrane domain. In silico
translation analysis (via MacVector) predicted that deletion of exon 5 would result
in a frame shift mutation and the introduction of potential stop codons
downstream, including one right after the deletion site, six others before the
endogenous stop codon site, and more in the 3’UTR region (Figure 2.2A).
Once the frame shift is created by Cre mediated excision, the resulting
mRNA (Htr4 mRNA exon 5 deleted) should be subject to nonsense-mediated
decay or the translated protein would be truncated (green amino acid sequence),
non-functional, and tagged for degradation. This would effectively result in
animals null for this allele. Similar targeting of other seven transmembrane
proteins has worked efficiently in the past (personal communication, inGenious
Targeting Laboratory).
Three lines of chimeric mice were generated at the Janelia Research
Campus Gene Targeting and Transgenic Facility; and one of these lines, ROXY
Htr4 1G12, showed germline transmission of the mutation. We have established
a colony of the mice from the 1G12 line in our laboratory. In Figure 2.2B,
genotyping results show examples of PCR products in agarose gel
electrophoresis, using genomic DNA samples from mice that are WT (+/+),
heterozygous (loxP/+) and homozygous for the floxed Htr4 allele (loxP/loxP).
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Figure 2.2. Analysis of the generation of Htr4-floxed line.
(A) In silico translation analysis predicting the loss of exon 5 from Htr4 mRNA would lead
to immediate early stop codons. Green amino acid sequence represents the translation
up to exon 5. Red squared X represents the translation of the stop codons.
(B) Example genotyping results for mice that are WT (+/+), heterozygous (loxP/+) and
homozygous for the floxed Htr4 allele (loxP/loxP).
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PCR primers were designed to amplify 172 basepair (bp) region in WT allele
where 5’ loxP was inserted in the floxed Htr4 allele. Hence, genotyping from mice
containing floxed Htr4 allele results in longer, 239 bp, amplicons.
We crossed these mice to several Cre-driver lines to delete Htr4 from
specific cell populations in the mouse brain. Htr4-floxed mouse line is a novel tool
that will enable us to better understand the contribution of 5-HT4R signaling in
many neurological processes, from mood regulation and antidepressant
responses to cognition and memory, as well as any other biological processes in
other systems, such as gastrointestinal system.

2.2.2. RNAi knockdown strategy: screening for shRNA’s against Htr4.
Cre dependent knockout is a powerful approach to study cell specific
functions of a gene. However, in the unlikely event that the protein function
remains following the deletion of exon 5 in the Htr4 conditional KO mice, we have
generated small hairpin RNA (shRNA) expressing vectors to knock-down Htr4
expression in spatially isolated brain regions by combining with AAV-mediated
gene delivery.
RNA interference (RNAi) is an RNA-dependent gene silencing process
controlled by the RNA-induced silencing complex (RISC) which uses the
endogenous microRNAs in the cytoplasm to regulate mRNA translation (Sharp,
2001). miRNA’s are processed from double-stranded RNAs (dsRNA) by Dicer,
an endogenous cytoplasmic ribonuclease protein. By utilizing the RISC,
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exogenous expression of small short hairpin RNAs (shRNA), can also be used to
regulate transcription. shRNAs designed for a specific gene are cleaved and
processed by Dicer into 20-25 bp double-stranded small interfering RNAs
(siRNA). siRNAs are further processed into single stranded antisense RNAs, and
RISC-mediated binding to the mRNA product of a gene of interest downregulates
its translation.
RNAi has been used as a powerful tool to generate region-specific
knockdowns in the brain (Raoul et al., 2005). AVV-mediated delivery of plasmid
vectors capable of expressing a shRNA was one of the major advances in this
field. These vectors use a PolIII promoter (e.g U6) to permit high level of
expression of shRNA molecules with very specific start and stop sites, which is
ultimately trimmed and resolved into siRNA. This can act to efficiently decrease
the mRNA levels of targeted genes very efficiently in animal brains in vivo
(Hommel et al., 2003).
To find a potent shRNA, we screened five shRNA constructs against
mouse Htr4 gene (designed by The RNAi Consortium, Broad Institute) in human
embryonic kidney (HEK) cells. shRNA sequences were cloned into an AAVexpression vector pGFP-shRNA (Hommel et al., 2003) (Figure 2.3A). To
determine the knockdown efficiencies of five shRNAs (sh249, sh261, sh270,
sh284 and sh308), we cotransfected pGFP-shRNA vectors with a mouse Htr4
overexpression vector into HEK cells; and performed quantitative RT-PCR (qRTPCR) using a TaqMan assay for mouse Htr4 gene. A scrambled shRNA
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sequence, similar in length and base-pair constitute to other shRNAs, was used
as a control shRNA (shControl).
Compared to shControl, three constructs significantly reduced the
overexpression of mouse Htr4 mRNA by at least 50%, and one of them, sh308,
being the most potent and reducing to ~30% (31.01± 6.63%, p=0.009) (Figure
2.3.B). pGFP-sh308 construct showed a significant knockdown efficiency and
can be packed into suitable AAV viral vectors to be delivered in vivo as a
powerful alternative to the transgenic conditional KO approach.
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Figure 2.3. Screening for shRNAs against Htr4.
(A) Schematic of AAV-expression vector pGFP-shRNA. EGFP is expressed under CMV
promoter and shRNA is under mU6 promoter.
(B) qPCR quantification of the Htr4 mRNA expression in HEK cells transfected with
different pGFP-shRNA constructs. Data are shown as percent (%) of control (black bar).
Data are represented as mean ± SEM. Ordinary one-way ANOVA followed by post
hoc Fisher’s LSD test, n=4 per group, *p<0.05, **p<0.01.
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2.3. Conditional loss of 5-HT4R from excitatory neurons of pallial origin
Given the prominent expression of 5-HT4R in the hippocampus and the
neocortex, and the extensive literature documenting a role for the hippocampus
and cortex in anxiety and mood regulation, we were particularly interested in the
role of 5-HT4R in these regions. In addition, our lab’s previous work showing that
the conditional deletion of p11 from the hippocampus and neocortex using Emx1Cre driver line suggested that 5-HT4R in these regions may be involved in
behavioral antidepressant responses. Accordingly, we deleted Htr4 specifically in
hippocampal and neocortical excitatory neurons by crossing our newly generated
Htr4-floxed line with Emx1-IRES-Cre (Emx1-Cre) driver line to investigate
whether 5-HT4R mediated behaviors related to anxiety, mood and antidepressant
responses in the hippocampus and neocortex.
Heterozygous Emx1-Cre animals were crossed with Htr4-floxed animals
homozygous for the floxed allele (Htr4loxP/loxP) for two generations to obtain
Emx1/Htr4 cKO mice (Emx1-Cre::Htr4loxP/loxP). To maintain the colony, Emx1/Htr4
cKO animals were bred with homozygous Htr4-floxed animals. The litters from
this breeding should be Emx1/Htr4 cKO in 1:2 ratio and Htr4-floxed in 1:2,
referred as control or wildtype (WT) littermates.
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2.3.1. Emx1-Cre driver line
The Emx1-Cre line expresses Cre recombinase specifically in the
excitatory neurons of most brain structures of pallial origin, including the entire
hippocampus and neocortex in the adult mouse brain (Gorski et al., 2002). This
line was generated by homologous recombination of an internal ribosome entry
site (IRES) and Cre recombinase coding region into the 3’ untranslated region of
the mouse Emx1 gene. Due to the use of IRES for the translation of Cre, this
strategy prevents reduction in Emx1 expression in Emx1-Cre transgenic mice.
Emx1 encodes a homeodomain protein that is expressed primarily in the pallium,
the cortical subdivisions of the telencephalon. The expression data is available
as early as embryonic day 10.5 showing Cre expression dependent
recombination of a reporter in the pallium. In adult mice, Cre expression was
observed in ~88% of the neurons in the hippocampus and cortex while over 98%
of the GABAergic interneurons did not express Cre. Overall, most pallial
excitatory neurons, astrocytes and oligodendrocytes but not GABAergic neurons
expressed the Cre reporter in the Emx1-Cre line.
To have our own reference and confirm that Emx1-Cre line in our lab did
not go through under any other recombination events altering the expected
expression pattern, we also crossed Emx1-Cre with Cre dependent EGFPRPL10a (EGFP-L10a) expressing reporter mouse line, and Emx1-Cre expressing
cells and brain regions were revealed using anti-EGFP DAB
immunohistochemistry (Figure 2.4)
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Figure 2.4. Emx1-Cre expression is restricted to pallial structures.
(A) Anti-EGFP immunohistochemistry images of the coronal sections of a Emx1Cre::EGFP-L10a mouse brain exhibiting the expression pattern of Emx1-Cre driver line.
(B) Higher magnification images of somatosensory cortex and dentate gyrus
corresponding to the squares in Figure 2.4.A.
White arrowheads show labeled astrocytes and black arrowheads show labeled
oligodendrocytes in cc. CTX: neocortex, STR: striatum, S: septum, NAc: nucleus
accumbens, HIPP: hippocampus, DG: dentate gyrus, TH: thalamus, HY: hypothalamus,
L: lateral amygdala, BL: basolateral amygdala, BM: basomedial amygdala, MB:
midbrain, cc: corpus callosum. Section coordinates are displayed as from bregma.
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Consistent with the literature, we saw the recombination of EGFP-L10a in
virtually all projection neurons (e.g. pyramidal neurons), astrocytes (with spiny
and cloudy morphology, white arrowheads) and oligodendrocytes (positively
labeled cells in the corpus collosum, black arrowheads) in pallial structures such
as the hippocampus and neocortex. These interpretations were made by the
morphology of immunolabeled cells. Note that basomedial, basolateral and
lateral amygdala cells also express, consistent with the literature documenting
that excitatory neurons of most pallial regions showed Emx1-Cre recombination.
Some small scattered populations of cells are also labeled especially in the
striatum and septum. Although the astrocytes and oligodendrocytes of pallial
structures expressed Emx1-Cre::EGFP-L10a, 5-HT4R is expected not to be
expressed in glia based on the expression profiles observed in the transgenic
Htr4 reporter mice.

2.3.2. qRT-PCR confirmation of the deletion of Htr4 exon 5
The expected deletion of the exon 5 of Htr4 from the hippocampus and
neocortex in Emx1/Htr4 cKO mice was confirmed using qRT-PCR (qPCR). We
selected TaqMan qPCR assays that uses probes amplifying on Htr4 mRNA
exons 3 and 4 (Probe 3-4) and exons 4 and 5 (Probe 4-5) (Figure 2.5A). Probe
4-5 failed to amplify the cDNA produced from the total RNA samples from the
hippocampus (HIPP) and neocortex (CTX) of Emx1/Htr4 cKO mice (Figure
2.5B).
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Figure 2.5. Exon 5 was deleted from Htr4 mRNA in the hippocampus and
neocortex in Emx1/Htr4 cKO mice.
(A) Schematic showing the TaqMan probes used to amplify on Htr4 mRNA.
(B) qPCR quantification of the expression of Htr4 in the hippocampus (HIPP) and
neocortex (CTX) in Emx1/Htr4 cKO (purple bars) and WT (black bars) using Probe 4-5.
(C) qPCR quantification of the expression of Htr4 in the hippocampus (HIPP) and cortex
(CTX) in Emx1/Htr4 cKO (grey bars) and WT (black bars) by Probe 3-4.
Data are represented as mean ± SEM. n=4 per group. Two-tailed unpaired t-test.
*p<0.05, ***p<0.001, ****p<0.0001.
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In contrast, this assay did amplify in the cDNA samples from their Crenegative control littermates (WT). Moreover, Probe 3-4 amplified in samples from
the hippocampus of cKO significantly higher compared to WT (Figure 2.5C). It
also amplified cortex samples equally well both in cKO and WT. These data
suggested that exon 5 was deleted from the Htr4 mRNA transcripts in the
hippocampus and neocortex of Emx1/Htr4 cKO mice while the exon 5 deleted
mRNA was being made at higher (in the hippocampus) or similar (in the
neocortex) levels.

2.3.3. Confirmation of the loss of function of 5-HT4R
To confirm the loss of function of the mutant 5-HT4R, we used a cell
culture based cyclic AMP (cAMP) induction assay. 5-HT4R is a Gs-coupled
receptor and therefore induces cAMP signaling in cells upon activation. We
cloned the exon 5 deleted mutant Htr4 cDNA (cKO) and the intact floxed Htr4
cDNA (control) from the total RNA samples obtained from the hippocampus of
Emx1/Htr4 cKO and their control littermates, respectively. The cDNA constructs
were then inserted into a mammalian expression vector (pCMV6-Entry) under the
CMV promoter and to be tagged with MYC and DDK epitope sequences for
further immmunodetection.
We expressed both cKO and control vectors in HEK cells and
immunofluorescent staining using anti-MYC antibody confirmed the expression
and cellular localization of both cKO and control 5-HT4R (Figure 2.6A).
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The cKO 5-HT4R, the product of exon 5 deleted Htr4, showed significant
difference in cellular sublocalization compared to the control 5-HT4R. The low
magnification images show that control 5-HT4R were distributed relatively
homogenously in the cell, resulting in cell images with sharp and uniform
borders. On the other hand, the distribution of cKO 5-HT4R were less
homogenous producing punctate stained cells with vague edges. Imaging at a
higher magnification revealed that the control 5-HT4R was localized highly in the
cellular membrane, seen as sharp and bright cellular borders (arrowheads). Note
also that the control 5-HT4R was localized in filopodia. However, the cKO 5-HT4R
seemed not to localize to the cellular membrane, failing to form uniform cellular
borders. Furthermore, intracellular location of control 5-HT4R was more
homogenous compared to the highly punctate localization of cKO 5-HT4R. These
results suggested that overexpressed cKO 5-HT4R was still translated but not
integrated into the cellular membrane where it is supposed to function.
Next, to confirm that the cKO 5-HT4R is not functional, we compared 5HT4R mediated cAMP induction using a 5-HT4R agonist, zacopride, in HEK cells
transfected with control and cKO Htr4 cDNA. For the cAMP induction, we used a
stimulation buffer supplemented with IBMX, a phosphodiesterase inhibitor, to
prevent the inactivation of cAMP and promote its intracellular accumulation
during stimulation. 30 min after the addition of either stimulation buffer (basal) or
stimulation buffer with zacopride (100 µM), the cells were lysed in 0.1 M HCl to
prevent cAMP degradation.
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Figure 2.6. 5-HT4R was non-functional after the deletion of Htr4 exon 5.
(A) cKO 5-HT4R did not localize on the cellular membrane in transfected HEK cells.
Lower (above) and higher (below) magnification images of anti-MYC
immunofluorescence of control and cKO 5-HT4R-MYC transfected HEK cells.
Arrowheads indicate the membrane localization of control 5-HT4R.
(B) A 5-HT4R agonist, zacopride, increased cAMP in HEK cells transfected with control
(floxed) Htr4 cDNA. Transfection with mutant cKO Htr4 cDNA (exon 5 deleted) led to
lower baseline levels of cAMP in HEK cells and zacopride did not induce cAMP in these
cells. Data are represented as mean ± SEM. n=4 per group. Two-way ANOVA followed
by post hoc Fisher’s LSD test. ****p<0.0001, n.s. p>0.05.

48

cAMP concentrations in the lysates were measured using a monoclonal anticAMP antibody based ELISA and cAMP levels were normalized to the protein
concentrations in each sample for accurate comparison.
As shown in Figure 2.6B, the basal cAMP levels in the control were
significantly higher compared to the cKO (100 ± 2.9% versus 17.1 ± 4.9%,
p<0.0001, n=4 per group). cKO 5-HT4R expressing cells stimulated with
zacopride did not show a difference in cAMP levels compared to their basal
levels (Basal: 17.1 ± 4.9%, Zacopride: 12.6 ± 1.1%; p=0.76, n=4 per group). On
the other hand, control cells stimulated with zacopride had a significant 88%
increase in cAMP levels (Basal: 100 ± 2.9%, Zacopride: 188 ± 19.3 %; p<0.0001,
n=4 per group). These results indicate that the cKO 5-HT4R could not be
activated with the 5-HT4R agonist and therefore it is nonfunctional. On the other
hand, the floxed Htr4 allele could still produce a functional 5-HT4R receptor.

2.3.4. Antibody screening against mouse 5-HT4R
The exact subcellular localization of 5-HT4R in the brain is not well
established due to a lack of reliable antibodies. In situ hybridization (PeñasCazorla and Vilaró, 2014; Vilaro et al., 2005), and transgenic reporter mice
(Warner-Schmidt et al., 2009) have helped to establish the cell types expressing
5-HT4R. Much of our knowledge on the localization of 5-HT4R is based on
radioligand binding assays using antagonists against the receptor (Bonaventure
et al., 2000; Varnäs et al., 2003). An attempt to use custom antibodies for the
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immunolocalization of 5-HT4R showed a somatodentridic localization in the rat
brain and spinal cord (Manzke, 2003; Suwa et al., 2014). However, the data
failed to show subcellular localization while overall distribution was similar to the
expected expression pattern of 5-HT4R. In mouse, another custom antibody was
used for the immunostaining of myenteric and submucosal plexuses in mouse
enteric nervous system (Liu, 2005), indicating 5-HT4R may be expressed in
axons terminals, at least in the peripheral nervous system. However, the
antibody was not able to show immunolabeling in the mouse brain tissue
(personal communication).
Showing the subcellular localization of 5-HT4R in the mouse brain with a
good antibody may bring novel insights regarding the function of the receptor in
central synapses. Therefore, we systematically screened twelve of the
commercially available antibodies by immunofluorescence on mouse 5-HT4RMYC expressing mammalian cells and on 4% PFA fixed mouse brain tissue with
or without antigen retrieval. Table 2.1 shows the results of the antibody
screening. All commercial antibodies were generated against synthetic peptides
of a part of human 5-HT4R sequence. Human and mouse 5-HT4R share >90%
homology in their peptide sequence. Some of the antibodies, such as 1, 2 and 12
successfully immunolabeled the mouse 5-HT4R when overexpressed in cell
culture. On the mouse brain tissue, only antibody 1 and 2 achieved some specific
staining, yet, with inconsistent results in between experiments. Antigen retrieval
procedures did not improve the success of the staining for any antibodies tested.
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Table 2.1. Summary of the antibody screening against mouse 5-HT4R.
Antibody 1 and 2 achieved some specific immunofluorescent labeling on the
mouse brain tissue, yet, with inconsistent results in between experiments. Some
of the antibodies, such as 1, 2 and 12 successfully immunolabeled the mouse 5HT4R when overexpressed in cell culture. All commercial antibodies were
generated against synthetic peptides of a part of human 5-HT4R sequence
(immunogen peptide).
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2.3.5. Generation of a novel custom antibody against mouse 5-HT4R
Due to the unavailability of a commercial antibody that successfully detect
mouse 5-HT4R, we have generated a custom rabbit polyclonal antibody in
collaboration with Green Mountain Antibodies, Inc. (VT, USA) We selected the
peptide sequence (GATSESRPQPADQHSTH) corresponding to the 233-249
amino acid sequence in the third cytoplasmic loop of 5-HT4R (Figure 2.7A). CG
was also added for conjugation to a carrier protein. This sequence was selected
as the immunogen because it has more surface exposure in the predicted mouse
5-HT4R structure and higher hydrophilicity due to the higher ratio of charged
amino acids compared to other possible short sequences (Figure 2.7B). The
hydrophilicity is necessary for the peptide to be soluble for the conjugation to the
carrier proteins. In addition, the presence of two amino acid proline (P) would
lead to the formation of secondary structures in the short peptide sequence
rendering a more unique 3-D structure for a short peptide rather than a straight
one. Theoretically, these would result in an immunogen with higher antigenicity.
The synthetic full length peptide was purified to >85% by HPLC and the
net peptide content was 77.4% in the purified solution (New England Peptide
Inc., MA, USA). The peptide was conjugated to a highly immunogenic and widely
used carrier protein, KLH (keyhole limpet hemocyanin), before being injected into
two rabbits systematically. We first tested the 5-HT4R antibodies on HEK cells
expressing intact (control) or exon 5 deleted (cKO) Htr4 cDNA described earlier
in section 2.3.3 (Figure 2.7.C).
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Figure 2.7. Custom antibody generation against mouse 5-HT4R.
(A) Amino acid sequence and relevant information of custom immunogen peptide. CL-3:
cytoplasmic loop 3. # aa: number of amino acids. Seq: sequence. m 5HT4R: mouse 5HT4 receptor.
(B) Predictive analysis of antigenicity of mouse 5-HT4R sequence (Courtesy of Green
Mountain Antibodies) Selected peptide (red rectangle) show antigenicity that other
possible sequences (left and right panels).
(C, D) Polyclonal antibodies generated against custom m5-HT4R peptide from two
rabbits, rb1 (C) and rb2 (D), were used for immunofluorescence (green) of HEK cells
expressing either control or cKO 5-HT4R. anti-MYC staining (red) was used as
colabeling to detect 5-HT4R. Note the colocalization of rb1 and rb2 x 5-HT4R with MYC
in control panels. Also note the weaker labeling of rb1 x 5-HT4R in cKO panel. Scale
bars, 50µm.

53

rb1 x 5-HT4R labeling colocalized with MYC staining in control while it did
not detect cKO 5-HT4R as efficiently, suggesting that it was able to detect intact
5-HT4R better than cKO 5-HT4R. rb2 x 5-HT4R labeling colocalized with MYC
staining in control as well as in cKO, suggesting that although it specifically
detects the mouse 5-HT4R in HEK cells, it may not discriminate between intact 5HT4R and mutant 5-HT4R. Together these data indicated that our custom
polyclonal rabbit antibodies were able to detect overexpressed mouse 5-HT4R in
HEK cells, rb1x 5-HT4R displaying some selectivity towards the cKO 5-HT4R.
Next, we tested the custom antibodies on the mouse brain tissue. Custom
peptide was mixed with the antibodies as a negative control. DAPI was used as a
counter stain to visualize all nuclei. In mouse brain tissue, rb1 x 5-HT4R antibody
showed specific labeling in the hippocampus and neocortex. For example, in the
dentate gyrus (DG) of a wildtype (WT) mouse, rb1 x 5-HT4R labeled the granule
cells and some but not all cells in hilus (Figure 2.8A). When the peptide was
added, the specific staining in DG was not observed. In somatosensory cortex
(Figure 2.8B), rb1 x 5-HT4R labeling was mostly specific to layers 5 and 6 in WT
mice with some staining in higher layers. Although there was some staining in the
cortex of Emx1/Htr4 cKO mice, it was not as layer-specific and defined.
Together, these results indicate that our custom rb1 x 5-HT4R antibody showed
staining of 5-HT4R in the hippocampus and neocortex in a similar pattern to the
expected expression, and that it is a novel tool for specific immunolabeling of 5HT4R.
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Figure 2.8. Custom rb1 x 5-HT4R antibody showed specific immunostaining on
mouse brain tissue.
(A) Fluorescent confocal images showing the immunolabeling of rb1 x 5-HT4R (left) and
rb1 x 5-HT4R mixed with custom immunogen peptide (right) in dentate gyrus (DG) of a
wildtype mouse (green). DAPI was used as a nuclear counterstain (blue). Note that the
staining in granule cell layer (GC) was not observed when peptide was added. In
addition, rb1 x 5-HT4R stained some but not all cells in hilus. ML: molecular layer. Scale
bars 50 µm.
(B) Tiled fluorescent confocal images showing the immunolabeling of rb1 x 5-HT4R
(green) in the somatosensory cortices of a wildtype (WT, above) and an Emx1/Htr4 cKO
(cKO, below) mice. Note that the staining was localized in layer 5 and 6 in WT but not in
cKO. Scale bars 50 µm.
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2.4. Anxiety and depression related behaviors and behavioral
antidepressant responses

After confirming the loss of functional 5-HT4R following Cre-mediated
recombination in the cKO mice, we next tested whether pallial 5-HT4R is
necessary for regulating anxiety, mood and behavioral responses to chronic
SSRI treatment. To this end, Emx1/Htr4 cKO mice were put through a battery of
behavioral assays assessing anxiety and depression related behaviors with or
without chronic SSRI treatment.
Figure 2.9A shows the timeline for drug treatment and following
behavioral assays. Briefly, 8-week-old Emx1/Htr4 cKO mice and their Cre
negative Htr4-floxed littermates (WT, control) were either given 0.167 mg/ml
fluoxetine (FLX) (~18 mg/kg/day) or vehicle (VEH) in drinking water for 18 days
(Schmidt et al., 2012). For behavioral phenotyping, a battery of assays was
performed with four groups (WT-VEH, WT-FLX, cKO-VEH, cKO-FLX; n= 33, 30,
28, 28, respectively), combining three cohorts, unless otherwise noted. The drug
treatment continued until the end of behavioral assessments.

2.4.1. Thigmotaxis and locomotor activity in the open field test
Thigmotaxis is a measure of anxiety-like behavior which is the ratio of time
a mouse spends near the walls of an open field (OF) arena. It measures the
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balance between the innate tendency of mice to avoid well-lit, open areas and
their drive to explore novel environments (Gould et al., 2009).
In the OF test, each mouse was placed in a high-walled square arena and
tracked for 60 mins (Figure 2.9B). In the first 10 mins of the OF test, Emx1/Htr4
cKO and their control littermates (WT) did not show any significant difference in
thigmotaxis (time spent in periphery/total time) compared to their control
littermates (cKO-VEH: 0.751 ± 0.01, WT-VEH: 0.763 ± 0.01, p=0.55) (Figure
2.9C, left). Over 60 min, Emx1/Htr4 cKO mice showed slightly increased
thigmotaxis compared to WT (Figure 2.9C, right) although this difference did not
reach statistical significance (cKO-VEH: 0.724 ± 0.02, WT-VEH: 0.691 ± 0.02,
p=0.26), indicating the loss of 5-HT4R may be anxiogenic. When chronically
treated with fluoxetine, control mice showed significantly increased thigmotaxis,
both in first 10 mins (WT-VEH: 0.763 ± 0.01, WT-FLX: 0.879 ± 0.02, p<0.0001)
and over 60 mins (0.691± 0.02 versus 0.764 ± 0.02, respectively, p=0.01),
indicating that chronic fluoxetine treatment increased anxiety-like behaviors in the
OF. This result is consistent with other studies showing that naïve mice of some
strains, including C57B6J, when administered with fluoxetine chronically,
exhibited increased anxiety-like behaviors in some tests (Baek et al., 2015).
Although Emx1/Htr4 cKO displayed similar increase in thigmotaxis in the first 10
mins after fluoxetine treatment (cKO-VEH: 0.751 ± 0.02, cKO-FLX: 0.862 ± 0.02,
p<0.0001), this anxiogenic effect was not observed in cKOs over 60 mins (cKOVEH: 0.724 ± 0.02, cKO-FLX: 0.754 ± 0.03, p=0.33).
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Figure 2.9. The loss of pallial 5-HT4R resulted in slightly elevated anxiety-like
behaviors in the open field.
(A) Schematic showing the timeline for the battery of behavioral assays.
(B) Schematic of the open field (OF) test. Mice with increased anxiety-like behaviors
tend to spend more time in periphery (green) and less time in the center (red) compared
to wildtype mice.
(C) Emx1 Htr4/cKO mice (cKO-VEH) showed slightly increased thigmotaxis
(periphery/total time) in the OF in 60 min (right), compared to their control littermates
(WT-VEH). Following chronic fluoxetine (FLX) treatment, both Emx1 Htr4/cKO and WT
littermates showed significantly increased thigmotaxis in 10 mins (left) and 60 mins
(right), compared to vehicle treated counterparts.
(D) Emx1 Htr4/cKO mice (cKO-VEH) showed less locomotor activity (total distance) in
the first 10 mins of the OF test, compared to control littermates (WT-VEH). There was no
significant effect of chronic fluoxetine on the locomotor activity. Data are represented as
mean ± SEM. Two-way ANOVA followed by post hoc Fisher’s LSD test. *p<0.05,
****p<0.0001.
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Together, these results indicate that 5-HT4R in the pallium may mediate anxietylike behaviors and the anxiogenic responses to chronic fluoxetine treatment in
mice.
Spontaneous locomotor activity is also measured in the open field as total
distance traveled (cm). Since tests measuring anxiety-like behaviors rely on the
locomotor activity, it should be taken into account while interpreting anxiety-like
behaviors. The activity data is shown in 10 min bins in Figure 2.9D. In the first 10
min, Emx1/Htr4 cKO mice were less active compared to their WT littermates
(WT-VEH: 2044 ± 96 cm, cKO-VEH: 1711 ± 81 cm, p=0.02). However, over 60
min, the difference in the spontaneous locomotor activity between groups was
not statistically significant (p=0.17, Repeated measures two-way ANOVA).
Therefore, either the loss of 5-HT4R or fluoxetine treatment did not alter
locomotor activity in the OF over 60 min.

2.4.2. Elevated-plus maze test
The elevated-plus maze (EPM) is a “plus” shaped maze with two open
arms located at opposite sides connected by a neutral center to two
perpendicular closed arms (Figure 2.10A). The mice were placed in the center,
facing an open arm, and their time spent in open versus closed arms in 5 mins
were calculated as a measure of anxiety. Similar to the thigmotaxis in the OF, the
EPM employs the innate conflict between the tendency to explore versus the
aversion from a well-lit open environment. The commonly used anxiety measures
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in the EPM are the amount of time spent in the open arms, the amount of time
spent in the closed arms and the ratio of time spent in open versus both arms
(Walf and Frye, 2007).
Emx1/Htr4 cKO mice spent significantly less time spent in the open arms
compared to their WT littermates (cKO-VEH: 26.3 ± 6.1 s, WT-VEH: 51.6 ± 6.9 s,
p=0.0085) (Figure 2.10B), indicating that the loss of 5-HT4R resulted in
increased anxiety-like behaviors. Following chronic treatment with fluoxetine,
control mice showed significantly less time in the open arms (WT-VEH: 51.6 ±
6.9 s, WT-FLX: 5.7 ± 2.2 s, p<0.0001), while chronic fluoxetine treated
Emx1/Htr4 cKO mice did not display a significant difference in time spent in open
arms compared to VEH treated cKO mice (cKO-VEH: 26.3 ± 6.1 s, cKO-FLX:
27.4 ± 9.4 s, p=0.91). These results indicated that while increasing anxiety-like
behaviors in naïve mice, chronic fluoxetine treatment did not induce similar
behaviors in the absence of 5-HT4R in the EPM, a result similar to the OF.
Since the EPM also relies on locomotor responses, we also measured the
velocity during the test. There were no significant differences between groups
(WT-VEH-: 6.2 ± 0.5 cm/s, WT-FLX: 5.2 ± 0.4 cm/s, cKO-VEH: 5.3 ± 0.6 cm/s,
cKO-FLX: 5.3 ± 0.5 cm/s, p=0.35, two-way ANOVA) (Figure 2.10C). Together,
these results suggest that 5-HT4R in the pallium mediates anxiety-like behaviors
and the anxiogenic responses to chronic fluoxetine treatment in mice.
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Figure 2.10. The loss of pallial 5-HT4R led to increased anxiety-like behaviors in
the elevated plus maze.
(A) Schematic representation of the elevated plus maze (EPM) test. Mice were placed in
the center, facing an open arm, and the time they spent in the open versus closed arms
in 5 mins were calculated as a measure of anxiety-like behavior.
(B) Emx1/Htr4 cKO (cKO-VEH) spent significantly less time in the open arms compared
to their control littermates (WT-VEH). Following chronic treatment with fluoxetine (FLX),
Emx1/Htr4 cKO mice (cKO-FLX) did not display a significant difference in time spent in
open arms compared to vehicle (VEH) treated cKO mice (cKO-VEH) whereas control
mice (WT-FLX) spent significantly less time in the open arms compared to WT-VEH.
(C) There were no significant differences between groups in the velocity in the EPM.
Data are represented as mean ± SEM. Two-way ANOVA followed by post hoc Fisher’s
LSD test. **p<0.01, ****p<0.0001, n.s. p>0.05.
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2.4.3. Novelty suppressed feeding test
Hyponeophagia, the inhibition of feeding produced by novelty, provides a
measure of anxiety-related behavior in rodents. It can be evoked by the novelty
of the test environment compared to the housing environment. Hyponeophagiabased tests are also conflict tests in which animals face a choice between
engaging in feeding and neophobic behaviors. While hyponeophagia-based tests
offer strong predictive validity as anxiety measures, they have also found to
predict the time-course of action of many therapeutic compounds including
SSRIs. For example, the novelty suppressed feeding (NSF) test is one of the few
tests that is responsive to chronic fluoxetine administration in mice (Dulawa and
Hen, 2005). Therefore, the NSF is popularly used to study the mechanisms
underlying therapeutic effects of chronic antidepressant treatment.
In the NSF, mice were food deprived for 24 h before the test to instigate
feeding behavior. The efficiency of food deprivation was measured as decreased
body weight (data not shown). Mice were then tested in a brightly lit arena where
a food pellet was placed in the middle and the latency to bite the food was
measured in 15 min-trials (Figure 2.11A). Since the NSF relies on feeding, each
animal was put in a clean cage similar to their home cage for 30 min with food ad
libidum after each trial to measure home cage feeding behavior.
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Figure 2.11. Emx1/Htr4 cKO mice did not show a difference in anxiety-like
behaviors in the novelty suppressed feeding (NSF) test and responded to chronic
fluoxetine treatment.
(A) Schematic representation of the novelty suppressed feeding (NSF) test. The latency
to bite the food of 24-hour fasted mice in a novel environment was calculated as a
measure of anxiety-like behavior.
(B) Emx1/Htr4 cKO mice (cKO-VEH) did not show any significant differences in the
latency to bite the food compared to their control (WT-VEH) littermates. Following
chronic treatment with fluoxetine, both Emx1/Htr4 cKO mice and WT littermates showed
significant decrease in the latency to bite compared to vehicle treated counterparts.
(C) There were no significant differences between groups in their home cage food
intake.
Data are represented as mean ± SEM. Two-way ANOVA followed by post hoc Fisher’s
LSD test. **p<0.01, ***p<0.001, n.s. p>0.05.

63

Emx1/Htr4 cKO mice did not show any significant differences in the
latency to bite the food compared to their control littermates (cKO-VEH: 475 ± 37
s, WT-VEH: 511 ± 36 s, p=0.47, n=19, 20, respectively) (Figure 2.11.B),
indicating that they did not display any difference in the levels of anxiety-like
behaviors in the NSF. Following chronic treatment with fluoxetine, Emx1/Htr4
cKO mice and WT littermates showed similarly significant decrease in the latency
to bite compared to vehicle treated counterparts (WT-VEH/FLX: 511 ± 36 / 336 ±
37 s, p=0.0009, n=20/19; cKO-VEH/FLX: 475 ± 37 / 333 ± 33 s, p=0.0066,
n=19/19). None of the groups showed significant differences in their home cage
feeding (WT-VEH: 0.35 ± 0.02 g, WT-FLX: 0.35 ± 0.03 g, cKO-VEH: 0.36 ± 0.03
g, cKO-FLX: 0.31 ± 0.02 g, p=0.26, Two-way ANOVA) (Figure 2.11C). Together,
these results indicate that the loss of 5-HT4R in the hippocampus and neocortex
did not alter the chronic antidepressant responses in NSF.

2.4.4. Tail suspension test
The tail-suspension test (TST) is a widely-used assay for screening
potential antidepressant drugs and behavioral characterization of genetically
modified mice to identify novel targets mediating depression and antidepressant
response. The test is based on the principle that mice subjected to inescapable
stress of being suspended by their tail, will move and struggle in an attempt to
escape. The amount of time they are not struggling (immobility) is used as an
indication of the level of behavioral despair.
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Figure 2.12. Emx1/Htr4 cKO mice did not display a difference in depression-like
behaviors in the tail suspension test (TST) and responded to chronic fluoxetine
treatment.
(A) Schematic representation of the tail suspension test (TST). Mice were suspended by
the tip of their tails for 6 min, and the immobility time was measured in the last 4 min as
an indication of the level of behavioral despair.
(B) Emx1/Htr4 cKO mice (cKO-VEH) did not exhibit any differences in immobility
compared to their control (WT-VEH) littermates. Both Emx1/Htr4 cKOs and controls
treated with chronic fluoxetine showed significantly decreased immobility compared to
vehicle treated counterparts.
Data are represented as mean ± SEM. Two-way ANOVA followed by post hoc Fisher’s
LSD test. ****p<0.0001, n.s. p>0.05.
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Acute and chronic treatments with variety of antidepressants including SSRIs
have been reported to decrease the immobility in mice during the TST (O'Leary
and Cryan, 2009).
In the TST, mice were suspended by the tip of their tails for 6 min, and the
immobility time was measured in the last 4 min (Figure 2.12A). Emx1/Htr4 cKO
did not exhibit any differences in immobility compared to their control (WT)
littermates (cKO-VEH: 128 ± 6 s, WT-VEH: 131 ± 5 s, p=0.74) (Figure 2.12B),
indicating that they do not show any difference in the levels of despair-like
responses. In addition, both Emx1/Htr4 cKOs and controls treated with chronic
fluoxetine showed significantly decreased immobility compared to vehicle treated
counterparts (WT-VEH/FLX: 131 ± 5 / 80 ± 8 s, p<0.0001; cKO-VEH/FLX: 128 ±
6 / 80 ± 9 s, p<0.0001). Together, these results indicate that the loss of 5-HT4R in
the hippocampus and neocortex does not affect the depression-like behaviors
and chronic antidepressant responses in the TST.

2.4.5. Forced swim test
The forced swim test (FST) is another most commonly used behavioral
assay to screen depression-related and antidepressant behavior. It is also a
despair based assay in which mice are subjected to inescapable stress of
swimming and immobility is the measure of depressive-like behavior. Both acute
and chronic treatments with variety of antidepressants including SSRIs have
been reported to decrease the immobility in mice during the FST (Cryan and
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Lucki, 2000). It has also been used for behavioral characterization of genetically
modified mice to assess the levels of despair-like behavior and to identify targets
for novel antidepressants (Nestler et al., 2002).
In the FST, mice were placed in a cylinder with water for 6 min, and the
immobility time was measured in the last 4 min (Figure 2.13A). Emx1/Htr4 cKO
mice did not display any significant difference in immobility compared to their
control (WT) littermates (cKO-VEH: 132 ± 7 s, WT-VEH: 140 ± 6 s, p=0.38)
(Figure 2.13B), indicating that they do not show any difference in the levels of
despair-like responses. Emx1/Htr4 cKOs and controls treated with chronic
fluoxetine showed significantly increased immobility compared to vehicle treated
counterparts (WT-VEH/FLX: 140 ± 6 / 177 ± 5 s, p=0.0002; cKO-VEH/FLX: 132 ±
7 / 167 ± 9 s, p=0.0006), showing an opposite effect from the expected
antidepressant-like response, leading to an inconclusive result. Other studies
have also reported that the observation of antidepressant-like response in the
FST depends on the strain of mice, the antidepressant and its dose (David et al.,
2003; Dulawa et al., 2004; Lucki et al., 2001). Together with the TST, these data
indicate that 5-HT4R in the hippocampus and neocortex may not be necessary
for mediating depressive-like and antidepressant behaviors in mice.
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Figure 2.13. Emx1/Htr4 cKO mice did not show a difference in depression-related
behaviors in the forced swim test (FST).
(A) Schematic representation of forced swim test (FST). Mice were placed in a cylinder
with water for 6 mins, and the immobility time was measured in the last 4 mins as an
indication of the level of behavioral despair.
(B) Emx1/Htr4 cKO mice (cKO-VEH) did not display any significant difference in
immobility compared to their control (WT-VEH) littermates. Emx1/Htr4 cKOs and
controls treated with chronic fluoxetine showed significantly increased immobility
compared to vehicle treated counterparts.
Data are represented as mean ± SEM. Two-way ANOVA followed by post hoc Fisher’s
LSD test. ***p<0.001, n.s. p>0.05.
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2.4.6. Splash test
In mice, grooming behavior serves the purpose of hygiene as well as other
rewarding functions such as stress reduction and social interaction. It is sensitive
to stress and various genetic and pharmacological manipulations. For example,
mouse models with depression-like behaviors generally display poor coat status,
such as matte, dirty, and unkempt coat, whereas antidepressant treatments tend
to reverse this phenotype (David et al., 2009; Griebel et al., 2002).
To measure induced grooming, mice were sprayed with 10% sucrose on
their lower back (Figure 2.14A). Grooming time was measured in 5 min trials and
displayed as percent of control (WT-VEH). Emx1/Htr4 cKO mice groomed slightly
more compared to their control littermates, although this difference did not reach
statistical significance (cKO-VEH: 112.3 ± 6.3 %, WT-VEH: 100 ± 4.9 %, p=0.15,
n= 20, 20 respectively) (Figure 2.14B), indicating that Emx1/Htr4 cKO mice may
have displayed slightly enhanced hedonic behaviors. Following chronic treatment
with fluoxetine, both Emx1/Htr4 cKO and control did not show a significant
change in time spent grooming compared to vehicle treated counterparts (WTVEH/FLX: 100 ± 4.9 / 108 ± 5.6 %, p=0.34, n=20/17; cKO-VEH/FLX: 112.3 ± 6.3
/ 106 ± 9 %, p=0.48, n=20/17), indicating that chronic fluoxetine did not regulate
hedonic behaviors in the splash test in these mice. Together, these results
suggest that pallial 5-HT4R may mediate hedonic behaviors.
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Figure 2.14. Emx1/Htr4 cKO mice showed slightly higher grooming in the splash
test.
(A) Schematic representation of the splash test. Mice were squirted with 10% sucrose by
a spray bottle on their back. Grooming time was measured in 5-min as a measure of
hedonic behavior.
(B) Emx1/Htr4 cKO mice (cKO-VEH) groomed slight more compared to their control
littermates (WT-VEH). Following chromic treatment with fluoxetine, Emx1/Htr4 cKO and
control littermates did not show a significant change in time spent grooming compared to
vehicle treated counterparts.
Data are represented as mean ± SEM. Two-way ANOVA followed by post hoc Fisher’s
LSD test. ***p<0.001, n.s. p>0.05.
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2.4.7. Sucrose preference test
The sucrose preference test is another reward-based assay assessing
anhedonia-like phenotype in mice. Sucrose has a natural hedonic value and
given a choice between sucrose and water, mice prefer sucrose. A drop in the
ratio of sucrose to water consumption below 65% is established as anhedonialike behavior (Strekalova et al., 2004).
In the sucrose preference test, non-treated naïve mice were water
deprived for 24 h to encourage more drinking during testing. Each mouse was
then placed in a clean cage containing a 1% sucrose bottle and a water bottle
(Figure 2.15A). Sucrose and water consumption for 6 hours was measured by
the decrease in the weight of the bottles. At the 3-hour mark, bottles were
switched places to avoid side preference. Sucrose preference was calculated for
6 h as the ratio of total 1% sucrose consumed (g) to total drinking. Since the
sucrose preference test relies on drinking, we calculated total drinking amount to
see whether water deprivation was effective. Mice without an enhanced drinking
drive were excluded from analysis (Total drinking cutoff = 1 g)
There was not any significant difference in total drinking amount between
Emx1/Htr4 cKO and control littermates (WT: 3.6 ± 0.3, cKO: 3.9 ± 0.5, p=0.59, n=
16, 11, respectively) (Figure 2.15D). Emx1/Htr4 cKO mice and control littermates
showed similar over 85% preference for 1% sucrose over water (WT: 0.88 ±
0.02, cKO: 0.86 ± 0.03, p=0.62) (Figure 2.15B).
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Figure 2.15. Emx1/Htr4 cKO mice did not exhibit a difference in hedonic behaviors
in the sucrose preference test.
(A) Schematic representation of sucrose preference test. Each 24-hour water deprived
mouse was placed in a cage containing a 1% sucrose bottle and a water bottle. Sucrose
and water consumption for 6 hours was measured and sucrose preference was
calculated as a measure of hedonic behavior.
(B) Both Emx1/Htr4 cKO mice and control littermates (WT) showed over 85% preference
for 1% sucrose.
(C) There was not any difference in the amount of sucrose consumption between
groups.
(D) There was not any significant difference in total drinking amount between groups.
Data are represented as mean ± SEM. Two-tailed unpaired t-test. n.s. p>0.05.
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There was also no difference in the amount of sucrose consumption between
groups (WT: 3.2 ± 0.3 g, cKO: 3.4 ± 0.5, p=0.80) (Figure 2.15C). Together these
data indicate that the loss of pallial 5-HT4R did not alter hedonic behaviors in
mice in the sucrose preference test.

2.4.8. Marble burying test
The animal models of anhedonia show decreased marble burying, and
anxiolytics and SSRIs reduce the marble burying behavior in mice (GreeneSchloesser et al., 2011). Hence, marble burying has been associated with
changes in anxiety and mood related behaviors. Mice spontaneously dig as an
innate behavior when given a suitable substrate such as deep bedding. A way of
measuring the digging behavior is the marble burying test in which a set of
marbles is distributed on the surface of a bedding-filled cage. The number of
marbles buried by displaced bedding due to digging after a set time is counted.
To measure digging, we placed equally spaced 12 marbles (4x3) on a
deep woodchip bedding filled in a small mouse cage with open top (Figure
2.16A). The number of marbles buried in each 15 min trial per mouse was
counted as a measure of spontaneous digging. Emx1/Htr4 cKO did not exhibit
any differences in the number of marbles buried compared to their control
littermates (cKO-VEH: 9.7 ± 0.6, WT-VEH: 10.7 ± 0.3, p=0.38, n=7, 11,
respectively) (Figure 2.16B), indicating that they do not show any difference in
the levels of spontaneous digging.
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Figure 2.16. Emx1/Htr4 cKO mice did not show a difference in digging behavior
and responded to chronic fluoxetine treatment in the marble burying test.
(A) Example images of mice tested in marble burying test for 15 min. Left, a control mice
(WT-VEH) having buried 8 marbles. Right, a control mice treated with fluoxetine (WTFLX) having buried zero marbles.
(B) Emx1/Htr4 cKO (cKO-VEH) did not exhibit any differences in the number of marbles
buried compared to their control littermates (WT-VEH). Both Emx1/Htr4 cKOs and
controls treated with chronic fluoxetine (FLX) buried significantly decreased number of
marbles compared to vehicle (VEH) treated counterparts.
Data are represented as mean ± SEM. Two-way ANOVA followed by post hoc Fisher’s
LSD test. ****p<0.0001, n.s. p>0.05.
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Emx1/Htr4 cKOs and controls treated with chronic fluoxetine buried
significantly decreased numbers of marbles compared to vehicle treated
counterparts (WT-VEH/FLX: 10.7 ± 0.3 / 3.4 ± 1.1, p<0.0001, n=11/10; cKOVEH/FLX: 9.7 ± 0.6/ 2.9 ± 1.3, p<0.0001, n=7/8), showing a significant behavioral
antidepressant effect independent of pallial 5-HT4R. Together, these results
indicate that the loss of pallial 5-HT4R did not affect baseline digging behavior or
chronic antidepressant-dependent changes.

2.4.9. Acoustic startle response and pre-pulse inhibition
The acoustic startle reflex is a defensive motor response to a sudden,
intense auditory stimulus. The measurement of acoustic startle responses (ASR)
can provide general information regarding sensorimotor processing (Geyer and
Swerdlow, 2001), but it is also subjected to modulatory influences from higher
cortical and limbic structures (Kaviani et al., 2004). Prepulse inhibition (PPI) of
the ASR is the suppression of the startle response when a startling acoustic
stimulus is preceded by an immediate, weaker pre-stimulus (Figure 2.17A). PPI
is an operational measure of sensorimotor gating, and used as a clinical measure
of schizophrenia (Valsamis and Schmid, 2011a). However, startle reactivity and
inhibition of startle are altered in some anxiety and mood disorders, and
associated animal models. Enhanced ASR was linked with increased anxiety and
its physiological features (Miller and Gronfier, 2006), while decreased ASR was
observed in patients with anhedonia (Giakoumaki et al., 2010).
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To measure ASR, acoustic stimuli were presented in five different
intensities (120, 110, 100, 90 and 80 dB), each for four trials in a pseudorandom
order. Maximum startle responses (Vmax) were recorded for each trial and
averaged for each stimulus intensity per subject. Emx1/Htr4 cKO mice showed
significantly larger startle response at the 120 dB intensity of acoustic stimulus,
compared to their control littermates (Vmax at 120 dB; cKO-VEH: 484 ± 38, WTVEH: 404 ± 36, p=0.001, n= 21, 21, respectively) (Figure 2.17B), demonstrating
that the loss of pallial 5-HT4R led to increased startle responses. Following
chronic treatment with fluoxetine, both Emx1/Htr4 cKO mice and control
littermates showed significantly decreased startle responses overall (Two-way
ANOVA, WT-VEH/FLX: p=0.0078, cKO-VEH/FLX: p=0.0004), indicating that
chronic fluoxetine treatment in mice reduces ASR independent of pallial 5-HT4R.
There was not any significant difference in ASR between Emx1/Htr4 cKO and
their control littermates treated with chronic fluoxetine, suggesting that the
treatment was compensated for the effects of the loss of pallial 5-HT4R.
To measure PPI, 120 dB acoustic stimuli preceded by four different prepulse (PP) intensities (0, 3, 6, 12 dB) were presented, each for ten trials in a
mixed order. Maximum startle responses (Vmax) were recorded for each trial and
averaged for each pre-pulse intensity per subject. PPI was measured as percent
(%) inhibition which is the percent decrease in startle response in PP3, PP6 and
PP12 compared to PP0 per subject.
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Figure 2.17. The loss of pallial 5-HT4R led to increased acoustic startle responses.
(A) Schematic representation of the acoustic startle and prepulse inhibition paradigm.
Mice that are subjected to a sudden, intense auditory stimulus exhibit startle responses.
Prepulse inhibition (PPI) is the suppression of the startle response when a startling
acoustic stimulus is preceded by an immediate, weaker pre-pulse (PP).
(B) Emx1/Htr4 cKO mice (cKO-VEH) showed significantly larger startle response at the
120 dB, compared to their control littermates (WT-VEH). Following chronic treatment
with fluoxetine, both Emx1/Htr4 cKO mice and control littermates showed significantly
decreased startle responses.
(C) Emx1/Htr4 cKO (cKO-VEH) did not show any changes in PPI, compared to control
littermates (WT-VEH). Following chronic treatment with fluoxetine, both Emx1/Htr4 cKOs
and controls exhibited significantly enhanced PPI.
Data are represented as mean ± SEM. Two-way ANOVA followed by post hoc Fisher’s
LSD test. *p<0.05, ¥¥p<0.01, ¥¥¥p<0.001.
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Emx1/Htr4 cKO did not show any changes in the inhibition of the startle
reflex with any pre-pulse stimuli and overall, compared to control littermates
(Two-way ANOVA, p=0.88) (Figure 2.17C). Following chronic treatment with
fluoxetine, both Emx1/Htr4 cKOs and controls exhibited significantly enhanced
pre-pulse inhibition overall (Two-way ANOVA, WT-VEH/FLX: p=0.0004, cKOVEH/FLX: p=0.0074), indicating that chronic fluoxetine treatment in mice
enhances the PPI independent of pallial 5-HT4R. Even though baseline startle
responses were lower in Emx1/Htr4 cKO, the prepulse inhibition of startle was
more significant with fluoxetine, indicating that the decrease in ASR in the cKO
was not a confounding factor in PPI.

2.4.10. Social Interaction
Social withdrawal represents a common symptom in psychiatric conditions
such as depression, social anxiety, and PTSD (Ressler et al., 2015). The threechamber sociability test was developed as an ethologically relevant test for
rodents to measure sociability and lower sociability may be associated with
increased anxiety-like behaviors (File, 1985; Kaidanovich-Beilin et al., 2011). In
this test, the subject is placed in the center chamber and allowed to freely
explore the other two chambers, one of which contains a novel mouse while the
other contains an unfamiliar inanimate object (Lego® piece) (Figure 2.18A).
Decreased time spent in interacting with the novel mouse can be interpreted as
social avoidance, an anxiety-related phenotype.
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Figure 2.18. Emx1/Htr4 cKO mice showed normal social interaction.
(A) Schematic representation of the three-chamber social interaction test. Mice were
placed in the center chamber and allowed to freely explore the other two chambers, one
of which contains a strange mouse (red) while the other contains a Lego® piece (yellow
and green), both inside identical wire containment cups. Time spent in interacting with
the novel mouse is a measure of social interaction.
(B) Emx1/Htr4 cKO did not show any difference in time spent interacting the novel
mouse in the three-chamber sociability test, compared to control littermates (WT-VEH).
For both groups, social interaction time was significantly higher than time spent
interacting with Lego®.
Data are represented as mean ± SEM. Two-way ANOVA followed by post hoc Fisher’s
LSD test. ****p<0.0001, n.s. p>0.05.
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Emx1/Htr4 cKO did not show any difference in time spent interacting the
novel mouse in the three-chamber sociability test, compared to control littermates
(cKO: 85 ± 4 s, WT: 81 ± 5 s, p= 0.32, n=28, 25 respectively) (Figure 2.18B). For
both groups, social interaction time was significantly higher than time spent
interacting with Lego®. Together, these result show that Emx1/Htr4 cKO mice did
not show any social anxiety-like phenotype in this paradigm.

2.4.11. Summary of the behavior analysis of Emx1/Htr4 cKO mice
The loss of functional 5-HT4R from excitatory neurons in mouse pallial
brain structures including the hippocampus and neocortex led to elevated
anxiety-like behaviors in mice; significantly in the EPM and ASR, and slightly in
the OF. This effect was not detected in other anxiety-based assays such as NSF
and three-chamber social interaction. Chronic antidepressant treatment was
anxiogenic in control mice in the OF and EPM. Interestingly, this response was
not observed when the functional 5-HT4R in the pallium was ablated. In addition,
the loss of 5-HT4R in the pallium did not alter depression-like behaviors and
chronic antidepressant responses in the NSF, TST, FST, sucrose preference test
and marble burying test. It only led to slightly enhanced basal hedonia levels in
splash test. Finally, the ablation of pallial 5-HT4R did not result in any changes in
basal sensorimotor processing during the PPI assessment while chronic
fluoxetine improved it independent of 5-HT4R.
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2.5. Discussion

2.5.1. Generation of new tools to study 5-HT4R function in the brain
We have successfully generated a new tool, Htr4-floxed mice, to study the
function of 5-HT4R in specific cell types. By employing an intersectional strategy
using Emx1-Cre and Htr4-floxed mice, we restricted the conditional knockout of
the 5-HT4R in the excitatory neurons in brain regions of pallial origin, such as the
hippocampus and neocortex. This approach allowed us to analyze 5-HT4R
function in anxiety and mood related behaviors in a region and cell type specific
manner. In addition, a conditional knockout strategy may circumvent
compensatory neuroplastic changes in a constitutive knockout approach to some
extent. Therefore, our Htr4 conditional knockout mice is an invaluable tool for the
investigation of the function of 5-HT4R, not only in the emotion circuitry but also
in other biological processes. We also identified an shRNA for the efficient
knockdown of Htr4 expression as a valuable tool for AAV-mediated gene
knockdown experiments.
We initially crossed Htr4-floxed mice to Emx1-Cre reporter line and
generated Emx1/Htr4 cKO mice to confirm the functional loss of 5-HT4R in pallial
structures and investigate its behavioral consequences. We showed the deletion
of exon 5 in the mouse hippocampus and neocortex by qRT-PCR at the RNA
level. While the exon 5 was deleted, exon 5 deleted Htr4 mRNA was still being
produced. The increase in the cKO mRNA expression in the hippocampus of
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Emx1/Htr4 cKO was possibly due to a compensation mechanisms detecting the
absence of wildtype 5-HT4R and effectively increasing the Htr4 transcription.
Nonetheless, this would not have any effect on the efficiency of the cKOs.
We expected that the deletion of exon 5 in Htr4 would result in a truncated
protein due to immediate early stop codons generated right after exon 5. This
was not the case, at least in a heterologous system, when we cloned the mutant
Htr4 cDNA and overexpressed in HEK cells. We detected the expression of the
cKO 5-HT4R protein tagged with MYC epitope using anti-MYC
immunofluorescence. This could be due to the possibility that the overexpression
may have led to some translational read through at the early stop codons.
Nevertheless, the cKO 5-HT4R seemed not to localize on the cellular membrane.
Furthermore, we confirmed that the cKO 5-HT4R was non-functional as it did not
increase intracellular cAMP levels upon 5-HT4R agonist stimulation in HEK cells.
As another tool to study 5-HT4R in laboratory settings, we have
successfully generated a novel custom polyclonal antibody that could detect the
mouse 5-HT4R protein in both a heterologous system and fixed mouse brain
tissues. Our initial commercial antibody screening did not yield any reliable
antibodies possibly due to the fact that they were generated against custom
peptide sequences of human 5-HT4R. Our custom antibody was generated
against a custom peptide sequence in the third cytoplasmic domain of mouse 5HT4R. The difference in immunolabeling between two batches produced by two
rabbits was possibly a result of the heterogeneity in the immune responses
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between rabbits. Further studies using this antibody will help extend our
knowledge in the cellular localization of 5-HT4R in vivo.

2.5.2. 5-HT4R in the excitatory neurons of pallial origin mediates anxiety-like
behaviors
The behavioral analysis of Emx1/Htr4 cKO mice revealed decreased basal
levels of anxiety-like behaviors in the cKO. These data suggest that 5-HT4R may
be necessary in the excitatory neurons of pallial origin to mediate the anxiety
levels at appropriate levels.
The decrease in the locomotor activity in only the first 10 min of the open
field test in Emx1/Htr4 cKO mice may be attributed to attenuated response to
novelty as seen in the constitutive Htr4 knockout line (Compan, 2004). This may
be also interpreted as an anxiogenic response to the novel arena since the
locomotor activity is at normal levels for the rest of the OF test as the animal
habituates. In addition, the loss of 5-HT4R did not alter locomotor activity in the
EPM test. Therefore, we conclude that locomotor activity did not influence the
anxiety-like behavioral measurements over 60 min in the OF and in the EPM.
Moreover, enhanced acoustic startle responses seen following the ablation of
pallial 5-HT4R may be attributed to anxiogenic effects. On the other hand, other
anxiety-related behaviors such as hyponeophagia and social interaction were not
altered in Emx1/Htr4 cKO mice. This may be due to the differences in the nature
of the assays, such as the sensitivity in the measurement parameters, or the
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distinct factors inducing the anxiety-like behaviors. Furthermore, the expression
of 5-HT4R in the pallium was not necessary for the modulation of mood related
behaviors in mice in the TST, FST, sucrose preference test and marble burying
test. It is important to note that the slightly enhanced hedonic behaviors observed
in the splash test may be relevant to regulation of mood.
Our findings suggest that 5-HT4R mediates anxiety-like behavior through
modulating hippocampal and/or neocortical excitatory circuits. Further studies
using cell type specific driver lines in the hippocampus and cortex or spatially
restricted conditional manipulations of 5-HT4R expression is necessary to further
dissect the role of 5-HT4R in anxiety related behaviors.

2.5.3. Pallial 5-HT4R is not necessary for behavioral responses to chronic
SSRI treatment
We further investigated the involvement of pallial 5-HT4R in the
therapeutic actions of SSRIs. Our results suggest that 5-HT4R in the pallial
excitatory neurons is not necessary for antidepressant mediated behavioral
effects in the NSF, TST, FST, marble burying, acoustic startle responses and
PPI. Although chronic SSRI treatment increased the level of Htr4 mRNA
expression in p11 layer 5 pyramidal cells in neocortex, and the deletion of p11
from these cells blunted the responses to antidepressants, our results suggest
that this increase was not necessary to mediate the p11 dependent
antidepressant responses. Htr4 upregulation may be a result of secondary
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mechanisms and it may not play a critical role in the antidepressant response.
On the other hand, it is possible that 5-HT4R is mediating other characteristics of
antidepressant response (efficacy, time-course etc.) for which current behavioral
assays may not be sensitive enough to assess. An intriguing possibility
supported by our data is that 5-HT4R in the neocortex or hippocampus may
regulate other antidepressant effects that are not related to anhedonia or
despair-like behavior. In fact, our results showed that anxiogenic responses
induced by chronic fluoxetine were not observed when the functional 5-HT4R in
the pallium was ablated. This suggests that 5-HT4R may modulate anxiogenic
side effects of SSRIs that are observed in clinical settings in some patients
(Sinha et al., 2017), and in preclinical settings in naïve rodents (Baek et al.,
2015). Another possibility to consider is that the anxiogenic effects of fluoxetine
may have not been detectable in the OF and EPM due to the already anxiogenic
profile seen after the genetic manipulation.
We also showed that the loss of pallial 5-HT4R led to increased acoustic
startle responses, an indication for enhanced anxiety-like behaviors. However,
the effects of chronic fluoxetine, which was anxiogenic in the OF and EPM, on
ASR was diminishing suggesting that ASR may be a measure discriminating
between anxiogenic and antidepressant-like responses. On the other hand, PPI
was enhanced following treatment with chronic fluoxetine, suggesting an
enhancement in sensorimotor gating. This effect has also been documented in
other rodent studies (Vorhees et al., 2011) and SSRIs were indicated to reduce
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some symptoms of Schizophrenia patients (Singh et al., 2018). It is possible that
enhanced serotonergic tone acts on various circuitries responsible for the
execution and modulation of startle responses (emotion, sensorimotor gating
etc.). The mechanism of action of enhanced central serotonin on the circuitry of
startle reflex and the inhibition of startle via sensory gating is needed to be
studied more in detail for a better understanding on how SSRIs may change
these behaviors.

2.5.5. Caveats and future directions
We restricted the ablation of 5-HT4R to the pallium, including almost all
excitatory neurons in the hippocampus and neocortex, and some in basal and
lateral amygdala. It is possible that this manipulation may not be specific enough
to detect circuit or cell type specific roles of 5-HT4R in distinct emotive behaviors.
There may still have been adaptive changes compensating for the absence of 5HT4R in the pallium. Indeed, for example, neuroadaptations in cholinergic
systems such as the hyperfunction of muscarinic receptors maintains memory
processing in a constitutive Htr4 KO mice (Segu et al., 2010). Moreover, 5-HT4R
expressing neurons in the hippocampus, neocortex and amygdala may have
contradicting regulations on the same downstream circuits, shadowing its
functional deficit in defined circuits.
The discrepancy in the response of naïve control mice to chronic
fluoxetine (anxiogenic versus antidepressant-like) observed in anxiety-based

86

tests (EPM/OF versus NSF, respectively) may be due to the participation of
distinct brain areas engaged in each test. The NSF relies on feeding and it was
shown to respond to only chronic fluoxetine treatment. In addition, the daily drug
dosage, the timing and means of drug administration (injection, drinking water,
oral gauge etc.), and the mouse strain has been also shown as major sources of
variation in behavioral responses (Võikar et al., 2001). The inconclusive
response to chronic fluoxetine in the FST could also be ascribed to the mouse
strain since many studies found the effects of acute or chronic SSRI treatments
in C57Bl/6J mouse strain to be ineffective (Petit-Demouliere et al., 2005).
It remains to be investigated whether 5-HT4R is involved in the
development of the pathological anxiety and depression related behaviors upon
chronic stress and whether the treatment of the pathological anxiety and
depression in animal models of depression via SSRIs depend on the 5-HT4R at
any levels. Lastly, 5-HT4R may regulate other behaviors beyond anxiety and
mood in the hippocampus and cortex considering the involvement of these
regions in cognition, learning and memory which will be investigated in Chapter
5.

2.5.6. Conclusion
Our findings show that 5-HT4R in pallial excitatory neurons are necessary
to modulate anxiety-like behaviors, but does not mediate the antidepressant-like
behavioral responses to chronic SSRI administration. Following chapter will focus
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on dissecting the role of 5-HT4R in distinct cell populations in the hippocampus
and neocortex to better understand these results.
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CHAPTER 3.
DISSECTION OF CELL TYPE SPECIFIC 5-HT4 RECEPTOR FUNCTION
IN THE HIPPOCAMPUS AND NEOCORTEX IN ANXIETY AND DEPRESSION
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3.1. Introduction

The hippocampus and neocortex has been two of the most highly
implicated brain regions in the pathophysiology and treatment of anxiety and
mood disorders due to their extensive involvement in emotive and cognitive
circuitries. In Chapter 2, we investigated the consequences of the loss of function
of 5-HT4 Receptor in the excitatory circuits of pallium, including these two
regions. However, pallial neurons are comprised of many cell types which may
have opposing functions within the extended limbic circuit. Therefore, to tease
apart the function of 5-HT4R in more defined cell types and circuits, we
investigated the behavioral consequences of the conditional loss of 5-HT4R
specifically from either the hippocampus or a subpopulation of cortical layer 5a
projection neurons that express p11. Our results indicating a role for pallial 5HT4R in anxiety related behaviors and anxiogenic effects of antidepressants
emphasize the need to selectively target distinct cell populations to further
understand the underlying circuits mediating these behaviors.

3.1.1. Hippocampus in anxiety and depression

3.1.1.a. Hippocampal circuitry in the rodent brain
Understanding the function and modulation of hippocampal circuits within
its own boundaries and among other limbic structures requires a perspective of
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the physical and functional anatomy of hippocampal formation (for extended
review (The Hippocampus Book, 2007)). The hippocampus is a medial temporal
lobe structure that is crucially involved in episodic memory and spatial navigation
as well as emotional memory and responses (Strange et al., 2014). In animal
studies, the hippocampus describes dentate gyrus (DG) and cornu ammonis
(CA) subfields. Hippocampal formation is a more comprehensive term that also
includes subiculum complex and entorhinal cortex. It has a long, curved form that
is present across all mammals, and that runs along a dorsal (septal) to ventral
(temporal) axis in rodents, corresponding to a posterior-to-anterior axis in
humans. The major intrinsic circuitry is maintained throughout the long axis and
across species: a unidirectional circuit from the entorhinal cortex to the
hippocampus, specifically to the dentate gyrus - to - CA3 - to - CA1 - to - the
subiculum and back to the entorhinal cortex (Deng et al., 2010) (Figure 3.1A).
The dentate gyrus is comprised of three cell layers (Figure 3.1A). The
principal cell layer (granule cell layer) is made up of a densely-packed granule
cells. Superficial to this layer, the molecular layer is a relatively cell-free and
where the dendrites of granule cells lie. The granule cell and molecular layers
form the U-shaped structure that encloses the polymorphic cell layer, the third
layer of the dentate gyrus, in the hilus of DG. In this layer, mossy cells and
various types of interneurons are located (Freund and Buzsáki, 1996). The
dentate gyrus receives major glutamatergic input from the entorhinal cortex via
the perforant pathway that primarily innervates the molecular layer (van Groen et
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al., 2003). Other brain regions also projects to the DG via serotonergic,
norephinephrinergic, dopaminergic, cholinergic and GABAergic inputs. The
dentate gyrus projects to CA3 region outside this structure. Other projections are
made within DG amongst granule cells, interneurons, and hilar mossy cells.
The principal neuronal cell type of the CA fields is the pyramidal cell which
makes up most of the neurons in the pyramidal cell layer. Pyramidal cells have
basal dendrites that extends into the infrapyramidal region (stratum oriens) and
an apical dentride that extends towards the hippocampal fissure to the
suprapyramidal region (stratum radiatum) (Figure 3.1A). As in the dentate gyrus,
there is a heterogeneous group of interneurons that are scattered through all
layers (Freund and Buzsáki, 1996). Most of the synaptic input to CA fields arises
from within its own boundaries. CA3 and CA2 are heavily innervated by
collaterals of their own axons (i.e., associational connections), and from axons of
the contralateral CA3 and CA2 (i.e., commissural connections). CA1, in turn,
receives its heaviest input from collateral CA3 (via Schaffer collateral).
The hippocampus is connected to other brain regions through three major
fiber systems. The angular bundle carries fibers between the entorhinal cortex
and the other fields of the hippocampus (Deller et al., 1996). The fimbria-fornix
pathway interconnects the hippocampus with the basal forebrain, hypothalamus,
and brain stem (Daitz and Powell, 1954). Lastly, the dorsal and ventral
commissures connect the hippocampal formation across hemispheres (Laurberg,
1979).
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Figure 3.1. Hippocampal circuit and its role in anxiety and mood regulation.
A. An illustration of basic hippocampal circuitry. Modified from Deng et al. (2010).
DG: dentate gyrus, SUB: subiculum, ENT: entorhinal cortex, mi: molecular layer, gcl:
granule cell layer, pml: polymorph layer, sgz: subgranular zone, so: stratum oriens, pcl:
pyramidal cell layer, sr: stratum radiatum.
B. The neural circuitry of anxiety and mood involving the ventral hippocampus. Adapted
from Anacker et al. (20017). See text for details.
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3.1.1.b. The neural circuitry of anxiety and mood along the dorsoventral axis of
the hippocampus
Despite the conserved intrinsic circuitry, animal and human studies have
shown that the hippocampus is functionally not uniform along the septotemporal
(dorsoventral) axis (Strange et al., 2014). In rodents, lesion studies have been
used to examine the differential functions of the dorsal and ventral hippocampus
(dHIPP and vHIPP, respectively). These studies indicated that dorsal parts of the
hippocampus mediate cognitive functions, particularly spatial memory (Morris et
al., 1982) and contextual learning (Kheirbek et al., 2013). By contrast, the vHIPP
has been implicated in emotional behavior, social interactions and stress
resilience (Felix-Ortiz and Tye, 2014; Henke, 1990; Moser et al., 1993).
Furthermore, the human anterior hippocampus, which is analogous to the ventral
hippocampus in rodents, is smaller in patients with depression and larger in
antidepressant-treated patients than in healthy individuals (Boldrini et al., 2014).
Non-human primates with increased anxiety-like behavior and neuroendocrine
activity also show an increase in metabolism in the anterior hippocampus
(O'Leary and Cryan, 2014; Shackman et al., 2013).
The role of vHIPP in anxiety and mood regulation is also supported on the
basis that ventral connectivity with the other limbic structures regulating emotion
is heavier than those of dorsal. This circuit involves glutamatergic projections to
several structures that are involved in anxiety regulation, stress responses and
reward seeking (Figure 3.1B). For instance, the projections to the medial

94

prefrontal cortex (mPFC) promote anxiety and stress susceptibility (PadillaCoreano et al., 2016), and are also involved in antidepressant actions (Bagot et
al., 2015). Moreover, bidirectional connections between the vHIPP and the
amygdala have been implicated in fear and anxiety responses (Tovote et al.,
2015), social interaction (Felix-Ortiz and Tye, 2014), and the consolidation of
emotive memories (Richardson et al., 2004). There are also glutamatergic
projections from the vHIPP to the nucleus accumbens (NAc), promoting rewardseeking behavior in the absence of stress (Britt et al., 2012), while inducing
anxiety-like and depressive-like behavior during stress (Bagot et al., 2015).
Furthermore, glutamatergic projections from the vHIPP to bed nucleus of the stria
terminalis (BNST) drive the inhibition of hypothalamus–pituitary–adrenal (HPA)
axis activity and glucocorticoid release (Anacker et al., 2016).High levels of
glucocorticoids during chronic stress have been linked with depression, reduced
hippocampal neurogenesis and neuronal atrophy (David et al., 2009; Watanabe
et al., 1992)
It should be noted that differences in the connectivity with cortical and
subcortical structures along the dorsoventral axis of the hippocampus are
gradual, which suggests that functional differences along this long axis may also
exhibit a gradient-like organization (Amaral and Witter, 1989; Kjelstrup et al.,
2008). Given the extensive evidence suggesting a role for the hippocampus in
mediating emotive behaviors, it remains a central structure to identify specific
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cellular or molecular targets for better therapeutics in anxiety and mood
disorders.

3.1.1.c. Serotonergic modulation of the hippocampus
Consistent with the functional organization along the dorsoventral axis of
the hippocampus, the more ventral parts receive stronger monoamine
projections, such as serotonin (5-HT) (Gage and Thompson, 1980). The dorsal
raphe nucleus (DRN) serotonergic neurons projects extensively along the long
axis of the hippocampus whereas the projections from the median raphe nucleus
(MRN) is limited to dorsal parts (McQuade and Sharp, 1997). The serotonergic
terminals are primarily located in the subgranular zone of dentate gyrus
(Swanson, 1987).
Majority 5-HT receptors are expressed in the hippocampus. They display
expression patterns that varies along the dorsoventral axis, between the CA
fields and DG and amongst cell-types (Tanaka et al., 2012). Due to this
heterogeneous expression pattern and that many hippocampal neurons express
a combination of both excitatory and inhibitory 5-HT receptors with varying
affinity to 5-HT, the modulatory effect of 5-HT is under a complex regulation. For
example, in dentate gyrus granule cells, the inhibitory 5-HT1A heteroreceptors are
the highest expressed serotonin receptor (Yohn et al., 2017) with the most affinity
to 5-HT (Nichols and Nichols, 2008). Thus, the effect of 5-HT is overall inhibitory
in these cells. However, the co-expression of other excitatory receptors, such as

96

5-HT4R, has been shown to regulate the strength of this inhibitory action. For
example, in CA1, the stimulation of 5-HT4R has been shown to increase the
excitability of the pyramidal cells (Torres et al., 1995; 1994).
It has been appreciated that antidepressant treatment increase adult
hippocampal neurogenesis (Santarelli et al., 2003), some being preferentially in
the ventral DG (Banasr et al., 2006; Jayatissa et al., 2006). Some evidence
suggests that serotonin receptors in DG may mediate this action. For example, 5HT1AR in the DG was necessary for neurogenic effects of chronic fluoxetine
administration and behavioral antidepressant responses (Samuels et al., 2015).
Furthermore, a subchronic activation of 5-HT4R by an agonist was sufficient to
observe enhanced neurogenesis together with anxiolytic and antidepressant-like
behavioral responses (Lucas et al., 2007). Whether the hippocampal 5-HT4R
mediates these behaviors remains to be investigated.
Given that most 5-HT receptors are expressed on both excitatory and
inhibitory interneurons and can function in either a stimulatory or inhibitory
manner depending on the receptor subtype, it would be expected that the net
effect of 5-HT on hippocampal function depends on the local 5-HT concentration,
and the ratio and level of expression of different 5-HT receptor subtypes in a
particular population of cells. Thus, upon SSRI treatment, the change in local 5HT concentrations in distinct brain regions would determine which 5-HT receptor
subtypes become engaged. In addition, in disease conditions or after chronic
SSRI treatment, the desensitization or chronic activation of 5-HT receptors may
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lead to changes in 5-HTR expression. Therefore, understanding the functions of
5-HTRs in specific hippocampal cell types in mediating anxiety and mood may
give novel insights for the development of optimized therapies.

3.1.2. Neocortex in anxiety and depression
The neocortex has been implicated in mediating key symptoms in anxiety
and mood disorders, due to its executive role in the limbic system and extensive
connections with the hippocampus, amygdala, striatum, nucleus accumbens and
raphe nuclei (Price and Drevets, 2012). For example, altered cortical feedback to
amygdala was correlated with dysphoric emotions in humans (Drevets et al.,
2008) and heightened anxiety in both humans and monkeys (Birn et al., 2014).
The antidepressant effects of deep brain stimulation of the medial prefrontal
cortex (mPFC) are associated with restoration of both cortical and subcortical
brain activity to normal levels (Mayberg et al., 2005; Nahas et al., 2010). In
rodents, the mPFC-amygdala connections were also indicated to signal safety
and regulate anxiety (Likhtik et al., 2014). Additionally, chronic stress impairs the
structure and function of neurons in the mPFC (Radley et al., 2006), while
optogenetic stimulation of the mPFC reverses these deficits and exerts
antidepressant-like effects (Covington et al., 2010). In addition, surrounding
cortical structures such as the orbitofrontal cortex, anterior cingulate cortex, and
sensory-motor cortices have been associated with the pathological symptoms of
anxiety and mood disorders (Drevets et al., 2008). Nevertheless, the specific cell

98

types and molecular mechanisms that mediate the role of different cortical
regions in anxiety and mood regulation remain largely unknown.

3.1.2.a. Cortical circuitry in the rodent brain
The mammalian neocortex is divided into six major layers. The layer 4
defines the major input layer from thalamus and layer 5 defines the major output
layer that sends long distance subcortical and callosal projections. The
superficial layers 2 and 3 are involved in corticocortical connectivity and provide
two-thirds of the input to all neurons in the neocortex, while the deepest layer 6 is
primarily important for sending feedback to the thalamus. In addition to the
laminar structure of the neocortex, there are distinct functionally defined regions
parceled along the tangential axis. The cortical areas can be divided into three
general functional modalities: sensory cortices (including the primary
somatosensory, auditory and visual cortices), motor cortices (including the
primary motor cortex), and association cortices (including the prefrontal and
secondary motor cortices).
The neocortex, basal ganglia and thalamus are interconnected and closely
involved in the forebrain function (Alexander et al., 1986). There are three major
types of excitatory cortical neurons mainly classified by axonal anatomy:
intratelencephalic (IT), pyramidal tract (PT) and corticothalamic (CT) neurons
(Shepherd, 2013) (Figure 3.2A). IT neurons project ipsi- or bilaterally within the
neocortex and striatum (telencephalon), yet not to outside the telencephalon
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such as the thalamus or brainstem. Layer 2/3 neurons only have corticocortical
(CCor) projections while layer 4 neurons (stellate cells) have only local axonal
connections. IT neurons in layer 5 have both corticocortical (CCor) and
corticostriatal (CStr) projections. PT neurons are restricted to layer 5b. Their final
projections are in the brain stem structures such as the pons (corticopontene –
CPn neurons), or in the spinal cord (corticospinal – CSpi neurons). They also
send collateral branches off the pyramidal tract to innervate ipsilateral cortex and
other subcortical regions such as the striatum, thalamus, midbrain, etc. Notably,
the striatum is unique among all subcortical areas in receiving both IT and PT
inputs. CT neurons form a third class of cortical projection neurons located in
layer 6 and innervating the thalamus, but not the striatum.

3.1.2.b. Serotonergic modulation of the neocortex
The cortical circuits undergo extensive modulation by monoaminergic systems,
including serotonin. Serotonin has heterogeneous effects on cortical neurons
mostly due to the differential distribution of the serotonin receptors in distinct cell
types. For example, the expression of 5-HT2A receptors is the highest in layer 5a,
which is enriched in IT-CStr neurons (Weber and Andrade, 2010). Consequently,
5-HT seems to biphasically inhibit (via 5-HT1A receptors) and excite (via 5-HT2A
receptors) IT neurons while mostly inhibiting (via 5-HT1A receptors) PT neurons
(Avesar and Gulledge, 2012). In addition, IT-CStr neurons have higher
expression of 5-HT1BR and 5-HT4R than PT neurons (Egeland et al., 2011a).
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Figure 3.2. Corticostriatal circuit and its role in mood regulation.
A. Three major groups of excitatory cortical neurons and their axonal projections. IT:
inratelencephalic (CStr: corticostriatal, CCor: corticocortical), PT: pyramidal track, CT:
corticothalamic. Adapted from Shepherd (2013).
B. p11 expressing cells in p11-EGFP-L10a (bacTRAP) mouse line, detected by antiEGFP immunohistochemistry. Modified from gensat.org.
C. IT-CStr-related changes in major depressive disorder (MDD). Changes affecting the
CStr projection in MDD include abnormal activity in (1) neocortex and (2) striatum in
human imaging studies, and (3) IT-CStr p11 cell specific upregulation of 5-HT4R by
chronic treatment with fluoxetine (FLX). There were no observed effects on PT neurons
(blue). Modified from Shepherd (2013).
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A recent study from our lab also indicated that a population of IT-CStr
neurons mediate behavioral responses to chronic antidepressant administration
(Schmidt et al., 2012). These cells are p11 expressing pyramidal cells, located in
the upper layer 5 (5a) and projecting primarily to dorsal striatum and contralateral
neocortex (Figure 3.2B). These neurons showed a robust molecular response
upon chronic fluoxetine treatment including a significant increase in the
expression of Htr4, compared to non-responsive neighboring PT-CPn neurons
(Figure 3.2C). These results combined with the growing body of evidence
indicating a role for the dorsal striatum in reward processing, motivated behavior
and MDD pathology suggests that p11 CStr cells may underlie the
antidepressant responses (Delgado, 2007; Pizzagalli et al., 2009). However,
whether the CStr 5-HT4R mediates the behavioral consequences of SSRI action
had yet to be investigated.
Our findings by ablating 5-HT4R from pallial excitatory neurons indicated
that the antidepressant-like effects of chronic fluoxetine were not dependent on
5-HT4R. However, it is still possible that the loss of 5-HT4R from all cells in the
neocortex including IT and PT projection neurons may have triggered
compensation mechanisms during development or affected pallial circuits in
opposing ways, shadowing the possible roles of 5-HT4R in antidepressant
response in CStr p11 pyramidal cells. Therefore, a more specific and powerful
approach was essential to genetically manipulate the expression of 5-HT4R only
in p11 cells.
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3.2. Cell type specific dissection of the role of 5-HT4R in the hippocampus
and neocortex in anxiety and depression related behaviors

3.2.1. Drd3-Cre driver line to target the hippocampus
Although Emx1-Cre line comprehensively targets the excitatory neurons in
the hippocampus and neocortex, it is important to have a driver line that
exclusively targets the hippocampus to study hippocampus-specific effects of a
conditional genetic manipulation. We selected Drd3-Cre KI198 line (Drd3-Cre,
generated by GENSAT Project) because it expresses Cre in the hippocampus
the most exclusively and comprehensively among the available driver lines. This
transgenic line was generated by using a BAC clone, which was constructed by
inserting a Cre recombinase gene at the initiating ATG codon of the first coding
exon of the Drd3 gene in the BAC. Hence, Cre expression is driven by the
regulatory sequences of Drd3 in the BAC.
To reveal the Cre expressing cells, we crossed Drd3-Cre line with Credependent transgenic reporter expressing ribosomal protein L10a (RPL10a)
fused with EGFP (EGFP-L10a). Figure 3.3 shows the anti-EGFP
immunohistochemistry in coronal sections from the most rostral (top left) to the
most caudal (bottom right) of a Drd3-Cre::EGFP-L10a mouse brain. Cre was
expressed in the dentate gyrus in the granule cells layer, and some cells in the
polymorph layer in the hilus throughout the dorsoventral axis (dorsal DG (dDG),
intermediate DG (iDG) and ventral DG (vDG)). In the CA3 field of the
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hippocampus, Cre mediated EGFP expression was observed in the pyramidal
cell layer consistently along the dorsoventral axis (in dCA3 iCA3 and vCA3).
Finally, in the CA1 field, Cre targets many pyramidal cells of dorsal parts (dCA1).
Notably, the number of Cre expressing cells decreases as a gradient towards the
ventral CA1 region, leaving only a scatter of Cre positive cells in the pyramidal
layer of the vCA1. Outside the hippocampus, Cre expressing cells were observed
in a small cell population in the very rostral part of the lateral septum (LS), in the
islands of Calleja (ICj) as well as a few scattered cells in the dorsal nucleus
accumbens (NAc) and the medial mammillary nucleus (MM) of the hypothalamus
(HY).
Although, the CA1 is not fully targeted, we selected this driver line since it
targets most of the cells in the excitatory neuron layers in hippocampus in which
hippocampal Htr4 is primarily expressed. In addition, among the available Cre
driver lines, it has the least number of Cre-expressing cells outside the
hippocampus, making it a highly specific line for targeting the whole
hippocampus. Also note that, since endogenous Drd3 gene (Dopamine Receptor
D3) is expressed in other brain cells in regions such as neocortex and striatum,
this BAC transgenic Drd3-Cre line did not fully recapitulate the Drd3 expression
pattern. Nevertheless, it is useful as a tool to drive Cre-mediated genetic
manipulations specific to the hippocampus. Therefore, we crossed this line to our
Htr4-floxed line to investigate hippocampus specific functions of 5-HT4R in
emotion and cognition.
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Figure 3.3. Drd3-Cre reporter line specifically targets the hippocampus.
Anti-EGFP immunohistochemistry images of the coronal sections of a Drd3-Cre::EGFPL10a mouse brain showing the expression pattern of Drd3-Cre driver line. From the most
rostral (top left), to the most caudal (bottom right). Drd3-Cre is specifically expressed in
hippocampus. Note the small number of Cre positive cells scattered in other regions
such as rostral LS, NAc, ICj, Pir and MM. CTX: cortex, NAc: nucleus accumbens, LS:
lateral septum, MS: medial septum, ICj: islands of Calleja, STR: striatum, TH:
thalamaus, HY: hypothalamus, A: amygdala, Pir: piriform cortex, MM: mammillary
nucleus of hypothalamus, MB: midbrain; dDG, iDG, vDG: dorsal, intermediate, ventral
dentate gyrus, respectively; dCA, iCA, vCA1/3: (dorsal, intermediate, ventral CA1/3
fields, respectively.
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3.2.2. Tlx3-Cre line to target CStr p11 pyramidal cells
We sought to find a Cre driver line that could achieve CStr p11 cell type
specific conditional genetic manipulations. Although p11-Cre mouse line has
been successfully generated, Cre expression was not restricted to p11 cells in
adult mouse brain since it is expressed in progenitor cells during development
(personal communication). To target the p11 neurons, we selected Tlx3-Cre line
that expresses Cre exclusively in a cortical layer 5a population.
We crossed Tlx3-Cre line with the Cre dependent EGFP-L10a reporter
mice to (Tlx3-Cre::EGFP-L10a) to reveal Cre expressing cells via anti-EGFP
immunohistochemistry. Tlx3-Cre cells were pyramidal neurons located mainly in
layer 5a in the neocortex in a laminar pattern (Figure 3.4A). Note that Crepositive cells were sparse in the most medial and lateral regions of the cortex
such as the prelimbic (PL), infralimbic (IL), retrosplenial (RSC), perirhinal (PRh),
entorhinal (Ent) and piriform cortices. To confirm whether Tlx3-Cre expression is
specific to p11 neurons, we performed TRAP followed by qRT-PCR gene
expression analysis. Shortly, translating mRNAs from Tlx3-Cre neurons were
isolated by anti-EGFP immunoprecipitation (IP) from the cortices of Tlx3Cre::EGFP-L10a mice. mRNA isolated from whole cortex was used as the ‘input’
sample. Differential gene expression of actin beta (ActB - control), p11
(S100a10) and Colgalt2 (a marker gene for CPn pyramidal neurons in layer 5b)
was obtained between IP and input by qRT-PCR (Figure 3.4B).
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Figure 3.4. Tlx3-Cre reporter line targets corticostriatal (CStr) layer 5a pyramidal
neurons.
(A) Anti-EGFP immunohistochemistry images of the coronal sections of a Tlx3Cre::EGFP-L10a mouse brain showing the expression pattern of Tlx3-Cre driver line.
Tlx3-Cre was expressed in a laminar pattern in the neocortex primarily in layer 5a. Note
that Cre-positive cells were sparse in the most medial and lateral regions of the
neocortex such as PL, IL and RSC as well as PRh, Ent and Pir.
(B) qRT-PCR quantification of the expression of actin beta (ActB - control), p11
(S100a10) and Colgalt2 (a marker gene for CPn layer 5b neurons) in TRAP IP versus
input samples in the neocortex of Tlx3-Cre::EGFP-L10a mice. Note that S100a10 was
enriched in IP versus Colgalt2 in input. Data are represented as mean ± SEM. n=4 per
group.
(C) Schematic depicting the layer localization and projection of Tlx3-Cre neurons in the
cortex. Adapted by combining unpublished data from our lab and (Kim et al., 2015).
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S100a10 expression was significantly enriched in IP (3.2-fold) while Colgalt2 was
significantly enriched in the input (5.6-fold). ActB expression was similar in both
samples. These data suggested that Tlx3-Cre pyramidal cell population is
enriched in p11 and depleted in CPn neuron marker.
Together with the previous findings that Tlx3-Cre neurons projects to
dorsal striatum (CStr), and other ipsi- and contralateral cortical regions
(CCor)(Kim et al., 2015), these results indicated that Tlx3-Cre targets the IT-CStr
p11 expressing pyramidal neurons (Figure 3.4C). Therefore, Tlx3-Cre mouse
line can be a specific and useful tool to further investigate p11 neurons in the
neocortex. We crossed this line to our Htr4-floxed line to investigate the CStr
layer 5a neuron specific functions of 5-HT4R in emotion and cognition.

3.2.3. Hippocampus specific roles of 5-HT4R in anxiety and depression
related behaviors
To investigate the consequences of hippocampus specific deletion of 5HT4R, we crossed Htr4-floxed mice with the Drd3-Cre line. Heterozygous Drd3Cre animals were crossed with Htr4-floxed animals homozygous for the floxed
allele (Htr4loxP/loxP) for two generations to obtain Drd3/Htr4 cKO mice (Drd3Cre::Htr4loxP/loxP). To maintain the colony, Drd3/Htr4 cKO animals were bred with
homozygous Htr4-floxed animals. The litters from this breeding should be
Drd3/Htr4 cKO in 1:2 ratio, and Htr4-floxed in 1:2, referred as control or wildtype
(WT) littermates. Behavioral analysis was performed in two cohorts, comparing
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Drd3/Htr4 cKO and their control littermates (cKO versus WT, n=20, 18,
respectively), unless otherwise is noted.

3.2.3.a. Anxiety related behaviors in hippocampus specific Htr4 conditional
knockout mice
To assess whether hippocampal 5-HT4R modulates anxiety related
behaviors, and the ablation of 5-HT4R specifically in Drd3-Cre cells leads to
changes in anxiety-like behaviors, we tested Drd3/Htr4 cKO animals and control
littermates in anxiety related behavioral paradigms, including conflict-based open
field (OF), elevated plus maze (EPM) and novelty suppressed feeding (NSF),
sociability based three-chamber social interaction, and finally, the acoustic startle
responses (ASR) measuring motor defensive reflexes linked with anxiety-like
behaviors (detailed in Chapter 2).
In the OF, Drd3/Htr4 cKO mice showed significantly higher levels of
thigmotaxis both in the first 10 mins (Figure 3.5A) and over 60 mins (Figure
3.5B), compared to controls (10 mins – cKO: 0.82 ± 0.02 versus WT: 0.77 ± 0.01,
p=0.04; 60 mins – cKO: 0.75 ± 0.03 versus WT: 0.68 ± 0.02, p=0.04). There was
no significant difference in the locomotor activity between genotypes (p=0.45,
Two-way ANOVA) (Figure 3.5C). These results indicated that Drd3/Htr4 cKO
mice exhibited increased anxiety-like behaviors in the OF.
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Figure 3.5. Hippocampus specific loss of 5-HT4R led to increased anxiety-like
behaviors in the open field and elevated plus maze.
(A) Drd3 Htr4/cKO mice (cKO, blue) showed significantly increased thigmotaxis
(periphery/total time) in first 10 mins in the OF, compared to their control littermates (WT,
black).
(B) Drd3 Htr4/cKO mice (cKO) exhibited a significant increase in thigmotaxis over 60
mins in the OF, compared to their controls (WT).
(C) There was not any significant difference between genotypes (cKO versus WT) in
locomotor activity (total distance in cm) in OF.
(D) In the EPM, Drd3/Htr4 cKO and control (WT) did not exhibit a significant difference in
the time spent in the open arms.
(E) Drd3/Htr4 cKO mice spent significantly more time in the closed arms compared to
controls (WT).
(F) Drd3/Htr4 cKO mice showed significantly elevated locomotor activity as higher
velocity (cm/s) in EPM compared to controls (WT).
Data are represented as mean ± SEM. Two-tailed unpaired t-test. *p<0.05, n.s. p>0.05.
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In the EPM, Drd3/Htr4 cKO mice spent significantly more time in the
closed arms, compared to control (cKO: 182.5 ± 9.8 s versus WT: 155.8 ± 8.3 s,
p=0.046) (Figure 3.5E), demonstrating that the cKO mice exhibited elevated
levels of anxiety-like behaviors in the EPM as well.
Although the time spent in the open arms was not significantly different between
groups (p=0.58) (Figure 3.5D), Drd3/Htr4 cKO mice displayed significantly
increased velocity in EPM, compared to controls (cKO: 4.5 ± 0.2 cm/s versus
WT: 3.8 ± 0.2 cm/s, p=0.04) (Figure 3.5F). This suggested that higher locomotor
activity in cKO mice was not accompanied by an increase in the time spent in the
open arms, supporting the findings that Drd3/Htr4 cKO mice has elevated levels
of anxiety-like behaviors.
In the NSF paradigm, Drd3/Htr4 cKO displayed a significant increase in
latency to feed compared to controls (cKO: 740.7 ± 54.9 s versus WT: 523 ± 37.3
s, p=0.002) (Figure 3.6A), indicating a strong elevation in anxiety-like behaviors
in the cKO mice. Drd3/Htr4 cKO also showed a significant increase in home cage
feeding (cKO: 0.43 ± 0.04 g versus WT: 0.29 ± 0.03 g, p=0.01) (Figure 3.6B).
Together, these results suggested that even though the cKO mice were more
motivated in feeding in a less stressful environment, they did not approach the
food as fast as WT in the NSF arena, conveying even more significant
suppression of feeding in a novel environment. We also tested whether the
increase in home cage feeding had long term effects on the physiology of the
animals.

111

Figure 3.6. The loss of hippocampal 5-HT4R resulted in elevated anxiety-like
behaviors in the novelty suppressed feeding and social interaction tests.
(A) Drd3 Htr4/cKO mice (cKO, blue) displayed a significant increase in latency to feed
compared to controls (WT, black) in the NSF.
(B) Drd3/Htr4 cKO mice showed a significant increase in feeding in home cage following
NSF, compared to controls (WT).
(C)There was not any significant difference between groups in animal weight.
(D) Schematic representation of the three-chamber social interaction test.
(E) Drd3/Htr4 cKO mice spent significantly less time interacting with unfamiliar mouse in
the three-chamber social interaction test, compared to controls (WT). Interaction with the
Lego was not significantly different between groups.
Data are represented as mean ± SEM. Two-tailed unpaired t-test (A-C), two-way
ANOVA followed by post hoc Fisher’s LSD test (E). *p<0.05, **p<0.01, n.s. p>0.05.
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There was not any significant difference in the animal weights between groups
(p=0.68) (Figure 3.6.C). This suggested that the increase in home cage feeding
in the cKO mice was acute, possibly due to prolonged fasting in the cKO mice
compared to WT that had accessed the food much earlier in the NSF arena.
In the three-chamber social interaction test (Figure 3.6D), Drd3/Htr4 cKO
mice interacted significantly less with the novel mice compared to controls (cKO:
73.7 ± 6.8 s, versus WT: 91 ± 6 s, p=0.01, n=12 per group), whereas the
interaction with the novel inanimate object was not significantly different between
groups (p=0.90) (Figure 3.6E). These data suggest an elevated anxiety-like
behavior in social interaction in the cKO mice, supporting our previous behavioral
findings.
Finally, we assessed the acoustic startle response (ASR) and pre-pulse
inhibition (PPI) in Drd3/Htr4 cKO mice and their control littermates. The
measurement was performed in four blocks. In the first block (pre-test), mice
were presented with 120 dB acoustic stimuli for five trials for familiarization to the
test. Maximum startle responses (Vmax) were recorded per trial and averaged
per subject. In the second block (ASR), acoustic stimuli were presented in five
different intensities (120, 110, 100, 90 and 80 dB), each for four trials in a
pseudorandom order. Maximum startle responses (Vmax) were recorded for
each trial and averaged for each stimulus intensity per subject. In the third block
(PPI), 120 dB acoustic stimuli preceded by four different pre-pulse (PP)
intensities (0, 3, 6, 12 dB) were presented, each for ten trials in a pseudorandom
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order. Maximum startle responses (Vmax) were recorded for each trial and
averaged for each prepulse intensity per subject. PPI was calculated as the
percent decrease in the startle response in PP3, PP6 and PP12 compared to
PP0 per subject. Lastly, in the fourth block (post-test), 120 dB stimuli were
presented for five trials. Maximum startle responses (Vmax) were recorded per
trial and averaged per subject to compare to the pre-test responses to assess the
habituation of ASR during the testing. Habituation is a form of non-associative
learning as the subject learns the repeated stimuli is non-threatening. It can also
be viewed as a form of sensory filtering, since it desensitizes the organism to the
stimuli. Disrupted habituation and PPI of ASR indicate cognitive dysfunction and
observed in schizophrenia patients, while other mental and neurodegenerative
disorders may also be accompanied by problems in the habituation and PPI
(Geyer and Swerdlow, 2001; Valsamis and Schmid, 2011b).
In the ASR test, Drd3/Htr4 cKO mice exhibited enhanced startle response
at 120 dB, compared to controls (cKO: 287.1 ± 32.8, versus WT: 212.8 ± 43.7,
p=0.008, n=12 per group) (Figure 3.7A). At 110 dB, the cKOs also startled more
that WT however this difference did not reach statistical significance (p=0.17). At
lower dBs, the difference in the startle response between groups were not
detectable, possibly due to a floor effect. Together, these data indicate that
Drd3/Htr4 cKO mice showed elevated levels of anxiety-like responses to the
acoustic startling stimuli.
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Consistently, the cKO mice showed significantly increased startle
responses during the pre-test (cKO: 277.4 ± 22.7, versus WT: 184.9 ± 33.3,
p=0.03) and post-test blocks (cKO: 215.1 ± 27, versus WT: 132 ± 33.1, p=0.05)
(Figure 3.7B). In addition, startle responses were significantly decreased in the
post-test compared to the pre-test for both groups (cKO: -62.2 ± 23.1, p=0.01;
WT: -52.9 ± 24, p=0,04), indicating a prominent habituation of ASR, independent
of genotype. We also measured percent habituation per animal between the preand post-test to assess whether there was any effect of the conditional loss of 5HT4R on the extent of habituation. Both cKO and control mice habituated to 120
dB stimuli around 30% without any significant difference between genotypes
(cKO: 27.9 ± 7.6, versus WT: 35.7 ± 10.8, p=0.55) (Figure 3.7C).
When PPI was measured, there was not any significant difference
between Drd3/Htr4 cKO and control mice in the inhibition of startle at any prepulse intensities and overall (p=0.65, Two-way ANOVA) (Figure 3.7D). During
the PPI block, consistent with the measurements in other blocks, Drd3/Htr4 cKO
mice exhibited significantly higher startle responses to 120dB stimulus preceded
by any pre-pulse (PP0, PP3, PP6 and PP12; p=0.01, 0.02, 0.02, 0.01,
respectively), and overall (p=0.008, Two-way ANOVA) (Figure 3.7E). Together,
these results suggested that, compared to controls, Drd3/Htr4 cKO mice
displayed increased ASR throughout the test although they showed similar
habituation and PPI of ASR.
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Figure 3.7. Drd3/Htr4 cKO mice exhibited increased anxiety-like behaviors as
elevated acoustic startle responses.
(A) Drd3 Htr4/cKO mice (cKO, blue) displayed significantly larger startle responses to
the 120dB acoustic pulse, compared to controls (WT, black). At 110 dB, the cKOs also
startled more that WT however this difference did not reach statistical significance.
(B) Drd3/Htr4 cKO mice showed significantly elevated startle responses during the preand post-test blocks, compared to controls (WT). Note also that the startle responses
were decreased significantly in the post-test compared to the pre-test for both groups.
(C) Percent habituation per animal between the pre- and post-test to 120 dB stimuli was
not significantly different between groups.
(D) Prepulse inhibition (PPI) was not significantly different between groups.
(E) During the PPI measurements, Drd3/Htr4 cKO mice exhibited significantly higher
startle responses to 120dB stimulus preceded by any pre-pulse and overall.
Data are represented as mean ± SEM. Two-way ANOVA followed by post hoc Fisher’s
LSD test (A, B, D, E), two-tailed unpaired t-test (C). ¥¥ p<0.01, *p<0.05, **p<0.01, n.s.
p>0.05.
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Anxiety-like behavioral measures in the OF, EPM, NSF, social interaction
and ASR taken together, our data strongly suggest that the ablation of functional
5-HT4R specifically from the hippocampus led to a prominent increase in anxietylike behaviors.

3.2.3.b. Depression related behaviors in hippocampus specific Htr4 conditional
knockout mice
Serotonergic neuromodulation in the hippocampus has been extensively
implicated in anxiety and depression, and the hippocampus is one of the main
structures responding to SSRI treatments including changes in the molecular and
physiological properties in this area. Although the loss of 5-HT4R from the
excitatory neurons of pallium including the hippocampus in Emx1/Htr4 cKO mice
did not result in a change in depression-related behaviors, there may be
compensation mechanisms shadowing any depression-related effects. Perhaps,
the slight increase in hedonia levels when pallial 5-HT4R was ablated (Chapter
2.4.6) is an indication of the modulation of depression-like behaviors via 5-HT4R
in this area. To investigate whether 5-HT4R in the hippocampus modulates
depression related behaviors, we tested Drd3/Htr4 cKO animals and control
littermates in several behavioral paradigms including despair-based tail
suspension test (TST) and forced swim test (FST), and anhedonia-based splash
test and sucrose consumption test.
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Intriguingly, Drd3/Htr4 cKO exhibited significantly lower immobility
compared to controls in both TST (cKO: 80.6 ± 7.4 %, versus WT: 100 ± "100 ±
4.2 %, p=0.02) (Figure 3.8A), and FST (cKO: 57.8 ± 10.1 s, versus WT: 115.6 ±
7.9 s, p<0.0001) (Figure 3.8B), revealing diminished despair-like behaviors
(antidepressant-like). In splash test, Drd3/Htr4 cKO mice showed significant
increase in grooming compared to controls (cKO: 73 ± 4.7 s, versus WT: 45.5 ±
3.2 s, p<0.0001) (Figure 3.8C), indicating enhanced hedonic behaviors in the
cKO mice.
In addition, the sucrose consumption test was employed to evaluate the
hedonic phenotype in the cKOs. In this test, each mouse was placed in a clean
cage containing a 1% sucrose bottle and a water bottle. Sucrose and water
consumption was measured for 72 hours. At each 12 hour-mark, bottles were
switched places to avoid side preference. Sucrose and water consumption was
measured per animal weight to normalize for the drinking needs of differently
sized animals. The decrease in sucrose consumption is a measure of anhedonia.
While animal models of depression have been established to consume less
sucrose over time, antidepressant treatments tend to reverse this phenotype and
increase sucrose consumption (Strekalova et al., 2011). This test was chosen
instead of sucrose preference test since the enhanced hedonic behaviors in
Drd3/Htr4 cKO mice would not have been evaluated by merely comparing the
already-high levels of preference of sucrose in mice.
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Figure 3.8. The loss of hippocampal 5-HT4R led to antidepressant-like behavioral
responses in the tail suspension, forced swim, splash and sucrose consumption
tests.
(A) Drd3/Htr4 cKO mice (cKO, blue) showed significantly lower immobility in the TST,
compared to controls (WT, black).
(B) Drd3/Htr4 cKO mice spent significantly less time immobile in the FST compared to
controls (WT).
(C) Drd3/Htr4 cKO mice spent significantly more time grooming in the splash test.
(D) Drd3/Htr4 cKO mice consumed significantly more 1% sucrose over 72 hours.
(E) Water consumption during the sucrose consumption test was not significantly
different between groups.
Data are represented as mean ± SEM. Two-tailed unpaired t-test (A-C), two-way
ANOVA followed by post hoc Fisher’s LSD test (D, E). *p<0.05, **p<0.01, ****p<0.0001,
n.s. p>0.05.
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Compared to control littermates, Drd3/Htr4 cKO mice consumed more
sucrose throughout the test reaching statistical significance in difference over 72
hours (72 hours; cKO: 0.43 ± 0.03 ml/g, versus WT: 0.37 ± 0.02 ml/g, p=0.008)
(Figure 3.8D). There was not any significant difference in water consumption
between groups (Figure 3.8E). These results indicate that Drd3/Htr4 cKO mice
showed enhanced hedonic behaviors in the sucrose consumption test.
In conclusion, Drd3/Htr4 cKO mice showed antidepressant-like behaviors
in the TST and FST as well as in the splash and sucrose consumption tests.
Hence, hippocampus specific loss of 5-HT4R resulted in comprehensive
antidepressant-like responses, implicating that 5-HT4R modulates depressionrelated behaviors in Drd3-Cre positive cells in the hippocampus in addition to
anxiety-related behaviors.

3.2.4. CStr layer 5a cell specific roles of 5-HT4R in anxiety and depression
To investigate the consequences of the loss of 5-HT4R specifically from
the CStr layer 5a pyramidal neurons on anxiety and depression related behaviors
as well as antidepressant-like responses, we crossed Htr4-floxed mice with the
Tlx3-Cre line. Heterozygous Tlx3-Cre animals were crossed with Htr4-floxed
animals homozygous for the floxed allele (Htr4loxP/loxP) for two generations to
obtain Tlx3/Htr4 cKO mice (Tlx3-Cre::Htr4loxP/loxP). To maintain the colony,
Tlx3/Htr4 cKO animals were bred with homozygous Htr4-floxed animals. The
litters from this breeding should be Tlx3/Htr4 cKO in 1:2 ratio, and Htr4-floxed in
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1:2, referred as control or wildtype (WT) littermates. To asses antidepressant-like
behavioral responses, 8-week-old Tlx3/Htr4 cKO mice and control littermates
were either given 0.167 mg/ml fluoxetine (~18 mg/kg/day) (FLX) or vehicle (VEH)
in drinking water for 18 days (Schmidt et al., 2012). Behavioral analysis was
performed in one cohort divided in four groups (WT-VEH, WT-FLX, cKO-VEH,
cKO-FLX; n= 12, 12, 12, 11, respectively). The drug treatment continued until the
end of behavioral assessments.
In the OF, Tlx3/Htr4 cKO mice and their control littermates showed similar
thigmotaxis levels in first 10 mins (cKO-VEH: 0.87 ± 0.02, WT-VEH: 0.85 ± 0.01
p=0.38) (Figure 3.9A), and over 60 mins (cKO-VEH: 0.82 ± 0.02, WT-VEH: 0.81
± 0.02 p=0.88) (Figure 3.9B). Following chronic treatment with fluoxetine, both
the cKO and control mice showed significant increase in thigmotaxis both in 10
mins (cKO-VEH/FLX: 0.87 ± 0.02 / 0.97 ± 0.01 p=0.0003; WT-VEH/FLX: 0.85 ±
0.01 / 0.95 ± 0.02, p=0.0003), and 60 mins (cKO-VEH/FLX: 0.82 ± 0.02 / 0.94 ±
0.02, WT-VEH/FLX: 0.81 ± 0.02 / 0.91 ± 0.02, p<0.001). There was not any
significant difference in the locomotor activity amongst groups (Figure 3.9C).
Together, these data indicated that Tlx3/Htr4 cKO mice did not show any
difference in anxiety-like behaviors, and that the anxiogenic effects of chronic
fluoxetine was independent of genotype in the OF.
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Figure 3.9. The loss of 5-HT4R specifically from CStr layer 5a neurons led to
slightly decreased anxiety-like behaviors in the EPM.
(A) Tlx3/Htr4 cKO mice (cKO-VEH) and controls (WT-VEH) showed similar thigmotaxis
in the first 10 mins in the open field (OF). Following chronic fluoxetine (FLX) treatment,
both cKO and WT showed significantly increased thigmotaxis in 10 mins, compared to
vehicle treated counterparts.
(B) There was not any significant difference in thigmotaxis between genotypes (cKOVEH versus WT-VEH) in OF over 60 mins. Following FLX treatment, both cKO and WT
had significantly increased thigmotaxis in 60 mins, compared to vehicle treated
counterparts.
(C) Locomotor activity (total distance traveled) in the OF was not significantly different
amongst groups.
(D) Tlx3/Htr4 cKO mice (cKO-VEH) spent slightly longer time in open arms in EPM
compared to controls (WT-VEH). Following chronic treatment with fluoxetine, both cKO
and control mice showed significant decrease in the time spent in the open arms. Note
that cKO-FLX spent slightly more time in open arms than WT-FLX. Two-way ANOVA,
p=0.06 for genotype factor.
(E) Time in closed arms in the EPM were similar for both genotypes. Following FLX
treatment, both cKO and WT spent significantly more time in closed arms in the EPM,
compared to their vehicle treated counterparts.
(F) Locomotor activity (velocity) during the EPM was similar amongst groups.
Data are represented as mean ± SEM. Two-way ANOVA followed by post hoc Fisher’s
LSD test. *p<0.05, **p<0.01, ***p<0.001.
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In the EPM, Tlx3/Htr4 cKO mice spent slightly higher amount of time in
open arms, compared to controls, although this difference did not reach statistical
significance (cKO-VEH: 53.6 ± 12.6 s, WT-VEH: 37 ± 8.6 s, p=0.20) (Figure
3.9.D), suggesting that the cKO mice may have had slightly lower levels of
anxiety. Following chronic treatment with fluoxetine, both cKO and control mice
showed significant decrease in the time spent in the open arms (cKO-VEH/FLX:
53.6 ± 12.6 / 26.9 ± 9 s, p=0.049; WT-VEH/FLX: 37 ± 8.6 / 7.5 ± 1.1 s, p=0.033).
Note that cKO-FLX mice spent slightly more time in open arms than WT-FLX
which was also not statistically significant (26.9 ± 9 s versus 7.5 ± 1.1 s, p=0.16).
This trend may be attributed to a marginally anxiolytic phenotype of the cKO
(p=0.06 for genotype factor, Two-way ANOVA). Furthermore, Tlx3/Htr4 cKOs
and controls treated with chronic fluoxetine spent significantly more time in the
closed arms in the EPM compared to their vehicle treated counterparts (p=0.03
for both comparisons) (Figure 3.9E), detecting similar anxiogenic effects of the
drug for both genotypes. There was not any significant difference in the velocity
in the EPM amongst groups, indicating similar locomotor activity regardless of
genotype and drug treatment (Figure 3.9F).
In the NSF, Tlx3/Htr4 cKO mice showed a slight decrease in latency to
feed compared to controls while the difference did not reach statistical
significance (cKO-VEH: 372 ± 96 s, WT-VEH: 550 ± 58 s, p=0.06) (Figure
3.10A).
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Figure 3.10. The loss of CStr 5-HT4R led to slightly decreased anxiety-like
behaviors in the NSF and anti-depressant-like behavioral responses in the FST.
(A) Tlx3/Htr4 cKO mice (cKO-VEH) showed slightly decreased in latency to feed in NSF,
compared to control (WT-VEH). Following chronic treatment with fluoxetine (FLX), both
cKO and WT exhibited slightly lower latency to feed. Overall effects of genotype and
FLX treatment were significant. Two-way ANOVA, p=0.021 for genotype factor, p=0.017
for treatment factor.
(B) There was not any significant difference in food intake between genotypes in home
cage following NSF. FLX treatment led to an increase in the food intake in home cage,
significantly in cKO and slightly in WT.
(C) There was not any significant difference in animal weights between groups.
(D) cKO-VEH and WT-VEH groups displayed similar immobility in TST. Following FLX
treatment, both cKO and WT showed a significant decrease in immobility compared to
their VEH treated counterparts.
(E) cKO-VEH exhibited significantly lower immobility compared to WT-VEH in FST.
Immobility was significantly increased in both genotypes treated with FLX.
(F) In splash test, there was not any significant difference in grooming between cKOVEH and WT-VEH. FLX treatment led to more grooming in WT while it did not alter
grooming in cKO. Data are represented as mean ± SEM. Two-way ANOVA followed by
post hoc Fisher’s LSD test. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
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In addition, Tlx3/Htr4 cKO and control mice treated with fluoxetine showed
a trend towards a decrease in the latency to feed compared to their vehicle
treated equivalents (cKO-VEH/FLX: 372 ± 96 / 221 ± 41 s, p=0.12; WT-VEH/FLX:
550 ± 58 / 366 ± 47 s; p=0.06). Interestingly, two-way ANOVA analysis on the
effect of genotype and drug treatment on the latency to feed in the NSF suggest
that, overall, the cKO mice showed significantly less latency to feed compared to
WT (p=0.021), and fluoxetine treatment significantly decreased the latency to
feed (p=0.017), independent of genotype factor (genotype-drug interaction,
p=0.81). Since NSF relies on feeding, we also measured home cage feeding
immediately after the test. There was not any significant difference in food intake
between genotypes in home cage following NSF (cKO-VEH: 0.31 ± 0.05 g, WTVEH: 0.30 ± 0.04 g, p=0.76) (Figure 3.10B). Chronic fluoxetine administration
significantly increased the food intake in in the cKO mice (p=0.049), and slightly
in the controls, which did not reach statistical significance (p=0.19). However,
overall, fluoxetine significantly elevated food intake in home cage independent of
genotype (p=0.02, Two-way ANOVA). Finally, we measured the weight of
animals to acquire whether the increase in food intake observed after the NSF
had any effects of the physiology of the animals in the long term. There was not
any significant difference between the animal weights among groups (Figure
3.10C). The NSF offers a strong predictive power for alterations in anxiety-like
behaviors while it is also sensitive for detecting the behavioral responses to
chronic antidepressant administration in mice. Our data suggest that, in the NSF,
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Tlx3/Htr4 cKO mice showed anxiolytic behaviors compared to controls, while
both cKO and control mice exhibited antidepressant-like behavioral responses to
chronic fluoxetine.
In the TST, there was not any significant difference in immobility between
Tlx3/Htr4 cKO and their control littermates (cKO-VEH: 143 ± 7 s, WT-VEH: 140 ±
6 s, p=0.80) (Figure 3.10D). Following chronic treatment with fluoxetine,
immobility was significantly decreased in both genotypes (cKO-VEH/FLX: 143 ±
7 / 86 ± 12 s, p=0.0003; WT-VEH/FLX: 140 ± 6 / 84 ± 13 s; p=0.0002). Together,
these results indicate that Tlx3/Htr4 cKO mice did not display an alteration in
depression-like behaviors in the TST, and that chronic fluoxetine resulted in
antidepressant-like behavioral responses independent of genotype.
In the FST, Tlx3/Htr4 cKO mice exhibited significantly lower immobility
compared to controls (cKO-VEH: 81 ± 17 s, WT-VEH: 120 ± 14 s, p=0.80)
(Figure 3.10E), indicating reduced despair-like behaviors in the cKO. Following
chronic treatment with fluoxetine, immobility was significantly increased in both
genotypes (cKO-VEH/FLX: 81 ± 17/ 176 ± 7 s, p<0.0001; WT-VEH/FLX: 120 ±
14 / 177 ± 8 s; p=0.003), showing an opposite effect from the expected
antidepressant-like response, leading to an inconclusive result. Similar results
were observed in some mouse strains and in our previous experiments (Chapter
2.4.5), rendering the FST inconclusive in determining chronic antidepressant
effects in our model as well. The FST in this cohort only suggested that Tlx3/Htr4
cKO mice displayed antidepressant-like behaviors.
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In the splash test, there was not any significant difference in grooming
between genotypes (cKO-VEH: 61 ± 6 s, WT-VEH: 53 ± 3 s, p=0.33) (Figure
3.10F). Control mice treated with fluoxetine groomed longer compared to vehicle
treated counterparts (WT-VEH/FLX: 53 ± 3 / 72 ± 5 s, p=0.04), while there was
not any difference in grooming between fluoxetine and vehicle treated cKO mice
(cKO-VEH/FLX: 61 ± 6 / 54 ± 8 s, p=0.36). Together, these data indicated that
hedonic behaviors in Tlx3/Htr4 cKO was not altered in the splash test, however
that the antidepressant-like behavioral responses observed in control mice were
not evident in the cKO. This suggested that the loss of CStr 5-HT4R may have
diminished the hedonic behavioral effects of fluoxetine in Tlx3/Htr4 cKO mice.
In conclusion, Tlx3/Htr4 cKO mice showed anxiolytic phenotype, slightly in
the EPM and significantly in the NSF, as well as an antidepressant-like
behavioral response in the FST, implying that the loss of 5-HT4R in CStr layer 5a
neurons led to improvements in some anxiety and mood related behaviors. The
anxiogenic effect of fluoxetine in the OF and EPM, and the antidepressant-like in
the NSF and TST were observed in both genotypes. Only in the splash test,
Tlx3/Htr4 cKO did not respond to chronic fluoxetine as increased grooming
observed in the control group. This indicates that CStr 5-HT4R was not necessary
for most of the chronic antidepressant-like behavioral responses.
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3.3. Spatial dissection of the role of 5-HT4R in the hippocampus and
neocortex in anxiety and depression related behaviors

3.3.1. The role of 5-HT4R along the dorsoventral axis of the hippocampus
To gain insights into whether the function of 5-HT4R in Drd3-Cre
expressing neurons in spatially distinct parts of DG along the dorsoventral axis
mediate the behavioral changes in Drd3/Htr4 cKO, we devised a rescue
experiment such that functional 5-HT4R would be conditionally re-expressed via
AAV-mediated gene delivery in Drd3/Htr4 cKO mice either in the ventral or dorsal
DG. We generated an expression construct (pAAV.Ef1a.DIO.Htr4-MycDDK.WPRE.hGH) that, in the presence of Cre, would recombine to express
mouse Htr4 mRNA under the EF1a promoter, a constitutive promoter of human
origin that is standard for use to drive ectopic gene expression (Figure 3.11A).
Htr4-Myc-DDK was cloned in the reverse orientation into the Cre-dependent
pAAV.EF1a.DIO.EGFP plasmid, replacing EGFP. The presence of flanking loxP
and lox2272 sites resulted in a construct that had a ‘‘double-floxed’’ inverted
open reading frame (DIO) (Atasoy et al., 2008), to allow for cell type specific
expression of 5-HT4R tagged with MYC-DDK. This construct is hereafter referred
to as pAAV-DIO-Htr4-Myc. In the presence of Cre recombinase, Htr4-Myc
sequence would be reverted back, allowing for conditional expression of a
functional protein.
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To confirm Cre-dependent expression of the 5-HT4R-MYC, HEK cells
were both transfected by the pAAV-DIO-Htr4-Myc construct and transduced with
AAV-Cre-EGFP, for AAV mediated Cre-EGFP expression. Immunofluorescent
labeling with anti-MYC antibody revealed the Cre dependent expression of 5HT4R-MYC (Figure 3.11B). The expression of 5-HT4R was restricted to CreEGFP expressing cells (above). There was not any 5-HT4R-MYC expression in
HEK cells transfected with our construct but negative for Cre (control, below).
These results indicated that our pAAV-DIO-Htr4-Myc construct showed efficient
Cre dependence.
For in vivo gene delivery, we generated AAV-DIO-Htr4-Myc, AAV2.9 virus
packaging our rescue construct (UPenn Vector Core). To confirm the Cre
dependent expression of viral construct in vivo, AAV-DIO-Htr4-Myc was
stereotaxically injected into the dentate gyrus (DG) of Drd3-Cre::EGFP-L10a
mice. The expression was checked three weeks later by immunofluorescent
labeling in the coronal brain sections. Anti-MYC antibody was used to detect 5HT4R-MYC expression and EGFP was used to label EGFP-L10a in Drd3-Cre
positive cells (Figure 3.11C). AAV-DIO-Htr4-Myc injected DG (below) was highly
labeled with anti-MYC antibody, compared to control DG without AAV injection.
However, EGFP expressing Drd3-Cre positive DG granule cells (DG), hilar cells,
and CA3 pyramidal neurons were not observed in AAV injected hippocampus,
compared to intact expression in control (arrowheads in EGFP panel).
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Figure 3.11. AAV-mediated Cre-dependent overexpression of 5-HT4R in the
hippocampus of Drd3-Cre mice led to neurotoxicity.
(A) Schematic of the design of the Cre-dependent pAAV-DIO-Htr4-Myc vector.
(B) Anti-MYC immunofluorescent staining of HEK cells transfected with pAAV-DIO-Htr4Myc (red). 5-HT4R-MYC was only detected in cells transduced with AAV-Cre-EGFP
(above), but not in control cells negative for Cre (below).
(C) Anti-MYC immunofluorescent staining (red) of the Cre-dependent AAV-DIO-Htr4Myc delivery in the hippocampus in a Drd3-Cre::EGFP-L10a mouse. 5-HT4R-MYC was
detected at the injection site, however, EGFP-L10a expressing cell layer in DG and CA3
were lost (arrowheads). Note the intact GC layer in MYC negative area (asterisk). Scale
bar, 500 µm.
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DAPI staining clearly showed granule cell and CA3 pyramidal cell layer in control
while these layers were absent in the AAV injected site (arrowheads in DAPI
panel). Note that, at the most ventral part of AAV injected DG, there were still
EGFP expressing DG GCs (asterisk).
At a higher magnification, there were numerous small round cells stained
with anti-MYC, scattered around the DG and CA3 in AAV injected hippocampus
(MYC panel, below). These cells were also detected in green channel (EGFP
panel, below). This suggests that they are Drd3-Cre::EGFP-L10a expressing,
AAV-infected dying cells which were disintegrated from the layer. Also note that
the injection area has a higher autofluorescence than the rest of the tissue in all
three channels, which is an indication of damaged cells and tissues (Je et al.,
2017). These data suggest that, at the AAV injection site, the DG GC and CA3
pyramidal neuron layers were disintegrated and EGFP expressing cells were
lost, possibly due to the death of neurons overexpressing 5-HT4R-MYC which
was still detected in the tissue. Due to this neurotoxicity of AAV-DIO-Htr4-Myc,
we did not pursue these rescue experiments further.
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3.4. Discussion

In this chapter, we investigated the role of 5-HT4R in emotive behavior in
specific cell types and brain regions. As discussed in Chapter 2, the loss of 5HT4R from excitatory neurons of pallial origin resulted in increased anxiety-like
behaviors suggesting that hippocampal and/or cortical 5-HT4R may play a role in
mediating anxiety and mood related behaviors. To target 5-HT4R specifically in
the hippocampus or neocortex, we used two Cre-driver lines, Drd3-Cre and Tlx3Cre, that expresses Cre in non-overlapping cell populations, and that selectively
target two of the most relevant population in each region in terms of serotonergic
neuromodulation.

3.4.1. Hippocampal 5-HT4R mediates anxiety and depression related
behaviors
We found that the loss of 5-HT4R specifically from the hippocampus
resulted in a significant and comprehensive anxiogenic phenotype, measured by
variety of assays that assess innate anxiety-like behaviors. These phenotypes
included increased thigmotaxis, avoidance of open arms in EPM, hyponeophagia
and startle responses as well as decreased social interaction. These finding
suggest that 5-HT4R mediates innate anxiety through a hippocampal pathway.
Remarkably, the ablation of 5-HT4R from the hippocampus induced a
significant antidepressant-like behavioral effect observed both in despair-based
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task as decreased immobility, and hedonic/reward-based tasks as enhanced
sucrose intake and grooming. Hereby, our findings implicate a unique role for
hippocampal 5-HT4R in modulating anxiety and mood, by showing that, in the
hippocampus, 5-HT4R modulates anxiety and depression related symptoms in
opposite directions.
Growing evidence supports that especially the ventral hippocampus (vHIPP)
mediates anxiety and depression related behaviors through various
glutamatergic projections. For example, elevating the activity of GCs in the vDG
via optogenetic stimulation suppresses innate anxiety in mice (Kheirbek et al.,
2013). This supports our findings showing the anxiogenic consequences of the
loss of an excitatory 5-HT receptor from DG GCs. However, the hippocampus
regulates downstream neural pathways distinctly due to different circuit
connections and dynamics. For instance, the inhibition of specific vHIPP-mPFC
afferents via optogenetics were anxiolytic (Padilla-Coreano et al., 2016), while
these connections promoted antidepressant-like properties via both optogenetic
(Bagot et al., 2015) and chemogenetic activation (Carreno et al., 2015). Similarly,
connections to the amygdala, BNST and NAc either enhance or inhibit different
aspects of these behaviors. Considering the overall effect of serotonin is
inhibitory in hippocampal neurons, how an excitatory 5-HT receptor subtype
could regulate each component of the extended anxiety and mood circuit
remains to be investigated. Our behavioral findings suggest that 5-HT4R within
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the hippocampus was necessary to sustain normal levels of anxiety while its
absence resulted in the improvement of depression related behaviors.
As Drd3-Cre targeted cells in both the dorsal and ventral hippocampus, it
still remains to be investigated whether the anxiogenic and antidepressant-like
consequences of the deletion of 5-HT4R from these cells were originated from
the ventral or dorsal hippocampus. To dissect the function of 5-HT4R in the
dorsoventral axis of the hippocampus and to understand whether 5-HT4R was
sufficient to mediate these behaviors transiently, we designed rescue
experiments using AAV-mediated cell type specific gene expression. However,
we found that the overexpression of 5-HT4R was neurotoxic in the hippocampus.
Further studies should consider using other promoters to drive an optimal
expression of 5-HT4R. For example, another study used human synapsin (hSyn)
promoter for successful AAV-mediated overexpression of 5-HT4R in the mPFC
(Castello et al., 2017), although mPFC neurons could be more resilient for 5HT4R overexpression.

3.4.2. 5-HT4R in corticostriatal circuit mediates some anxiety and
depression related behaviors
In contrast to the hippocampal 5-HT4R function, the ablation of 5-HT4R
from CStr layer 5a p11 expressing neurons led to a slightly anxiolytic phenotype
suggesting that CStr 5-HT4R may regulate competing circuit elements against the
hippocampus in mediating anxiety-like behaviors. In addition, our results imply
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that CStr 5-HT4R may be necessary for regulating mood related behaviors since
the loss of CStr 5-HT4R was antidepressant-like in a despair based assay, FST.
In this context, the anxiolytic phenotype observed in NSF in CStr 5-HT4R cKO
mice could be also interpreted as antidepressant-like since NSF paradigm has
predictive validity for chronic antidepressant responses. Taken together, the loss
of 5-HT4R form CStr layer 5a pyramidal neurons had some anxiolytic and
antidepressant-like behavioral consequences.

3.4.3. 5-HT4R in corticostriatal circuit may regulate hedonic effects of SSRIs
We also tested the specific hypothesis that 5-HT4R in CStr p11 neurons
may be mediating the behavioral antidepressant-like responses to chronic SSRI
treatment. Our results suggested that CStr 5-HT4R was not necessary for the
antidepressant-like behavioral effects of SSRI fluoxetine in the NSF and TST.
However, the expected antidepressant-like effects of the SSRI in the splash test
were blocked when CStr 5-HT4R was ablated, suggesting a role for 5-HT4R in
CStr neurons in mediating hedonic effects of SSRI treatment. In fact, the
dorsomedial striatum (DMS) plays a significant role in reward learning and
motivated behavior (Voorn et al., 2004). Since the splash test is based on
rewarding properties of grooming and sucrose, it is possible that 5-HT4R
mediates the effects of enhanced serotonergic tone by increasing the output from
p11 CStr cells to the DMS upon chronic SSRI treatment and ultimately driving the
hedonic antidepressant responses. These results provide an evidence that the
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SSRI mediated enhancement of various mood related behaviors may be
differentially mediated via distinct circuits and serotonin receptors. Another
possibility may involve the well-described role of CStr system in repetitive
behavior (Langen et al., 2012). Since grooming can also be considered as a type
of repetitive behavior in rodents, 5-HT4R may be necessary for the effects of
SSRI on the CStr connections mediating this behavior.
Lastly, it should be also considered that CStr layer 5a neurons targeted by
Tlx3-Cre are spanned across various functionally distinct cortical areas, and have
extensive local and long range CCor connections. It is a possibility that CStr 5HT4R may regulate any part of the cortical circuits that could lead to the observed
effects after the ablation of this receptor. Further studies that selectively target 5HT4R in functionally distinct subpopulations of CStr neurons will be necessary to
tease apart the neuromodulatory roles of this receptor in specific behaviors.

3.4.4. Conclusion
In Chapter 2, the loss of 5-HT4R from all excitatory neurons in the
hippocampus and neocortex elevated anxiety levels to some extent. Further cell
type specific analysis in Chapter 3 revealed some evidence for competing circuit
elements that possibly have diluted the robust anxiety-like behaviors observed in
hippocampal 5-HT4R cKO mice. In addition, the extensive enhancements in
mood related behaviors observed following the loss of 5-HT4R specifically from
the hippocampus support the idea that there could be neural adaptations
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compensating for these behavioral changes to surface when all pallial excitatory
neurons were missing 5-HT4R. These findings point out the importance of cell
type specific studies in the investigation of neuromodulation of emotive behaviors
regulated by a complex network. The molecular and physiological mechanisms
though which hippocampal 5-HT4R mediates these behaviors will be investigated
in the next chapter.
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CHAPTER 4.
CELLULAR AND MOLECULAR FUNCTIONS OF 5-HT4 RECEPTOR
IN THE HIPPOCAMPUS
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4.1. Introduction

The hippocampus accommodates various cell types with distinct
contributions to its circuitry. In Chapter 3, we have established that 5-HT4R in
Drd3-Cre cells mediates anxiety and depression related behaviors. Although we
gained insights into hippocampal cell types targeted in Drd3-Cre line by
morphology, that is, they target cells in granule cell layer and polymorph layer in
the dentate gyrus (DG), and pyramidal cell layer in the CA fields, within these
fields, cells vary in molecular and functional identity. To pinpoint cell types in
which 5-HT4R may modulate neuronal function regulating anxiety and mood
related behaviors, we sought to investigate the molecular identity of cells in which
Drd3-Cre is expressed to conditionally abolish 5-HT4R in Drd3/Htr4 cKO,
consequently resulting in anxiogenic and antidepressant-like behavioral
responses. This characterization will help us understand the function of 5-HT4R
within hippocampal circuits, and further electrophysiological and molecular
investigation will shed light into cellular and molecular roles of 5-HT4R.

4.1.1. Neuron types and the intrinsic connections of the hippocampus
As discussed in detail in Chapter 3.1.1, the hippocampus is extensively
connected to other brain regions especially within the limbic system. While
hippocampal afferents and efferents vary in topographical organization along the
dorsoventral axis of the hippocampus, the intrinsic hippocampal circuitry
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involving various cell types is well preserved and extensively studied (Figure
4.1). Here, we will discuss the basic properties of major cell types in the
hippocampus to help us understand the consequences of our genetic
perturbation within distinct cell types (for extended review (The Hippocampus
Book, 2007)).

4.1.1.a. Granule cells of the dentate gyrus
The principal cell type of the dentate gyrus (DG) is the granule cell (GC).
GCs have canonical spiny dendrites that extend into the molecular layer (Figure
4.1). They receive spatially isolated synaptic inputs on different parts of their
dendrites: the proximal third (closest to the cell body), from the
commissural/associational fibers arising from the mossy cells of hilus; middle
third, from the medial entorhinal cortex (EC); and the distal, from the lateral EC
(Amaral et al., 2007). In addition, GCs also receive neuromodulatory and
inhibitory input from several external sources and local interneurons either on
their dendrites or their cell bodies.
The resting membrane potential of a GC is more hyperpolarized than that
of a pyramidal neuron in the CA fields although both cell types have similar
action potential thresholds (Penttonen et al., 1997). Therefore, larger
depolarizations are required to bring a GC to threshold for action potential
generation. As the major excitatory input to the rest of the hippocampus, this
characteristic may provide a wider range for neuromodulatory signals.
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Figure 4.1. Hippocampal regions and intrinsic circuitry.
An illustration of basic hippocampal circuitry. Modified from Deng et al. (2010).
DG: dentate gyrus, SUB: subiculum, ENT: entorhinal cortex, mi: molecular layer, gcl:
granule cell layer, pml: polymorph layer, sgz: subgranular zone, so: stratum oriens, pcl:
pyramidal cell layer, sr: stratum radiatum.
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Upon reaching the threshold in response to long depolarizing input, granule cells
fire trains of action potentials demonstrating marked accommodation (Penttonen
et al., 1997). On the other hand, young adult-born GCs risen from the
subgranular zone (SGZ) have distinct electrophysiological properties, including
high input resistance and a lack of GABAergic inhibition. This results in lower
activation thresholds and higher excitability compared to mature GCs (Toni and
Schinder, 2015). Notably, young adult-born GCs inhibit the overall activity of the
mature GCs by recruiting local interneurons.

4.1.1.b. Mossy cells of the hilus
Another major excitatory neuron of the DG is the mossy cell in the
polymorphic layer (the hilus) (Figure 4.1). Mossy cells receive direct excitatory
input from the granule cell mossy fibers (Scharfman, 2013). Mossy cells exhibit
frequent and large excitatory postsynaptic potentials (EPSPs), that can trigger
bursts of action potentials (Scharfman and Schwartzkroin, 1988). The axons of
mossy cells form the majority of excitatory projections on to the proximal
dendrites of granule cells (Buckmaster et al., 1992). Indeed, individual mossy
cells contribute to both the ipsilateral and contralateral projections. The
projections from mossy cells located at any particular level of the dentate gyrus
are distributed widely to both septal and temporal regions of the DG from the
point of origin (Amaral and Witter, 1989). One of the most outstanding
characteristics of these projections regarding their contribution to the
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hippocampal circuit is that they are extremely weak at the level of the cells of
origin while becoming increasingly stronger at levels that are progressively more
distant. This indicates that the mossy cells transmit the collective output of GCs
from one septotemporal region to GCs located at distant levels of the DG.

4.1.1.c. Interneurons of the dentate gyrus
There is an extreme diversity of interneurons in dentate gyrus. Some have
axons that terminate on cell bodies, whereas others on the initial segments of the
axons of different DG neurons executing distinct functions in the local circuit
(Freund and Buzsáki, 1996). They are all GABAergic although can be
distinguished on the basis of their location in a specific layer, morphology, inputs,
electrophysiological properties or immunoreactivity to certain marker proteins and
peptides such as parvalbumin (PV), somatostatin (SST), cholecystokinin (CCK)
and vasoactive intestinal peptide (VIP).
One of the most widely studied interneuron classes is the basket cells due
to their extensive direct innervation of granule cells. They are generally located
along the hilar surface of the granule cells. Their axonal terminals form a basket
shaped axonal plexus surrounding the granule cells, with inhibitory synapses
located primarily on the cell bodies and proximal dendritic shafts of the granule
cells (Freund and Buzsáki, 1996; Hu et al., 2014). Within the subgranular region,
polymorphic and molecular layers of the DG, there are several other interneuron
types with distinct forms and molecular profiles. GABAergic neurons in the
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polymorphic layer are innervated by other extrinsic and local GABAergic
terminals. These polysynaptic inhibitory interconnections provide intricate
inhibitory and disinhibitory control of granule cell excitability. This inhibitory circuit
is also differentially modulated by monoaminergic neuromodulators based on the
specific receptors expressed in different cell types (Medrihan et al., 2017).

4.1.1.d. Neurons of the CA fields
The principal neuronal cell type of the CA fields is the pyramidal cell. As in
the dentate gyrus, there is also a heterogeneous population of GABAergic
interneurons scattered through all layers (Freund and Buzsáki, 1996). The inputs
to infrapyramidal parts of CA fields (between pyramidal cell layer and
hippocampal fissure) are relatively layer specific (The Hippocampus Book, 2007).
From distal (closer to subiculum) to proximal (closer to DG), these projections
consist of entorhinal afferents, Schaffer collaterals (from CA3 to CA1), recurrent
and commissural collaterals (CA3 to CA3), mossy fibers (DG to CA3) (Figure
4.1). Suprapyramidal parts of the CA fields (between pyramidal cell layer and
alveus) receive mostly recurrent connections. The CA3 to CA1 projection, the
major input to CA1 pyramidal cells, terminates on the basal and the apical
dendrites.
The connection from a particular CA3 pyramidal neuron to a CA1
pyramidal neuron depends on the septotemporal positions of the two cell bodies.
At one particular septotemporal level, a distal CA3 cell (closer to CA1) is more
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likely to interact with a proximal CA1 cell (closer to CA3), whereas a proximal
CA3 cell (closer to DG) is more likely to interact with a distal CA1 cell (closer to
subiculum).

4.1.2. Serotonergic modulation of hippocampal neurons
In the hippocampus, serotonergic input from the raphe nuclei terminates
primarily in the hilus where it differentially modulates the activity of distinct cell
types depending on the serotonin receptor composition (Swanson, 1987). 5-HT
induces a hyperpolarization in isolated GCs in rodent slice preparations, at least
in part, due to the expression of 5-HT1A heteroreceptors (Piguet and Galvan,
1994). Other serotonin receptors coexpressed within GCs may mediate this
inhibitory effect of 5-HT. For example, 5-HT4R has been shown to decrease the
afterhyperpolarization (AHP) following an action potential in the presence of 5-HT
mediating the excitability (Andrade, 2006; Fagni et al., 1992; Torres et al., 1995).
Moreover, in vivo, enhanced serotonergic tone in the DG after chronic SSRI
treatment inhibits the activity of GCs through 5-HT1AR which is necessary for
behavioral responses to SSRIs (Samuels et al., 2015). Interestingly, optogenetic
activation specific to the ventral dentate gyrus granule cells decreases innate
anxiety-like behaviors (Kheirbek et al., 2013).
In addition to the direct modulation of GCs, interneuron activity has shown
to be regulated via 5-HT by various 5-HTRs, and consequently, the activity of
GC. For instance, enhanced serotonergic tone after acute SSRI treatment leads
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to the inhibition of CCK-positive basket cells through 5-HT1BR, in turn,
disinhibiting PV-positive basket cells. As a result, the increased GABAergic input
to GCs decreases the excitability of GCs (Medrihan et al., 2017). Since SSRI
treatment leads to elevated neurogenesis in DG (David et al., 2009), and stress
and glucocorticoids increase dentate gyrus activity (Schoenfeld et al., 2013), the
neurogenic inhibition via young adult born GCs of the dentate gyrus may also be
relevant for anxiety and depression. Modulating the dentate gyrus activity may
direct the output strength from the hippocampus to downstream limbic centers
and moderate the extended anxiety and mood network.
A number of features of pyramidal cell physiology are also under
modulatory control by 5-HT. For example, serotonin has biphasic effects on CA1
pyramidal neurons, initially causing hyperpolarization due to the activation of a
potassium (K+) current possibly through 5-HT1AR, yet later leading to
depolarization and inhibition of the AHP, possibly via some excitatory 5-HTRs,
such as 5-HT4R (Tokarski et al., 2002). Numerous other modulatory effects have
been reported in pyramidal neurons of the CA fields, indicating that the resting
and active properties of these neurons in vivo are likely to regulate behavioral
states.
Serotonin has neuromodulatory effects depending on the serotonergic
receptor profile of a specific neuron. As an excitatory GPCR, 5-HT4R has been
indicated to play a role in the activity of the neurons, increasing the excitability in
the presence of 5-HT and 5-HT4R agonist. In addition, increased serotonergic
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tone via SSRI’s has shown to decrease the excitability of the granule cells in DG.
Thus, the investigation of neuronal activity and physiological properties in the
absence of 5-HT4R will provide more insights into both intracellular and circuit
functions of this receptor.

4.1.3. Differential gene expression along the dorsoventral axis of the
hippocampus
The development of a transcriptional map of the mouse hippocampus,
using genome-scale in situ hybridization, has provided more detailed molecular
evidence for distinct patterns of gene expression in mouse brain including
hippocampus (Allen Brain Atlas)(Lein et al., 2007). Using robust gene markers, it
has been proposed that the dentate gyrus, the CA3 and CA1 are segregated into
three major molecular domains: dorsal, intermediate and ventral (Strange et al.,
2014). Furthermore, the advancement in next generation genome-wide RNA
sequencing has allowed for the analysis of the transcriptome of the principle
excitatory neurons in the hippocampus, providing further evidence for the
molecular diversity of neurons within the same layer at spatially distinct regions
(Cembrowski et al., 2016).
Notably, four serotonin receptors, Htr1a, Htr2a, Htr2c and Htr7, also
display an expression pattern that varies along the dorsoventral axis (Tanaka et
al., 2012). The differential gene expression among discreet subpopulations of
hippocampal neurons may also underlie physiological differences in neuronal
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excitability (Dougherty et al., 2012) and synaptic plasticity (Dougherty et al.,
2013; Maggio and Segal, 2007).
In this chapter, we investigated the underlying cellular and molecular
mechanisms of the mediating function 5-HT4R in anxiety and depression related
behaviors. The identification of the cell types targeted by our genetic
perturbation, and the investigation of cellular and molecular responses to 5-HT4R
ablation (such as changes in gene expression along hippocampal long axis and
in electrophysiological properties of the neurons) will help us understand the
function of this receptor at the cellular level.
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4.2. Drd3-Cre and Htr4 expression in distinct cell types of the hippocampus

4.2.1. Cell type specific Drd3-Cre expression
To visualize the Cre expressing cells in Drd3-Cre mice, we used
immunofluorescent labeling of EGFP in coronal sections of whole brain samples
Drd3-Cre::EGFP-L10a mice. Drd3-Cre mice were crossed with a Cre dependent
EGFP-RPL10a (EGFP-L10a) expressing reporter mouse line to generate the
Drd3-Cre::EGFP-L10a line. Since EGFP is fused with the RPL10a (ribosomal
protein subunit L10a), it would primarily localize to the soma of Drd3-Cre
expressing neurons for an ideal identification without labeling the projections.
We first investigated the dorsal and ventral hippocampus expression
pattern of Drd3-Cre::EGFP-L10a by co-labeling the hippocampal sections with
anti-EGFP and anti-neuronal nuclei (NeuN) antibodies. NeuN is a neuronal
nuclear protein synthesized by feminizing locus on X-3 gene, Fox-3, and
commonly used as a histological marker for most neurons. In dorsal parts of the
hippocampus, most of the CA1 and CA3 pyramidal neurons expressed EGFPL10a and all of them co-localized with NeuN showing that all Cre expressing cells
are neuronal (Figure 4.2A, left). However, as also discussed previously, EGFPL10a expressing cells were not detectable more ventrally in CA1 (Figure 4.2A,
right). Notably, there was a consistent expression of EGFP-L10a in the granule
cell layer and some of the cells in the hilus of DG.
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To determine whether any Drd3-Cre neurons in CA field were inhibitory
interneurons, we colabeled the Drd3-Cre::EGFP-L10a brain sections with an antiGAD67 antibody. GAD67 is a glutamic acid decarboxylase (GAD) enzyme that
catalyzes the production of GABA, the primary neurotransmitter of the inhibitory
interneurons, and can be used as a histological marker for all GABAergic
interneurons. Both in the CA1 and CA3, none of the EGFP expressing cells were
positive for GAD67 (Figure 4.2B), indicating that all Drd3-Cre expressing
neurons are excitatory pyramidal cells in these regions.
To identify neuronal cell types of the Drd3-Cre expressing neurons in DG,
hippocampal sections from Drd3-Cre::EGFP-L10a mice were double-labeled with
antibodies for EGFP and neuronal-type markers (Figure 4.3). All EGFP
expressing cells in DG were neurons marked by NeuN. Moreover, EGFP
expressing cells were colabeled with calbindin (CBD) antibody, a marker for
mature granule neurons. Note that some CBD positive cells in the edge of GC
layer did not express EGFP (arrowheads), which are possibly the CBD-positive
interneurons. In the hilus, EGFP was detected in calretinin (CRT)-expressing
mossy cells. On the other hand, it was absent from CRT and doublecortin (DCX)expressing immature neurons, and GAD67-expressing GABAergic interneurons),
including the parvalbumin (PV)-expressing basket cells (asterisk in each
corresponding panel).
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Figure 4.2. Drd3-Cre targets excitatory neurons of the hippocampus.
A. Anti-EGFP (green) and anti-NeuN (red) immunofluorescent images showing Drd3-Cre
driven EGFP-L10a expression in the dorsal and ventral hippocampus. Note that EGFP
staining was not detected in vCA1.
B. Anti-EGFP (green) and anti-GAD67 (red) immunofluorescent images depicting that
none of the Drd3-Cre driven EGFP expressing cells were GAD67-positive GABAergic
interneurons, both in the CA1, and CA3 fields. Arrowheads, GAD67-postive cells.
Asterisks, GAD67-negative.
Scale bars, 100 µm.
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Figure 4.3. Drd3-Cre targets mature excitatory neurons in the dentate gyrus.
Immunofluorescent images showing neuronal-type specific marker expression (red) in
Drd3-Cre driven EGFP-L10 expressing neurons in dentate gyrus (DG). Arrowheads,
cells expressing a specific neuron-type marker but not EGFP. Asterisks, cells
coexpressing hilar mossy cell marker CRT and EGFP.
Scale bars, 50 µm.
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Together, we conclude that, in the DG, Drd3-Cre exclusively targets
mature excitatory neurons – mature granule cells and hilar mossy cells but not
immature neurons, interneurons and non-neuronal cells (such as glia). In the CA
fields, Drd3-Cre also only targets the excitatory pyramidal cells. This suggests
that using Drd3-Cre to genetically ablate 5-HT4R leads to its absence in the
mature excitatory neurons of the hippocampus.

4.2.2. Cell type specific expression of Htr4-EGFP-L10a
In order to determine whether Drd3-Cre targets all 5-HT4R expressing
cells in the hippocampus, we wanted to identify 5-HT4R expressing cell types.
Due to its recapitulation of Htr4 expression pattern, we used Htr4-bacTRAP mice
(Htr4-EGFP-L10a), which express EGFP-L10a under the regulatory elements
and promoter of the Htr4 gene. We investigated the distribution of EGFP-L10a
along the dorsoventral axis by colabeling the hippocampal sections with antiEGFP and anti-NeuN (Figure 4.4A). Throughout the hippocampus, Htr4-EGFPL10a was expressed in most of the pyramidal cells of CA regions, and most of
the cells in the granule cell layer and some cells in the hilus of DG. Notably, all
EGFP labeled cells were NeuN-positive showing that Htr4-EGFP-L10a
expressing cells are neuronal. In addition, anti-GAD67 immunofluorescent
labeling in CA fields revealed that Htr4-EGFP-L10a neuron population did not
include any GABAergic interneurons (Figure 4.4B), suggesting that Htr4 is
expressed only in excitatory neurons in the CA field.
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Figure 4.4. Htr4-EGFP-L10a is expressed in excitatory neurons of the
hippocampus.
A. Anti-EGFP (green) and anti-NeuN (red) immunofluorescent images showing Htr4EGFP-L10a expression in hippocampus (above). Higher magnification images showing
coexpression of Htr4-EGFP-L10a and NeuN in CA1 and CA3 pyramidal cell layer
(below).
B. Anti-EGFP (green) and anti-GAD67 (red) immunofluorescent images depicting that
none of the Htr4-EGFP-L10a driven EGFP expressing cells were GAD67-positive
GABAergic interneurons, both in the CA1, and CA3 fields. Arrowheads, GAD67-postive
cells. Asterisks, GAD67-negative. Scale bars, 100 µm.
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To identify which neuronal cell types express 5-HT4R in the DG,
hippocampal sections from Htr4-EGFP-L10a mice were double-labeled with
antibodies for EGFP and neuronal-type markers (Figure 4.5). Similar to the
Drd3-Cre line, Htr4-EGFP-L10a expressing cells were all neurons positive for
NeuN in DG. Moreover, Htr4-EGFP-L10a was detected in CBD-expressing
mature granule neurons and CRT-expressing mossy cells in hilus; whereas, it
was absent in DCX- and CRT-expressing immature neurons and GAD67expressing GABAergic interneurons, including PV-expressing basket cells.
Together, the expression pattern of transgenic Htr4-bacTRAP line suggests that,
in the DG, 5-HT4R is expressed in mature excitatory neurons – mature granule
cells and hilar mossy cells, similar to Drd3-Cre expression pattern. Therefore, in
the DG, Drd3-Cre possibly targets almost all of the Htr4 expressing cells. In CA
fields, most of the Htr4 expressing pyramidal cells were also targeted by Drd3Cre except in the ventral parts of CA1 where Drd3-Cre expression is absent.
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Figure 4.5. Htr4-EGFP-L10a is expressed in mature excitatory neurons in the
dentate gyrus.
Immunofluorescent images showing neuronal-type specific marker expression (red) in
Htr4-EGFP-L10a expressing neurons in dentate gyrus (DG). Arrowheads, cells
expressing a specific neuron-type marker but not EGFP. Asterisks, cells coexpressing
hilar mossy cell marker CRT and EGFP.
Scale bars, 50 µm.
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4.3. Cellular and molecular adaptations in hippocampus specific Htr4
knockout mice

As we identified the cell types in which 5-HT4R was ablated in the
Drd3/Htr4 cKO mice, we next sought to examine the cellular and molecular
neuroadaptations that may underlie the behavioral phenotype observed.
Specifically, since the absence of hippocampal 5-HT4R led to behavioral
antidepressant-like responses, we wanted to examine whether it also resulted in
any antidepressant-like responses at cellular and molecular levels, such as
enhanced adult hippocampal neurogenesis and increased expression of
neurotrophic factors.

4.3.1. The effect of hippocampus specific loss of 5-HT4R on neurogenesis

4.3.1.a. Changes in the number of young adult born granule cells
One of the hallmarks of antidepressant-like responses in the hippocampus
is increased adult hippocampal neurogenesis. SSRIs and other antidepressant
treatments boost neurogenesis in DG and neurogenesis is necessary for some of
the behavioral responses to antidepressant treatment. To determine whether the
loss of 5-HT4R from the hippocampus altered adult hippocampal neurogenesis,
we examined brains from the Drd3/Htr4 cKO mice and their control littermates
from which the behavioral measures were previously assessed. To measure any
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differences in adult hippocampal neurogenesis between groups, we measured
the number of immature adult born granule cells (abGC) which are neurons that
have recently been born in the SGZ of the DG, become post-mitotic, yet not fully
incorporated in GC layer. Briefly, we immunolabeled abGCs with antidoublecortin (DCX), a marker for immature neurons, in coronal brain sections of
Drd3/Htr4 cKO mice and their control littermates. Under a fluorescent
microscope, the number of DCX-positive cells was measured in the SGZ in every
sixth 40 µm section, counting the cells at any depth in a section while blinded for
genotype (Figure 4.6A). The hippocampus was divided into three subdivisions
depending on the position of the coronal sections according to bregma – dorsal,
intermediate and ventral (4 sections per subdivision) – to get a better estimate of
the number of immature abGCs in the dorsoventral axis. Neurogenesis was
calculated as the number of DCX+ neurons per granule cell layer area per
section (Figure 4.6B) and averaged per region for normalization between
sections and regions. We observed that there were more DCX+ neurons in the
ventral DG of Drd3/Htr4 cKO mice compared to the controls (WT) (Figure 4.6C).
Indeed, DCX+ neurons per area was significantly higher (67%) specifically in the
ventral DG in the cKO compared to WT (p=0.002, n=5 animals per group)
(Figure 4.6D). There was not any significant difference in the dorsal or
intermediate DG between genotypes. These results indicated that Drd3/Htr4 cKO
mice had increased number of immature abGC in the ventral DG, implying the
loss of 5-HT4R led to increased ventral hippocampal neurogenesis.
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Figure 4.6. Drd3/Htr4 cKO mice showed increased neurogenesis specifically in the
ventral dentate gyrus.
A. A schematic of the experimental approach. The hippocampus was divided into three
subdivisions depending on the position of the coronal sections according to bregma –
dorsal, intermediate and ventral (4 sections per region). The number of DCX-positive
cells was measured in every sixth 40 µm section.
B. A depiction of granule cell layer area calculation in Image J in sections from which
DCX+ neurons were counted.
C. Examples of immunofluorescent confocal microscopy images showing increased
number of DCX+ cells (green) in the ventral DG.
D. DCX+ cells per area was significantly higher (67%) in the ventral DG in the cKO
compared to WT. Data are represented as mean ± SEM. Two-way ANOVA followed by
post hoc Fisher’s LSD test. n=5 animals per group, **p<0.01.

159

4.3.1.b. Changes in the expression of neurotrophic factors
Increase in the levels of neurotrophic factors in the hippocampus have
been associated with increased neurogenesis and the action of serotonergic
antidepressants. To gain insight into the underlying molecular mechanism that
may lead to enhanced adult hippocampal neurogenesis, we measured the gene
expression levels of the neurotrophic factors, BDNF and VEGF, in the
hippocampus (Bdnf and Vegfa genes, respectively). Dorsal and ventral parts of
the DG and CA fields were dissected from the brains of the Drd3/Htr4 cKO mice
and their control littermates from which the behavioral measures were previously
assessed (Figure 4.7A). Total RNA samples from these four parts of the
hippocampus were isolated, and the microdissection quality was checked by
qRT-PCR measurements of the expression of region enriched genes: Dsp
(desmoplakin, specific for DG), Tyro3 (TYRO3 protein tyrosine kinase 3, specific
for CA), Lct (lactase, specific for dDG) and Trhr (thyrotropin releasing hormone
receptor, specific for vDG). All of our hippocampal regions were enriched for their
respective region-specific gene expression, confirming the quality of the
dissection (Figure 4.7B). In all four regions, Bdnf and Vegfa expression were
consistently and significantly increased in Drd3/Htr4 cKO samples compared to
control throughout the hippocampal regions (BDNF, p=0.0007; VEGF, p=0.0034;
Two-way ANOVA) (Figure 4.7C).
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Figure 4.7. Drd3/Htr4 cKO mice showed elevated expression of neurotrophic
factors in the hippocampus.
A. A schematic of the microdissection of different regions in hippocampus.
B. qRT-PCR measurements of the expression of region enriched genes in all samples:
Dsp (desmoplakin, specific for DG), Tyro3 (TYRO3 protein tyrosine kinase 3, specific for
CA), Lct (lactase, specific for dDG) and Trhr (thyrotropin releasing hormone receptor,
specific for vDG). Each hippocampal region was enriched for its respective regionspecific gene expression. Data points represent WT and cKO sample replicates.
C. qRT-PCR measurements of the expression of neurotropic factors BDNF and VEGF
showed significantly higher expression of both factors in Drd3/Htr4 cKO compared to WT
throughout the hippocampal regions. Two-way ANOVA, ¥¥p<0.01, ¥¥¥p<0.001. Post
hoc Fisher’s LSD test, **p<0.01, *p<0.05, #p<0.10. WT: n=2, cKO: n=5.
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4.3.2. Neuroadaptations in the serotonergic system in the hippocampus
upon the loss of hippocampal 5-HT4R
Serotonin receptors are expressed in various cell types in distinct
combinations and act synergistically to mediate the effects of 5-HT on gene
expression and cellular function. To determine whether there are
neuroadaptations in the cellular serotonergic system in response to the loss of 5HT4R specifically from hippocampal mature excitatory neurons, the gene
expression levels of different 5-HT receptors were measured in the total RNA
samples from dorsal and ventral parts of DG and CA fields of the hippocampus
by qRT-PCR, and compared between Drd3/Htr4 cKO mice and their control
littermates (WT). Here, we report the differential expression of five serotonin
receptors – Htr1a, Htr1b, Htr2a, Htr2c and Htr6 – and S100a10 (p11), as a
known regulator of 5-HTR expression. In situ hybridization data from Allen brain
atlas (Figure 4.7A) and other studies have shown the expression pattern of Htrs
in the hippocampal regions and cell types (Tanaka et al., 2012). Briefly, Htr1a is
expressed in all regions including GC in the DG, pyramidal cells in the CA fields
and interneurons. Htr1b is expressed mainly expressed in CA1 pyramidal cells
and some interneurons in the DG, while its expression in GCs and CA3
pyramidal cells are observed in lower levels. Htr2a is enriched in vCA3 pyramidal
cells proximal to the DG, and hilar mossy cells, retaining lower expression in
other cell types. On the other hand, Htr2c is more enriched in CA3 pyramidal
cells distal to the DG, especially in the ventral hippocampus. Htr6 have a
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ubiquitous expression pattern throughout the hippocampus. S100a10 is
expressed in some CA pyramidal cells and interneurons, and some interneurons
in the DG (Egeland et al., 2011b). Htr1d, Htr1f, Htr2b, and Htr7 expression were
too low to detect in our hippocampal samples by qRT-PCR. We did not measure
Htr5a and Htr5b expression in this experiment.
We first showed that mRNA expression levels in our samples from each
region, dDG, dCA, vDG and vCA, corresponded to observed expression in ISH
data previously reported (Figure 4.7B). To better analyze the difference in Htr
expression between Drd3/Htr4 cKO and WT, we plotted log2 fold change of each
gene in cKO compared to WT, per region (Figure 4.7C).
Overall, the most significant differential expression of Htrs between
genotypes was observed in the vDG. In the vDG, Htr1a expression was
significantly depleted in the cKO (1.35 fold), while Htr1b, Htr2c and Htr6 were
significantly enriched (1.93, 1.66, and 5.30 folds, respectively). Although the
differential expression pattern for these vDG significant genes was similar in the
dDG, it was subtle and not significant.
Similar to the DG, the differential gene expression of Htrs between
genotypes were more significant in the vCA compared to the dCA. In the vCA,
Htr1a expression was slightly diminished in the cKO (1.28 fold, p=0.07), while
Htr1b was significantly enriched (1.95 fold). In addition, Htr2c and Htr6
expression were also slightly enriched in the cKO in the vCA (2.83 fold, p=0.08;
2.22 fold, p=0.08; respectively).
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Figure 4.8. Region- and subtype specific-serotonin receptor expression changes
in the hippocampus were observed in Drd3/Htr4 cKO mice.
A. Different serotonin receptor (Htr) expression profiles by ISH. Images from Allen Brain
Atlas.
B. qRT-PCR quantification of each Htr expression in our hippocampal region samples.
Arbitrary units (a.u.).
C. qRT-PCR quantification of Htr expression in Drd3/Htr4 cKO compared to controls
(WT) in each hippocampal region.
Data are represented as mean ± SEM. Two-tailed unpaired t-test. WT: n=2, cKO: n=5,
***p<0.001, **p<0.01, *p<0.05, #p<0.10.
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Similar to the vCA, Htr1b and Htr2c also showed slight enrichment in the cKO in
the dCA (1.69 fold, p=0.05; 3.22 fold, p=0.10; respectively). There were not any
significant differences in the expression levels of Htr2c and S100a10 between
genotypes throughout the hippocampal regions.
Together these results showed that, in the Drd3/Htr4 cKO mice compared
to controls, Htr1a was depleted in the ventral DG and CA fields. Htr1b and Htr2c
were consistently enriched in all regions, more significantly in the ventral
hippocampus. Lastly, Htr6 was preferentially enriched in the ventral
hippocampus. Our data revealed that the loss of 5-HT4R from the mature
excitatory neurons of the hippocampus led to neuroadaptations in the
serotonergic system in a receptor type- and region-specific manner in the
hippocampus.

4.3.3. The role of 5-HT4R in mediating the electrophysiological properties of
dentate gyrus granule cells
To investigate if the specific loss of 5-HT4R from hippocampal neurons
has any electrophysiological consequences, we performed whole-cell patch
recordings in dentate gyrus (DG) granule cells (GCs) in acute hippocampal slices
from Drd3/Htr4 cKO mice and their control littermates (WT). First, we employed a
potent 5-HT4R agonist, BIMU-8, to test the effect of 5-HT4R activation in DG
GCs. Figure 4.9A shows representative traces of whole-cell recordings in the
voltage clamp configuration from DG GCs in WT and Drd3-Cre/Htr4 cKO mice.
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Figure 4.9. DG granule cells showed reduced firing in Drd3-Cre/Htr4 cKO mice.
A. Representative traces of whole-cell recordings in the voltage clamp configuration from
DG granule cells (GC) in WT and Drd3-Cre/Htr4 cKO mice. BIMU-8 (10 mM) was added
to the bath for 1 minute and subsequently washed.
B. Sample traces from whole-cell current-clamped DG GCs in WT and Drd3-Cre/Htr4
cKO mice showing the action potential (AP) firing of the cells in response to different
steps of injected current.
C. Graph of AP frequency of granule neurons in WT and Drd3-Cre/Htr4 cKO mice in
response to different steps of injected current.
D. Histogram of the rheobase (minimum amount of injected current necessary to elicit an
AP) in WT and Drd3-Cre/Htr4 cKO mice.
E. Representative single APs from WT and Drd3-Cre/Htr4 cKO DG GCs.
F. Action potential properties show no significant difference between genotypes. HAW=
half-amplitude width, fAHP = fast afterhyperpolarization potential.
Data are represented as mean ± SEM. For each genotype 11 neurons from 3 mice were
used for each experiment. *p < 0.05, **p < 0.01 two-tailed unpaired t-test.
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BIMU-8 (10 mM) was added to the bath for 1 minute and subsequently washed.
Tetradotoxin (TTX, 1 mM) was added previously to the bath to avoid activation of
neighboring neurons by BIMU-8.
BIMU-8 led to an inward current in WT GCs showing a depolarizing effect
of the activation of 5-HT4R. However, cKO GCs did not respond to BIMU-8,
confirming the absence of functional 5-HT4R in DG GCs in Drd3/Htr4 cKO mice.
Next, to measure the firing of DG GCs, and test whether 5-HT4R mediates
the excitability of DG GCs, we performed whole-cell current-clamp recordings
while injecting increasing currents in different steps. Specifically, steps of 25 pA
current were injected from a set starting membrane potential of -80mV. The firing
frequency (action potential, AP, frequency in Hz) of GCs in Drd3/Htr4 cKO mice
was significantly reduced when compared to WT (Figure 4.9B, C). We also noticed
in GCs from Drd3/Htr4 cKO a significant increase in the rheobase, the amount of
current (pA) necessary to be injected to elicit an action potential (Figure 4.9D). On
the contrary, the properties of a single action potential were not different between
GCs from Drd3/Htr4 cKO and WT mice (Figure 4.9E, F). Specifically, there were
not any difference in the AP threshold (mV), AP amplitude (mV), fast
afterhyperpolarization potential (fAHP, mV) and half-amplitude width (HAW, ms)
between genotypes. These data show that the loss of 5-HT4R from DG GCs leads
to reduced firing and excitability in DG GCs, indicating discreet and specific
physiological changes that may underlie the behavioral phenotype observed in the
Drd3/Htr4 cKO mice.
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4.4. Cell type specific genome-wide differential gene expression analysis
along the dorsoventral axis of the hippocampus

We have shown that 5-HT4R mediates the expression of neurogenic factor
and serotonin receptors, and physiological properties of neuronal activity. It is
highly possible that 5-HT4R regulates these mechanisms, and consequently,
anxiety and mood related behaviors, via other intracellular signaling
mechanisms. Identification of the novel pathways and the proteins that interact
with 5-HT4R presents a powerful approach to discover unique targets that may
contribute to anxiety and depression pathophysiology.
To investigate genome wide molecular neuroadaptations and elucidate
candidate mechanisms that might play role in the anxiogenic and antidepressantlike effects of the loss of 5-HT4R, we used TRAP-Seq method to identify proteins
actively transcribed in Drd3-Cre positive cells in the hippocampus. TRAP-Seq
combines the isolation of mRNA bound ribosomes from a genetically defined cell
type and next-gen genome-wide RNA sequencing to acquire differential
expression analyses (see Chapter 1 for details). We used this method to acquire
(1) differentially expressed genes between the dorsal and ventral DG in the
whole tissue, and specifically in mature excitatory neurons, (2) molecular
neuroadaptations in the dorsal and ventral DG upon conditional knockout of Htr4
from mature excitatory neurons of the hippocampus, and (3) changes in the
transcriptome of mature excitatory neurons upon the conditional Htr4 deletion.
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For the control samples (WT), we used Drd3-Cre::EGFP-L10a mice,
generated by crossing Drd3-Cre mice with Cre-dependent EGFP-L10a reporter
mice. These animals expressed the RPL10a-EGFP in the mature excitatory
neurons of the hippocampus in a “wildtype” genetic background. The expression
of EGFP-RPL10a in Drd3-Cre positive neurons in Htr4 conditional knockout
background was accomplished by two steps. First, we generated Cre dependent
EGFP-L10::Htr4loxP/loxP by crossing the Cre dependent EGFP-L10a reporter mice
with Htr4-floxed mice (Htr4loxP/loxP) for two generations. Second, Cre-dependent
EGFP-L10::Htr4loxP/loxP mice were crossed with Drd3-Cre::Htr4loxP/loxP (Drd3/Htr4
cKO) to generate Drd3-Cre::EGFP-L10a/Htr4 cKO. Consequently, these animals
expressed EGFP-RPL10a in Drd3-Cre cells with Htr4 cKO background, and were
used for the cKO samples.
For TRAP, three biological replicate samples were collected from the dDG
and vDG of both cKO and WT mice. Bilateral corresponding hippocampal region
of age matched (8-to-12 weeks old) one male and one female mice were pooled
for each sample, except for the first cKO replicate (cKO1) which used two
females, due to the challenging breeding of the cKO animals. The purified mRNA
from IP (Drd3-Cre specific TRAP mRNA) and input (whole mRNA) samples of
each replicate was sequenced. Normalized values of gene expression from IP
and input samples (2) from the dDG and vDG (2) for each of the three (3)
replicates of both genotypes (2) were obtained to yield a total of twenty-four (24)
RNA-Seq data sets (see Material and Methods for the details).
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For the quality control of our TRAP-Seq datasets, the percentage of bases
aligned to the genome, and the percentage of aligned bases corresponding to
the ribosomal RNA, coding, untranslated (UTR), intronic and intergenic regions
were calculated for all samples (Figure 4.10A). The analysis of the base
alignment data showed consistent percent alignment values for all samples (over
60%), and they were similarly distributed among the genomic regions; except
that the input and IP samples from the dDG of cKO1 showed irregularly lower
percentage of bases aligned. Furthermore, these datasets had lower percentage
of aligned bases to coding regions while higher percentage in intergenic and
intronic regions, respectively. Therefore, they (dDG cKO Input/IP 1) were
excluded from further differential expression analyses. In order to visualize
overall transcriptional variability between different biological replicates and
replicate quality, Pearson correlation statistics were performed using normalized
expression values between samples with the same origin of preparation (input or
IP) and brain region (dDG or vDG). All samples showed minimal variability (r
>90), except for the dDG input sample of cKO1 (Figure 4.10B).
Next, the visualization of reads from TRAP-Seq datasets mapped to the
mouse genome showed that in the cKO samples, there were not any reads
mapped to Htr4 exon 5, confirming the conditional deletion in Drd3/Htr4 cKO
mice (Figure 4.11A).
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Figure 4.10. Quality control of genome aligned TRAP-Seq replicates.
A. The percentage of alignment of mRNA bases to the genome (left), and the
percentage of the aligned bases corresponding to the ribosomal RNA, coding,
untranslated (UTR), intronic and intergenic regions (right). Input (above) and IP (below)
are shown in separate histograms. Note that “dDG cKO Input/IP 1” showed irregular
alignment.
B. Heatmaps showing Pearson correlation statistics performed using normalized
expression values between samples with the same preparation (input, left or IP, right)
and brain region of origin (dDG or vDG). All samples showed minimal variability (r >90),
except for the dDG input sample of cKO1. Legend shows corresponding heatmap colors
for r-values between 0.5 (red) and 1 (blue).
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Figure 4.11. Visualization of TRAP-Seq reads mapped to cell type and region
marker genes for each sample.
A. There was not any reads mapped to Htr4 exon 5 (red dotted borders) in samples from
Drd3/Htr4 cKO mice. dDG specific Lct expression was enriched in dDG samples, and
vDG specific Trhr expression in vDG samples. Note some CA specific Tyro3 expression
in the vDG. CA1 specific Fibcd1 expression was not particularly enriched while Coch
expression (specific to distal tip of vCA3) was observed in vDG samples.
B. Visualization of reads mapped to the cell-type specific marker genes revealed that all
IP samples compared to input counterparts were consistently enriched in granule cell
specific genes (Tdo2, Calb1), and depleted for genes specific for neuronal precursors
(Dcx, Nr2e1), interneurons (Slc32a1, Gad2), astrocytes (Aldh1l1, Cnp), oligodendrocytes
(Olig2), microglia (Olfml3), pericytes (Cldn5) and endothelial cells (Pdgfrb), except for
dDG cKO IP3 and vDG cKO IP3 (red dotted borderlines).
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Reads mapped to other exons of Htr4 confirmed the expression of exon 5
deleted mRNA (as previously confirmed with qRT-PCR). In addition, dDG
specific Lct expression was enriched in dDG samples, and vDG specific Trhr
expression in vDG samples, confirming the quality of our sampling. While some
CA specific Tyro3 expression was observed in vDG, CA1 specific Fibcd1
expression was not particularly detected. However, similar to Tyro3, some Coch
expression (a gene specific to the distal tip of the vCA3 innervating the vDG) was
detected in some of vDG samples, indicating that there may have been a small
number of vCA3 cells passed on to these samples. This is possibly due to the
anatomical difference between the dDG and vDG, the latter being innervated by
the CA3 deeper into the hilus. It would be advisable to keep this in consideration
in our analyses.
Further visualization of reads mapped to the cell type specific marker
genes revealed that all IP samples compared to their input counterparts were
consistently enriched in granule cell specific genes (e.g. Tdo2, Calb1), and
depleted for genes specific for neuronal precursors (e.g. Dcx, Nr2e1),
interneurons (e.g. Slc32a1, Gad2), astrocytes (e.g. Aldh1l1, Cnp),
oligodendrocytes (e.g. Olig2), microglia (e.g.Olfml3), pericytes (e.g. Cldn5) and
endothelial cells (e.g. Pdgfrb) (Figure 4.11B), except for dDG cKO IP3 and vDG
cKO IP3 (red dotted borderlines). We excluded these two IP samples from further
analysis because they failed to show a depletion for cell type marker genes
which are not expressed in Drd3-Cre cells. In addition, the enrichment/depletion

173

profile in the IP samples compared to inputs confirmed our previous
immunohistological findings indicating that Drd3-Cre cells are mature excitatory
neurons.

4.4.1. Differential gene expression between the dorsal and ventral dentate
gyrus of the hippocampus
Considering the functional and molecular differences observed along the
septotemporal axis of the hippocampus, and our results implying specific ventral
DG responses in the loss of 5-HT4R, we set out to compare the molecular
profiles of the dDG and vDG. We performed differential gene expression analysis
between samples from these regions that would allow us to identify region
enriched genes. In each differential expression analysis between two samples,
adjusted p-value (p-adj) <0.05 was considered significant.
The differential expression analysis between input samples from the
dorsal and ventral DG of WT animals revealed that 1440 genes were enriched in
vDG input versus 1041 genes in dDG input (Figure 4.12A), demonstrating the
extensive molecular differences between these regions. Lct and Trhr, two of the
previously identified genes enriched in the dDG and vDG respectively, show
enrichment in their respective regions confirming our analysis. These data and
further mining will serve as a useful reference for variety of analyses using
comparative transcriptomics; such as, identification of gene set enrichments, and
investigation of a certain cell type marker presence/abundance along the DG.
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Figure 4.12. Genome-wide gene expression analysis between the dDG and vDG
identified differentially expressed genes along the dorsoventral axis of the DG.
A. Scatter plot of normalized gene expression values between input samples from the
dDG and vDG of WT mice. Differentially expressed genes (p-adj<0.05) were colored
based on region specific enrichment.
B. Scatter plot of normalized gene expression values between IP samples from the dDG
and vDG of WT mice. Differentially expressed genes (p-adj<0.05) were colored based
on region specific enrichment.
C. Scatter plot of Htr expression and differentially expressed genes between IP samples
from the dDG and vDG of WT mice. Differentially expressed Htrs (p-adj<0.05) are shown
in red.
D. Heatmap visualizations of differentially expressed genes between IP samples from
the dDG and vDG of WT mice with fold changes ≥2.
E. ISH confirmation of dDG and vDG enriched genes. Images from Allen Brain Atlas.
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As we are more interested in the Drd3-Cre positive neurons in these
regions, we then performed differential gene expression analysis between IP
samples from WT animals to specifically enrich for genes expressed in the
mature excitatory neurons. There were 1067 genes significantly enriched in vDG
Drd3-Cre cells versus 726 genes in the dDG (Figure 4.12B). This implies a
marked divergence in molecular profiles between the mature excitatory neurons
of the dDG and vDG, although IP samples represent the transcriptome of the
same cell type - primarily DG granule cells - with only difference being that they
reside in spatially distinct parts of the DG. Moreover, the expression of all Htrs
were detected in the dDG and vDG, except for Htr1b, in IP samples, indicating
that mature excitatory neurons of the hippocampus express most of the serotonin
receptors to some extent, Htr1a and Htr4 being the highest two. Furthermore,
Htr4 was significantly enriched in the dDG (1.59 fold) while Htr1a and Htr7 were
enriched in the vDG (2.69 fold, each), demonstrating the differential expression
profile of Htrs in the mature excitatory neurons along the DG dorsoventral axis.
This molecular divergence between dDG and vDG mature excitatory
neurons calls for the identification of specific genes that may be expressed in
spatially distinct subsets. To this end, we further analyzed the significantly
enriched genes in dDG and vDG WT IPs to obtain genes that show >2 fold
change in each region compared to the other. We then filtered out those genes
that have normalized expression values <100 in their respective IP in order to
eliminate very low expressed genes from our analysis. With these criteria, we
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found that 176 genes in dDG and 374 genes in vDG were significantly enriched
by more than 2 fold in the mature excitatory neurons (Figure 4.12C). By mining
this gene list, we were able to identify genes expressed in granule cells
specifically in the dDG (e.g. Ptchd4, Abcb10, Gprc5b) or vDG (e.g. Ngb, Ano2,
Grp) (Figure 4.12D).

4.4.2. Genome-wide molecular neuroadaptations along the dorsoventral
axis of the dentate gyrus upon the loss of 5-HT4R
To assess neuroadaptations in gene expression that may underlie the
molecular, cellular and behavioral consequences of the loss of 5-HT4R from
hippocampus, we analyzed the differential gene expression between cKO and
WT in the whole dDG and vDG (inputs). As input samples represent the
transcriptome of both the granule cells, the major cell type in the DG, and other
cell types, we expected to capture any major transcriptional changes that may
have occurred in GCs as well as in interneurons and astrocytes in response to
the deletion of Htr4 in Drd3-Cre cells.
In the input samples from the dDG of the cKO compared to WT, there
were 185 genes significantly changed by 1.25 fold (84 genes up-regulated, 103
genes downregulated) (Figure 4.13A). Similarly, the expression of 186 genes
were significantly altered by 1.25 fold in the vDG of cKO (21 genes up-regulated,
165 genes downregulated) (Figure 4.13B), indicating a robust molecular
response both in the dDG and vDG of Drd3/Htr4 cKO mice.
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Figure 4.13. Genome-wide differential gene expression analysis in the dDG and
vDG revealed region-specific molecular adaptations in Drd3/Htr4 cKO mice.
A. Scatter plot of normalized gene expression values between WT and Drd3/Htr4 cKO
dDG input samples. Differentially expressed genes (p-adj<0.05, fold-change ≥1.25) were
colored based on genotype specific enrichment.
B. Scatter plot of normalized gene expression values between WT and Drd3/Htr4 cKO
vDG input samples. Differentially expressed genes (p-adj<0.05, fold-change ≥1.25) were
colored based on genotype specific enrichment.
C. Heatmap visualizations of differentially expressed genes between WT and cKO in the
dDG and vDG.
D. Venn-diagram showing the number of overlapping genes significantly changed in
cKOs between two regions.
E. Heatmap visualization of overlapping genes significantly changed in cKOs between
two regions. Cell-type specificity based on ISH data from Allen Brain Atlas is indicated
for each gene.
(Figure on next page)
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Heatmap visualization based on normalized expression values (Z-score,
normalization by row) showed that the significant differences in gene expression
was consistent across all replicates (Figure 4.13C). While the number of genes
that was significantly altered in expression was similar in both regions, the
discrepancy in the number of up-regulated and down-regulated genes between
the dDG and vDG suggested that the molecular response to the loss of Htr4
were tissue-specific. Indeed, there were only twelve (12) genes commonly
altered in response to Htr4 deletion between the dDG and vDG. On the other
hand, the rest of the significant expression changes were specific to each region
(173 genes in the dDG versus 174 genes in the vDG). Out of the 12 common
genes, four (Htr4, Pdzd2, Rab40b and Ggps1) were up-regulated and eight were
down-regulated in the cKO in both regions (Figure 4.13D), showing agreement
also based on the direction of gene regulation. Based on the ISH data from Allen
Brain Atlas, all commonly up-regulated genes were expressed in granule cells.
On the other hand, commonly down-regulated genes were mostly expressed in
genes outside the GCs: ubiquitously expressed (2), astrocytes specific (4), and
depleted in our IP samples (2, ISH data not available). Interestingly, Htr4
expression was commonly upregulated although exon 5 was deleted, suggesting
an enhanced transcriptional regulation on Htr4 trying, but inevitably failing, to
compensate for the absence of functional 5-HT4R. Two other commonly
upregulated genes (Ggps1 and Rab40b) may be involved in geranylgeranylation,
a lipid post-translational modification that facilitate membrane association
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(Kainou et al., 1999). Astrocyte-specific genes consisted two apolipoproteins that
may be linked to Alzheimer’s disease. Significantly dysregulated genes that may
be relevant in learning and memory are discussed in Chapter 5.
To identify entire pathways dysregulated in the dDG and vDG in Drd3/Htr4
cKO mice, we performed gene ontology (GO) and gene set enrichment analysis
(GSEA) using curated gene sets by Molecular Signature Database (MSigDB,
Broad Institute). In both regions, genes with significant changes in expression
showed enrichment of numerous and diverse terms (more than a hundred, FDR
<0.05). We report five of highly enriched terms for each category; GO Biological
Process (BP), GO Cellular Compartment (CC), GO Molecular Function (MF),
MSigDB canonical pathways (CP), MSigDB chemical and genetic perturbations
gene sets (CGP).
In dDG datasets (Figure 4.14A), most notably, the terms with the lowest
FDR were consistently related to RNA and protein processing. Note that nuclear
transcribed mRNA nonsense mediated decay (BP) and nonsense mediated
decay by exon junction complex (CP) related genes were enriched, possibly
indicating the transcriptional checkpoint responses to the transcription of the
exon 5 deleted Htr4 mRNA. Other functionally related enriched gene set were
related to synapse (CC-cell junction, synapse) and neurogenesis (BPneurogenesis, CC-neuron projection). Also note that genes enriched in
astrocytes (CGP) were detected in our significant gene set, suggesting astrocyte
involvement in response to Htr4 loss from mature excitatory neurons.
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Figure 4.14. Gene set enrichment analysis (GSEA) of significantly regulated genes
in Drd3/Htr4 cKO indicated both common and region specific gene sets were
altered in the cKO between the dDG and vDG.
A. GSEA of significantly regulated genes in the cKO in the dDG (dark green).
B. GSEA of significantly regulated genes in the cKO in the vDG (dark red).
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Finally, genes correlated with Alzheimer’s disease and bipolar disorder (CGP)
were enriched in our significant gene set.
In vDG datasets (Figure 4.14B), the most remarkably enriched terms with
the lowest FDR were consistently related to neurogenesis and neuronal
connections. Specifically, the terms related to neurogenesis such as
neurogenesis (BP), neuron differentiation (BP), neuron projection (CC) and
growth factor binding (MF) were among the most significantly associated with
genes significantly changed in the vDG upon the deletion of Htr4. Although
neurogenesis related genes were also significantly altered in the dDG (19
genes), the enrichment FDR was much lower in the vDG with higher number of
genes correlated (39), and with only four (4) genes in common, supporting our
results showing vDG specific enhanced neurogenesis in Drd3/Htr4 cKO mice.
Furthermore, the enrichment in terms related to neuronal connections such as
biological adhesion (BP), intracellular vesicle (CC), extracellular matrix (CC) and
synapse (CC) may be relevant to a change in synaptic strength. In addition,
enrichment in terms such as calcium ion binding (MF) and calcium signaling
pathway (CP) may be related to the absence of 5-HT4R and the decrease in
granule cell firing rate. Also note that genes enriched in astrocytes (CGP), and
genes correlated with Alzheimer’s disease and bipolar disorder (CGP) were also
enriched in vDG significant gene set.
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Together, our differential expression analysis in input samples between
genotypes suggests that the deletion of Htr4 leads to robust and region specific
molecular response in the dorsal and ventral DG. These data provide more
insights into molecular processes underlying 5-HT4R regulation of anxiety and
depression related behaviors.

4.4.3. Gene expression changes in mature excitatory neurons in the dentate
gyrus upon Htr4 deletion
To investigate the cell type specific changes within mature excitatory
neurons (Drd3-Cre) in the vDG upon the loss of Htr4, we performed differential
expression analysis in TRAP-Seq datasets between IP samples from the vDG of
WT and cKO mice. As IP samples represent the translating mRNA profile
specifically in mature excitatory neurons, we expect to identify transcriptional
changes that would give insights into the cellular 5-HT4R pathway, and that may
underlie functional cellular consequences of the loss of 5-HT4R.
In the IP samples from the vDG of the cKO compared to WT, there were
249 genes significantly changed by 1.25 fold (55 genes up-regulated, 194 genes
downregulated) (Figure 4.15A), indicating a robust molecular response in mature
excitatory neurons of the vDG in the cKO. Heatmap visualization based on
normalized expression values (Z-score, normalization by row) showed that the
significant differences in gene expression were consistent across all replicates
(Figure 4.15B).
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Figure 4.15. TRAP-Seq and differential gene expression analysis reveals a robust
molecular change in mature excitatory neurons of the vDG in Drd3/Htr4 cKO mice.
A. Scatter plot of normalized gene expression values between WT and Drd3/Htr4 cKO IP
samples from the vDG. Differentially expressed genes (p-adj<0.05, fold-change ≥1.25)
were colored based on genotype specific enrichment.
B. Heatmap visualizations of differentially expressed genes between WT and cKO IP
samples from the vDG.
C. Heatmap visualizations of top 30 up-regulated and down-regulated genes in cKO IP.
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Top 30 up-regulated and down-regulated genes based on p-adj values were also
listed (Figure 4.15C).
To identify dysregulated pathways in mature excitatory neurons of the
vDG in the cKO, we performed GO analysis and GSEA using curated gene sets
by MSigDB (Broad Institute). Up-regulated and down-regulated genes were
analyzed separately to gain insights into the directionality of a change in a
specific pathway. The genes with significant changes in expression showed
enrichment of numerous terms (FDR <0.05). Down-regulated genes were
consistently correlated with terms related to RNA and protein processing,
neurogenesis and neural connection while up-regulated genes were correlated
with RNA binding (Figure 4.16A). Consistently, both group of genes were
correlated with genes dysregulated in Alzheimer’s disease and bipolar disorder
(Figure 4.16B).
In order to categorize and visualize related GO terms and identify more
specific pathways, we generated a network of GO terms associated with the
genes significantly altered in the cKO using BiNGO (A Biological Network Gene
Ontology tool) (Maere et al., 2005). In these networks, each node represents a
specific GO term. The size and the color of a node indicate the number of genes
associated and the significance (lower FDR, darker; FDR cutoff <0.01),
respectively. The nodes located towards the ends of a network represent more
specific terms.
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Figure 4.16. Functional interpretation of the gene regulations in Drd3/Htr4 cKO.
A, B. GSEA gene sets list for significantly down-regulated and up-regulated genes in
vDG mature excitatory neurons in cKO, respectively.
C, D. Categorization and network of enriched gene ontology (GO) terms using BiNGO
for down-regulated and up-regulated genes, respectively.
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The most specifically enriched GO BP terms in down-regulated genes
were regulation of cell differentiation, neurogenesis, synaptic transmission,
glutamate metabolic process, calcium ion transport and reduction of cytosolic
calcium ion concentration (Figure 4.16C). These terms appeared to be highly
relevant for the biological phenotypes observed in the cKO mice. The enriched
GO CC and MF terms were also correlated with these biological processes.
Moreover, the specific terms such as protein folding (BP), spliceosomal complex
(CC) and unfolded protein binding (MF) may be related to the cellular response
to transcription and translation of exon 5 deleted Htr4.
On the other hand, the most specifically enriched, and functionally related,
GO terms by up-regulated genes were neural development (BP), regulation of
actin cytoskeleton organization (BP), cyclin-dependent protein kinase 5
activation, a process involved in neuronal maturation and migration (Jessberger
et al., 2008) (MF), prostaglandin-D synthase activity, and ATP binding (MF)
(Figure 4.16D). In addition, the up-regulated genes correlated term ubiquitin
protein ligase regulator (MF) may be relevant to the translation of truncated 5HT4R in the cKO.
Together, our analysis of differentially expressed genes in IP samples
between genotypes suggests that the deletion of Htr4 leads to a robust molecular
response in the mature excitatory neurons of the vDG. These transcriptomic
changes in the cKO were strongly associated with the cellular phenotypes
observed in the granule cell layer.
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4.5. Discussion

In Chapter 4, our findings demonstrate cellular and molecular mechanisms
that may underlie the anxiogenic and antidepressant-like behavioral phenotype
observed upon the loss of 5-HT4R in the hippocampus. We identified Drd3-Cre
neurons as the mature excitatory neurons of the hippocampus based on
established molecular markers. As hippocampus undergo marked cellular,
molecular and electrophysiological changes in response to antidepressant
treatment, we investigated these responses in the “antidepressant” Drd3/Htr4
cKO mice.

4.5.1. The loss of 5-HT4R from mature excitatory neurons of the
hippocampus led to enhanced neurogenesis
We found increased number of immature neurons specifically in the
ventral DG of Drd3/Htr4 cKO mice and elevated gene expression levels of
neurotrophic factors (BDNF and VEGF). These data revealed that, in addition to
the behavioral antidepressant-like responses, the loss of 5-HT4R from mature
excitatory neurons of the hippocampus led to molecular and cellular
antidepressant-like responses as enhanced adult hippocampal neurogenesis in
the ventral hippocampus and increased levels of neurogenic factors in the
hippocampus. Moreover, especially the increase in neurogenesis was ventral
DG specific providing additional information associating the antidepressant-like
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behavioral responses and the ventral hippocampus, and suggesting a differential
role for 5-HT4R in mediating anxiety and depression circuitry along the
dorsoventral axis of the hippocampus. The mechanism underlying neurogenic
effects of antidepressant response are still limited. Nevertheless, our findings
showing that Drd3-Cre and Htr4-EGFP-L10a are not expressed in immature
neurons suggest that the neurogenic phenotype was not induced directly by
intracellular mechanisms in neural precursors, rather possibly by the elevated
release of neurotropic factors from hippocampal neurons, or other extrinsic
signals.

4.5.2. The loss of 5-HT4R from mature excitatory neurons of the
hippocampus resulted in adaptations in 5-HT receptor expression
Antidepressant treatments affect the serotonergic system in the brain by
inducing adaptive changes in various 5-HT receptors subtypes (Adell et al., 2005;
Schechter et al., 2005). In our study, 5-HT receptor expression underwent region
and receptor type specific alterations when 5-HT4R was ablated in the mature
excitatory neurons of the hippocampus as a decrease in the expression of Htr1a
(inhibitory) in the ventral hippocampus, an increase in the expression of Htr2c
(excitatory, expressed prominently in CA3), Htr6 (excitatory), and Htr1b
(inhibitory, expressed in DG interneurons). Since 5-HT4R is an excitatory 5-HT
receptor, we suspect that the pattern in the regulation of other 5-HT receptor
expression in response to the loss of 5-HT4R implies compensatory changes to
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rebound the levels of serotonergic modulation in the hippocampus. Whether
these adaptations resist the functional ablation of 5-HT4R or underlie some of the
cellular and behavioral phenotypes yet to be investigated. Nevertheless, the
region- and receptor type specific changes in 5-HT4R shows the dynamic
regulations in the serotonergic system in the hippocampus.

4.5.3. 5-HT4R was necessary to maintain proper excitability of dentate
gyrus granule cells
In addition to the molecular and cellular adaptations, our results showed
that 5-HT4R was necessary to maintain proper granule cell excitability as the loss
of 5-HT4R resulted in decreased firing. The decreased excitability of DG GCs in
antidepressant-like action has also been indicated in several recent reports. For
example, indirect inhibition of the firing of GCs through PV neurons were
observed after acute SSRI administration (Medrihan et al., 2017) while chronic
SSRI inhibition of GCs through the 5-HT1AR has been shown to have an
antidepressant-like effect (Samuels et al., 2015). Furthermore, chronic SSRI
treatment has shown to desensitize 5-HT4R-dependent signaling and
functionality as it decreased the density of 5-HT4R receptor binding, reduced 5HT4R mediated cAMP induction, and attenuated 5-HT4R-induced excitability in
pyramidal cells in the hippocampus (Vidal et al., 2009). The incorporation of
young GCs upon neurogenesis has also been shown to inhibit the mature GC
activity (Anacker and Hen, 2017). Also note that optogenetic activation of
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specifically vDG granule cells resulted in a decrease in innate anxiety (Kheirbek
et al., 2013). Considering these reports and our findings together, a decrease in
5-HT4R-mediated excitability of the hippocampal excitatory neurons seems to be
positively correlated to the antidepressant-like cellular and behavioral responses
as well as increased anxiety levels.
The molecular mechanisms of 5-HT4R-mediated excitability of the granule
cells are still poorly understood. It is well established that 5-HT4R is coupled to Gs
proteins and positively linked to the adenylate cyclase in the brain ((Bockaert et
al., 2004)). The increase in cAMP levels leads to the activation of protein kinase
A that mediates closure of calcium (Ca+2) activated potassium (K+) channels
mediating afterhyperpolarizing (AHP) current. Thus, evidence suggests that 5HT4R contributes to the neuronal excitability of pyramidal neurons via this
pathway (Andrade, 2006). Although we did not observe a change in the AHP in
DG GCs, previous studies observed the mediating effect of 5-HT4R following the
activation of the receptor in the pyramidal neurons. Hence, cell type and receptor
activation may be important to mediate this property. It is possible that our results
showing a decreased firing in DG GCs missing 5-HT4R is mediated by other
molecular mechanisms following the long-term loss of 5-HT4R. Moreover, in
addition to its GPCR function, a direct coupling to both voltage-sensitive calcium
channels (Hoyer et al., 2002) and extracellular signal-regulated kinase pathway
(Barthet et al., 2007) has also been proposed for 5-HT4R function.
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4.5.4. TRAP-Seq may identify novel genes involved in 5-HT4R signaling,
anxiety and depression
Using TRAP-Seq, we performed a cell type and region specific genomewide differential gene expression analysis to identify the genes and pathways
that may underlie the phenotypic changes in the absence of 5-HT4R from the
mature excitatory neurons of DG. Since almost all excitatory neurons of DG are
targeted by Drd3-Cre line, and we observed remarkable cellular and molecular
adaptations in the vDG after the deletion of 5-HT4R, we restricted our
comparative transcriptomic analysis in the dDG and vDG. Mature excitatory
neuron specific differential gene expression analysis between the dDG and vDG
in WT animals allowed us to capture previously identified (Cembrowski et al.,
2016) and novel region specific GC genes. Therefore, further mining of our
TRAP-Seq datasets could be used to identify new genes that are specifically
expressed in the GCs and mossy cells in the dorsal or ventral DG. The
characterization of these genes that are differentially expressed within the same
cell type in a spatial gradient may give further molecular insights into the
functional difference between the dDG and vDG as well as distinct susceptibility
of these regions to various diseases and treatments.
We also showed that the overall molecular response to the deletion of
Htr4 was robust but distinct between the two poles of the DG, providing further
transcriptional evidence into the distinct modulations of the dDG and vDG in
anxiety and depression. These changes were observed in genes that are
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expressed in excitatory neurons of the DG as well as astrocytes and
interneurons, suggesting a possibly involvement of astrocytes and interneurons
in response to the loss of 5-HT4R in the excitatory neurons. Neurogenesis related
genes were consistently altered between the two poles, while showing more
significance in the vDG, providing further insights into the genes that may be
relevant for vDG specific neurogenic regulation. Furthermore, the synaptic and
cell junction related gene expression changes may indicate the adaptations in
synaptic strength and may be related to decreased firing of GCs after the loss of
5-HT4R.
Finally, TRAP-Seq analysis made it possible to capture the robust celltype specific transcriptomic changes in vDG mature excitatory neurons upon the
deletion of Htr4. Consistent with the function 5-HT4R as an excitatory GPCR,
Htr4 deletion led to more down-regulation than up-regulation in gene expression.
Gene set enrichment analysis showed that neurogenesis and neural
differentiation related gene expression was also altered specifically in mature
excitatory neurons. Surprisingly, these genes were mostly in down-regulated
gene group; nevertheless, it is important to investigate the function of these
genes in neurogenesis, that is, whether they are facilitatory or inhibitory. On the
other hand, other neural development, maturation and migration related genes
were also upregulated. Further exploration of these gene may help understand
vDG GC specific modulation of neurogenesis.
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More relevant to neuronal function and communication, the genes
involved in synaptic transmission including synaptic vesicle formation, transport,
and release, glutamate metabolic process, and Ca+2 ion transport and binding
were down-regulated in the mature excitatory neurons after conditional Htr4
knockout. The identification of specific genes related to these functions may
provide more understanding of the function of 5-HT4R in granule cell excitability.
For example, Cacna2d3 – calcium channel, voltage-dependent, alpha 2/delta
subunit 3 – was among significantly downregulated genes. This gene encodes a
protein that is a significant part of many voltage-gated Ca+2 channel complexes.
It has been shown to regulate Ca+2 current density and activation/inactivation
kinetics of various voltage-gated calcium channels in neurons upon membrane
depolarization as well as synapse formation (Geisler et al., 2015). Another strong
candidate for 5-HT4R pathway may be Ryr2, the gene encoding for type 2
ryanodine receptor/calcium release channel, which was found down-regulated
following the loss of 5-HT4R. This channel is responsible for intracellular Ca+2
release from endoplasmic reticulum (ER) and activated by cAMP-PKA pathway
(Liu et al., 2012). It is highly expressed in hippocampal excitatory neurons and
dysregulation of this receptor has been shown to strongly contribute to stress
induced cognitive dysfunction. Together, these two downregulated genes are
among the many strong candidates identified in our TRAP-Seq data sets that
may be involved in the intracellular 5-HT4R signaling. The downregulation in the
expression of these genes may underlie the decreased excitability of DG GCs.
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Further mining of this dataset and gene network analyses may identify more
candidate genes that may be involved in 5-HT4R signaling and its function in the
regulation of anxiety and depression related behaviors.

4.5.5. Conclusion
Whether enhanced neurogenesis, or adaptations in serotonergic system,
or decreased excitability of GCs is the cause of behavioral antidepressant-like
responses to the hippocampal loss of 5-HT4R is still unknown. Perhaps, these
neuroadaptations in the hippocampal circuitry acts synergistically to decrease the
hippocampal excitability and overall output to other relevant limbic regions.
Further experiments such as non-genetic manipulation of endogenous 5-HT4R
pathway in a region and cell type specific manner, as well as more investigation
of neurogenesis, and other serotonin receptors in antidepressant action are
needed to understand the exact function of 5-HT4R in these processes.
Our results strongly indicate ventral dentate gyrus granule cells and 5HT4R signaling as striking modulators of anxiety and depression related
behaviors. Therefore, a cell type or region specific approach may enable the
development of better acting anxiolytics and antidepressants. In this sense, our
TRAP-Seq datasets may serve as a reference for identification of specific genes
that may be targeted for more efficacious therapeutics with fewer side effects.
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CHAPTER 5.
THE ROLE OF 5-HT4 RECEPTOR IN LEARNING AND MEMORY
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5.1. Introduction
Memory is the storage of learned information in the brain and is crucial for
adaptive behavior in animals. The study of learning and memory is essential
because these processes underpin normal human behavior and they are
important abnormal behavioral components of disorders ranging from addiction,
anxiety, depression, schizophrenia and neurodegenerative diseases such as
Alzheimer’s disease (LaBar and Cabeza, 2006). The medial temporal lobe, in
particular the hippocampus, has been implicated in the memory of events or
episodes by studies in humans and animal models (Strange et al., 1999).
Our studies have indicated 5-HT4R in the hippocampus as a major
regulator for emotive behavior and neuronal activity. Considering the extensive
involvement of the hippocampus in memory processes, and growing body of
evidence suggesting a role for 5-HT4R in cognition (discussed below), we
investigated whether 5-HT4R mediates certain learning and memory functions in
the hippocampus and neocortex.

5.1.1. Assessment of learning and memory in laboratory mice
The elements regulating learning and memory have been investigated as
anatomical structures, physiological processes, neuromodulators, and molecular
pathways using behavioral tasks in animal models (Barnhill, 2006). In this
chapter, we sought to investigate, the involvement of 5-HT4R in distinct types of
episodic memories with varying emotional valence, such as fear memories
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(negative valence), object memory (neutral) and social memory (possibly positive
valence).

5.1.1.a. Fear memory
Fear and anxiety are defensive behavioral responses that enable an
organism to avoid harm. Fear is evoked upon acute sensory input, whereas
anxiety can be evoked by anticipated threats. Innately fearful stimuli or stimuli
that are associated with aversive events can induce fear (Peter Curzon, 2008).
Associative learning processes can be studied to elucidate the mechanisms
involved in learning and memory by the induction and acquisition of fear in
laboratory conditions.
In rodents, Pavlovian fear conditioning is the most commonly used
paradigm to induce learned fear. In this paradigm, a neutral stimulus, such as a
particular context or cue (for example, an auditory tone), is presented
sequentially with an aversive event, such as a footshock. In this case, the
aversive event, unconditioned stimulus (US), induces fear responses and the
neutral stimulus is associated with aversive properties through associative
learning, becoming the conditioned stimulus (CS). With successful training, the
subject will elicit fear responses even when the CS is presented alone. The fear
response in rodents is measured by increased defensive behavior as freezing.
During the fear acquisition phase, the expression of the conditioned fear
response gradually increase during the training when multiple CS-US couplings
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are presented. If one administers a foot shock paired with an auditory cue in a
particular context, fear will be associated with both the cue and the context. Fear
memories are consolidated after the training; hence, memory retrieval can be
induced by re-exposure to either the conditioning context (contextual fear test) or
the auditory cue in a novel context (cued fear test).
Studies using this model have revealed that there is a distributed network of
brain regions that are involved in the learning and expression of fear. These
include but are not limited to the local microcircuits in the amygdala (Letzkus et
al., 2011), and the projections among the amygdala (Fadok et al., 2017; McHugh
et al., 2004), hippocampus (Kjelstrup et al., 2002) and frontal cortex (Likhtik et
al., 2014). Sensory input from the neocortex and thalamus innervate several
amygdala nuclei which are central areas for fear acquisition and expression
(Asede et al., 2015). Reciprocal connections between the basal amygdala and
the ventral hippocampus as well as the prelimbic cortex modulate the fear related
neuronal plasticity (Sotres-Bayon et al., 2012). In addition, central amygdala
sends projections to the hypothalamus and brainstem promoting fear (Canteras
and Swanson, 1992). Hippocampus-amygdala interactions could be particularly
important for contextual fear as the hippocampus is established to encode spatial
information. In fact, there is a growing body of evidence demonstrating the
contribution of connection between these regions to contextual fear conditioning
(Kjelstrup et al., 2002; Sparta et al., 2014).
.
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Fear and anxiety are mediated by largely overlapping brain areas and
neuromodulatory systems (Davis et al., 2009) while the exact circuits mediating
anxiety have been investigated to a lesser extent. Recent developments in
optogenetic functional circuit mapping have led to the accumulation of the
evidence showing divergent circuits elements for anxiety related behaviors in the
brain regions that mediate fear related behaviors (Felix-Ortiz et al., 2013; Tye et
al., 2011). Furthermore, neuronal circuits that mediate emotive behavior with a
negative valence (for example, fear and anxiety) at least partially overlap with the
circuits that regulate positive valence (for example, reward) (Belova et al., 2007;
Lammel et al., 2012).

5.1.1.b. Object memory
Object memory is based on recognition and is a type of episodic memory
(Pause, 2013). In rodents, the novel object memory test (NORT) has been used
to assess non-spatial and object memory in rodents (Leger et al., 2013). The
novel object recognition offers advantages over other memory tests for assessing
recognition memory because it does not require any external motivation, reward
or punishment, dissociating it from emotionality.
The NORT is conducted in a familiar high-walled rectangular arena lacking
spatial cues. Subject familiarization with the arena is accomplished before the
test by a habituation session typically 24 hours before the test. During the
training or sample session, the subject explores two identical novel objects
encountered in the familiar arena during which object memory encoding is
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putatively occurring. After the sample session, the animal is removed from the
arena for a speciﬁed amount of time (retention delay), during which the object
memory is consolidated. For the subsequent test session, the subject is returned
to the same arena, containing the familiar object and a novel object, as a test of
object memory retrieval. Mice exhibit a natural proclivity to explore novel objects,
and hence, exhibiting a preference for exploring the novel object signiﬁcantly
more than the familiar one. Preference for the novel object, demonstrated by an
increase in exploration time, indicates that a memory trace for the familiar object
was properly encoded, consolidated and then retrieved to guide the behavior
during the test session.
Despite the wide use of the novel object memory test in assessing the
memory performances in animal models, underlying neural circuitry have not yet
been clearly defined. It has been suggested that the hippocampus is necessary
for the retrieval of object recognition memory when a delay greater than 10 min is
imposed between the sample and test sessions in the NORT (Cohen and
Stackman, 2015). However, at shorter retention delays, perirhinal cortex activity
has found to be necessary for the object memory. Essentially, episodic memory
for objects emerges from interactions, at least majorly, between the perirhinal
cortex and hippocampus.

5.1.1.c. Social recognition memory
Social memory, the ability to recognize and memorize familiar conspecifics
is crucial for animals that exhibit social interactions. It is also a form of episodic
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memory; however, it involves olfactory cues more than the visual representation
of the novel conspecific/object (Gabor et al., 2012). Therefore, the sensory and
associative inputs to form the social memory vary compared to the object
memory.
The social recognition task that is used to assess social memory in
laboratory conditions employs the innate tendency of mice to investigate an
unfamiliar conspecific more than a familiar one. Therefore, the three-chamber
social recognition test can be run right after the social interaction test during
which the subject is familiarized with a confined novel conspecific. For this task,
the inanimate object under the container is replaced with a novel, unfamiliar
mouse immediately after the social interaction test to assess the short-term
social memory. Social memory in a mouse can be quantified by comparing its
interaction durations with a novel and a familiar mouse. Ideally, the subject
spends more time exploring the unfamiliar mouse compared to the recently
familiarized mouse.
Human and non-human primate studies have identified the medial
temporal lobe including the hippocampus to be involved in social memory
(Viskontas et al., 2009). In rodents, it is also well established that the
hippocampus has an essential role in episodic memories including social
memory. For example, ventral CA1 pyramidal neurons has been indicated in the
storage of the social memory (Okuyama et al., 2016). More evidence from both
human and rodent studies suggest that the excitation and inhibition balance in
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the neocortex and specifically in the prefrontal cortex is strongly linked with social
recognition (Bicks et al., 2015).

5.1.2. Molecular basis of learning and memory
Long-term potentiation (LTP) and depression (LTD) are mechanisms that
alters the synaptic strength and mediate the storage of memories. These
processes initially involve modifications in intracellular signaling cascades using
secondary messengers (calcium-dependent protein kinases such as calciumcalmodulin-dependent kinase II, tyrosine kinase and protein kinase C) (Li et al.,
2010). The extend of synaptic plasticity is further mediated by changes in the
phosphorylation of key receptors of glutamatergic neurotransmission such as
subunits of the AMPA receptor (Malenka and Bear, 2004), the activity of
transcription factors (e.g. cyclic AMP response element binding protein, CREB,
and early growth response protein 1, Zif268) (Alberini, 2009) and protein
expression (e.g. BDNF) (Kovalchuk, 2002) especially in the hippocampus. LTP
and LTD play essential roles in memory consolidation and under extensive
neuromodulatory control.

5.1.3. Serotonergic modulation of learning and memory
Widespread serotonergic projections in the hippocampus and neocortex
underline the anatomical and neurochemical link between the serotonergic
system and brain areas associated with learning and memory. The
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neuromodulatory action of 5-HT on cognitive functions in both physiological and
pathological states largely depend on the specific subtypes of 5-HTRs, and their
localization (Seyedabadi et al., 2014). The activity of the 5-HT has been linked
with memory and cognitive performance, during aging as well as in many
psychiatric (anxiety, depression, addiction) and neurological (Alzheimer’s
disease, epilepsy) disorders (Meneses, 2015; Rodríguez et al., 2012). As current
treatments for learning and memory impairments are very limited, there is an
extreme need for developing novel therapeutic approaches, including drugs
acting on specific 5-HT receptors.
Several drugs targeting 5-HT receptors, including those specific to 5HT4R, have displayed pro-cognitive effects in preclinical behavioral paradigms.
For example, various studies reported the beneficial effects of 5-HT4R activation
on cognition in rodents and primates (Lo et al., 2014; Marchetti et al., 2008; Terry
et al., 1998). 5-HT4R agonists improved performance on various learning and
memory tests such as social and object recognition, and reversed age related or
pharmacologically-induced cognitive deficits (Darcet et al., 2016; Letty et al.,
1997; Orsetti et al., 2003). 5-HT4R have also been implicated in the expression of
genes that regulate synaptic plasticity (Vidal et al., 2011). Moreover, 5-HT4R
agonists modulate synaptic plasticity within the hippocampal regions by
augmenting LTP, attenuating depotentiation and altering the patterns of LTD
(Hagena and Manahan-Vaughan, 2016).
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In the human brain, reduced levels of 5-HT4R have been measured post-mortem
in the hippocampus and cortex of Alzheimer’s disease (AD) patients (Reynolds et
al., 1995). In rodents, 5-HT4R agonists have been shown to stimulate
acetylcholine release (a symptomatic therapeutic approach for AD), enhance
memory performance and have neuroprotective and neurotrophic effects in AD
models (Cachard-Chastel et al., 2007; Giannoni et al., 2013; Matsumoto et al.,
2001). Additionally, they stimulate the non-amyloid-forming metabolism of
amyloid precursor protein (APP), therefore, decrease the production of
neurotoxic amyloid beta (Aβ), involved in the AD pathology (Tesseur et al.,
2013).
Previous reports combined with our findings in Chapter 4 regarding 5HT4R-mediated modulation of granule cell firing, and possibly, the regulation of
genes associated with synaptic plasticity and Alzheimer’s disease, strongly
suggest that 5-HT4R pathway is a promising target for the modulation of synaptic
plasticity and memory. In this chapter, we investigated the role of 5-HT4R in
learning and memory both in excitatory neurons in pallial regions (including
neocortex, hippocampus, basolateral and lateral amygdala), and specifically in
hippocampal excitatory neurons.
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5.2. Hippocampus specific 5-HT4R function in in learning and memory.

Pharmacological studies detailed that the activation of 5-HT4R enhanced
memory performance in various behavioral tasks in rodents (Hagena and
Manahan-Vaughan, 2016). Although, there has been an extensive work in the
involvement of distinct brain regions, cell types and neuromodulators in various
type of learning and memory, the specific cell types and brain regions in which 5HT4R may mediate these processes remains unknown. Cre-dependent genetic
targeting of 5-HT4R will help us reveal whether 5-HT4R in specific cell types and
brain regions are involved in the modulation of various types of learning and
memory.
We crossed Htr4-floxed mice and two previously described Cre driver
lines to ablate 5-HT4R in excitatory neurons of pallial origin (Emx1/Htr4 cKO) and
mature excitatory neurons of the hippocampus (Drd3/Htr4 cKO). These animals
and their control littermates (WT) were tested in various assays measuring
different learning and memory performances including fear memory, object
memory and social memory. Comparison of the performances of these two lines
will help us understand the region-specific contributions of 5-HT4R in these
cognitive processes.
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5.2.1. The role of 5-HT4R in behavioral fear responses and fear memory
To investigate whether 5-HT4R in the excitatory neurons of any pallial
region mediate the fear memory and responses, Emx1/Htr4 cKO mice underwent
fear conditioning training, and their fear responses to fear-associated context and
auditory cue were acquired as freezing behavior. Figure.5.1A shows
experimental timeline and components for training (fear memory acquisition) and
test (fear memory retrieval) stages of contextual and cued fear conditioning (FC)
paradigm. Shortly, in day 1, animals were placed in the operant conditioning
chamber and an auditory tone was presented for 20 s preceding an electrical
footshock for three times at 140, 200 and 260 s in a 300-s training trial. Next day,
animals were returned to the operant chamber (same context) for 300 s, and
percent freezing was assessed as a measure of contextual fear memory. After a
delay in the same day, animals were returned to the operant chamber with
different context (altered by novel visual and odorant cues) for 300 s, and
conditioned auditory cue was presented in the same way as the training. Percent
freezing was assessed as a measure of cued fear memory. During the
acquisition phase, Emx1/Htr4 cKO mice showed no difference in freezing
compared to their control littermates (WT) (Figure 5.1B), indicating that both
groups showed similar exploration of the conditioning box before the first
footshock (at 140 s), or response to the footshock during the training.
Particularly, both groups showed an increase in freezing towards the end of the
acquisition phase, indicating a proper fear acquisition. During retrieval phase,
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Emx1/Htr4 cKO and WT showed similar context-induced freezing behavior
throughout the test and on average (~40%) (Figure 5.1C). On the other hand, in
the novel context, Emx1/Htr4 cKO displayed significantly lower cue-induced
freezing behavior compared to WT during the first and second cue, and on
average during all three cues (p<0.05, for each). Together, these data indicate
that Emx1/Htr4 cKO mice showed attenuated retrieval of cued fear memory.
To test the contribution of 5-HT4R specifically in the hippocampal
excitatory neurons to fear learning, Drd3/Htr4 cKO mice were trained in the same
contextual and cued fear conditioning paradigm. Drd3/Htr4 cKO and control
showed no difference in exploring the conditioning box before the first footshock
during the acquisition phase (0-140 s) (Figure 5.1D). Although both groups
showed increased freezing after the first footshock towards the end of the
training, Drd3/Htr4 cKO displayed blunted freezing response compared to WT,
indicating a possible difficulty in the acquisition of fear. Interestingly, during the
contextual fear memory retrieval phase, Drd3/Htr4 cKO mice showed significantly
low freezing levels compared to control littermates, throughout the test (Two-way
RM ANOVA, p<0.001) as well as on average (Figure 5.1E). When cued memory
retrieval was tested in a novel context, Drd3/Htr4 cKO mice also exhibited
significantly attenuated cue-induced freezing behavior compared to controls
during each cue and on average (p<0.0001). Together, these results indicated
that Drd3/Htr4 cKO mice showed attenuated retrieval of both contextual and
cued memories.
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Figure 5.1. Hippocampal 5-HT4R is necessary for proper retrieval of fear memories.
A. Schematic depicting the fear conditioning experimental design.
B. Emx1/Htr4 cKO mice showed similar freezing during memory acquisition training
compared to controls (WT).
C. There was not any difference between freezing between genotypes during contextual
fear memory retrieval.
D. Emx1/Htr4 cKO mice displayed attenuated freezing during cued fear memory retrieval.
E. Drd3/Htr4 cKO mice showed slight attenuation in acquisition of freezing during training.
F. Drd3/Htr4 cKO mice froze significantly less during contextual fear memory retrieval.
G. Drd3/Htr4 cKO mice displayed attenuated freezing during cued fear memory retrieval.
Data are represented as mean ± SEM. Two-way RM ANOVA was performed for line
graphs showing repeated measurements with 20 s bins, ¥, p<0.5, ¥¥¥, p,0.001; followed
by post hoc Fisher’s LSD test, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. Two-tailed
unpaired t-test was performed for bar graphs. *p<0.05, ***p<0.001, ****p<0.0001.
For Emx1/Htr4 cKO mice and their WT littermates, n=22, 22, respectively.
For Drd3/Htr4 cKO mice and their WT littermates, n=18, 17, respectively.
(Figure on next page)
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5.2.2. The role of 5-HT4R in object memory
The novel object recognition is based on memories neutral of emotionality.
Therefore, it can be used to discriminate whether changes in memory
performance are due to coding of emotional attachment or memory itself.
To investigate whether 5-HT4R in the excitatory neurons of pallial origin
contribute to object memory, Emx1/Htr4 cKO mice were tested in the novel
object recognition test (NORT). Figure 5.2A shows the NORT timeline. Animals
were habituated to the arena 24 hours before the test to eliminate any novelty
induced anxiety-like behaviors. During the sampling phase (7 min), each subject
was placed in the arena containing two identically object for familiarization. After
1 hour delay, each subject was returned to the arena containing an identical
object to the familiarized objects and another novel object. Time spend exploring
the objects were measured. While control littermates (WT) spent significantly
more time exploring the novel object compared to identical object, Emx1/Htr4
cKO mice did not show difference in exploration time between identical and novel
objects (Figure 5.2B). Novel object preference was above 50 percent for WT
showing positive preference while Emx1/Htr4 cKO showed around 50 percent
preference, significantly lower compared to WT (p<0.001) (Figure 5.2C).
Together, these data suggest that Emx1/Htr4 cKO mice displayed impaired
object recognition in the NORT.
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Figure 5.2. Hippocampal 5-HT4R is necessary for object recognition memory.
A. Schematic depicting the novel object recognition test (NORT).
B. Emx1/Htr4 cKO mice did not show a difference in exploration time between the
identical and novel objects, compared to controls (WT) showing significantly higher
exploration of the novel object. Emx1/Htr4 cKO n=32, WT n=32.
C. Emx1/Htr4 cKO displayed no preference for the novel object compared to WT
showing significantly higher percent novel object exploration.
D. Drd3/Htr4 cKO mice did not show a difference in exploration time between the
identical and novel objects, compared to controls (WT) showing significantly higher
exploration of the novel object. Drd3/Htr4 cKO n=12, WT n=12.
E. Drd3/Htr4 cKO displayed no preference for the novel object compared to WT showing
significantly higher percent novel object exploration.
Data are represented as mean ± SEM. Two-way ANOVA followed by post hoc Fisher’s
LSD test for exploration time (s). Two-tailed unpaired t-test for % novel object
exploration. **p<0.01, ***p<0.001.
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To delineate the contribution of 5-HT4R specifically in the hippocampal
excitatory neurons to object memory, Drd3/Htr4 cKO mice were tested in the
same novel object recognition paradigm. Drd3/Htr4 cKO mice did not show a
significant difference in the exploration of the novel and identical objects while
WT spent significantly more time exploring the novel object compared to identical
object (p<0.001) (Figure 5.2D). Novel object preference was above 50 percent
for WT showing positive preference while Emx1/Htr4 cKO showed around 50
percent preference, significantly lower compared to WT (p<0.01) (Figure 5.2E).
These results indicated that Drd3/Htr4 cKO mice displayed impaired object
recognition in the NORT.

5.2.3. The role of 5-HT4R in social recognition memory
To explore the role of 5-HT4R in social recognition memory in all excitatory
pallial neurons or specifically in the excitatory neurons of the hippocampus, we
used the three-chamber social recognition test. Figure 5.3A shows the social
recognition test timeline. Immediately after the social interaction test (discussed
in Chapter 2) during which each subject was familiarized with a previously
strange mouse, the inanimate object in one chamber was replaced with a novel
strange mouse of same appearance. The percentage of time exploring the novel
mouse was used to determine a subject’s ability to discriminate between the
unfamiliar and familiar mouse as a measure for social memory.
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During the recognition phase, Emx1/Htr4 cKO mice showed significantly
less percent time exploring the novel mice compared to control littermates
(p<0.05) (Figure 5.3B), indicating an attenuated preference towards exploring
the novel mice. On the other hand, both Drd3/Htr4 cKO and WT displayed similar
percentage of time exploring the novel mice (Figure 5.3C), showing equally high
preference towards exploring the novel mice. Together, these data suggested
that Emx1/Htr4 cKO mice displayed impaired social memory in the social
recognition task while Drd3/Htr4 cKO performed similar to controls.
Since, in mice, social memory relies on olfactory cues, we performed the
olfactory habituation/dishabituation test to control for the olfactory performance in
the Emx1/Htr4 cKO mice. Naturally, mice are expected to habituate to the same
odors when presented consecutively, while the presentation of a novel odor
should evoke higher interest (dishabituation) (Yang and Crawley, 2001). In
addition, mice’s ability to discriminate between social and nonsocial odors as well
as between two different social odors are necessary for normal social interaction
and recognition. In this test, water was used as a control, almond and mint
extracts as non-social cues, and the smell of the bedding from two novel cages
previously used by the same sex conspecifics were presented as social olfactory
cues. There was not any difference between the habituation and dishabituation
responses of Emx1/Htr4 cKO mice compared to WT littermates (Figure 5.3D),
supporting that the impairment in social recognition in Emx1/Htr4 cKO mice is not
due to an olfactory problem.
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Figure 5.3. Cortical, but not hippocampal, 5-HT4R may mediate social recognition.
A. Schematic depicting the social recognition test.
B. Emx1/Htr4 cKO mice showed attenuated percentage of novel mice interaction during
social recognition test compared to controls (WT). Emx1/Htr4 cKO n=25, WT n=29.
C. Drd3/Htr4 cKO and WT animals showed similarly high percentage of novel mice
interaction in the social recognition test. Drd3/Htr4 cKO n=12, WT n=12.
D. Emx1/Htr4 cKO did not show any difference in olfactory habituation/dishabituation
behavior compared to WT littermates. Arrows indicate the dishabituation when a new type
of odor was presented. Emx1/Htr4 cKO n=25, WT n=29.
Data are represented as mean ± SEM. Two-tailed unpaired t-test. *p<0.05, n.s.≥0.5.
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5.3. Discussion

Our behavior analysis in two different Emx1/Htr4 cKO and Drd3/Htr4 cKO
mice suggested that 5-HT4R in the excitatory neurons of the hippocampus and
neocortex mediates distinct features of learning and memory depending on the
brain region and the nature of the memory.

5.3.1. Hippocampal 5-HT4R mediates fear responses and memories.
We first showed that the loss of 5-HT4R in all excitatory neurons of brain
regions of pallial origin led to attenuation of the retrieval of cued fear conditioning
while context-associated fear memory was not affected. However, the ablation of
5-HT4R exclusively from hippocampal excitatory neurons resulted in impairments
in initial fear responses, possibly due to impairments in memory acquisition, as
well as the retrieval of contextual and cued fear memories. First, this suggests
that 5-HT4R in hippocampal excitatory neurons mediates both contextual and
cued fear memories. Second, the attenuation of fear responses and previously
reported increased innate anxiety-like behavior upon the genetic ablation of 5HT4R from the hippocampus suggest that innate anxiety and fear responses may
be differentially modulated by hippocampal excitatory neurons possibly through
5-HT4R receptors.
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The fact that the specific loss of hippocampal 5-HT4R resulted in more
robust dysregulation of fear memory compared to the pallial deletion promotes
the importance of cell type and circuit specific approaches in studying learning
and memory mechanisms. In addition, this may indicate that the hippocampal
circuits mediating contextual and cued fear conditioning may be distinct. Another
possible reason for this observation may be that the loss of 5-HT4R from the
hippocampus and LA/BLA in Emx1/Htr4 cKO mice may have dysregulated the
reciprocal connections between these regions in a synergistic way, rendering
contextual fear memory unaffected. There may as well be other compensation
mechanisms in the Emx1/Htr4 cKO mice since the robust behavioral phenotypes
observed in Drd3/Htr4 cKO mice, was either minimal or absent in Emx1/Htr4 cKO
mice (Chapter 2 and 3).

5.3.2. Hippocampal 5-HT4R mediates object memory.
Our findings in the novel object recognition test, showed that 5-HT4R in
the hippocampus was also necessary for emotionally neutral object memory.
These findings provide further evidence that hippocampus mediates object
memory and that 5-HT4R is a major regulator in this process. Together with its
role in fear memory, it seems possible that 5-HT4R mediates a relatively general
memory process, that may regulate functionally distinct hippocampal circuits
responsible for memories with varying valence.
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5.3.3. Pallial 5-HT4R mediates social recognition memory.
Social recognition memory was intact when 5-HT4R was ablated from
most of the hippocampal excitatory neurons while its deletion from almost all
pallial neurons blunted this memory. This indicates that 5-HT4R possibly
mediates social memory in pallial neurons, that are not targeted by Drd3-Cre. For
example, ventral CA3 pyramidal cells, which are the only neurons in
hippocampus that are Drd3-Cre negative, has been shown to store social
memory (Okuyama et al., 2016). In addition, the neocortex has been strongly
indicated in mediating the social recognition (Bicks et al., 2015). It is possible that
5-HT4R mediates social memory through these regions since its expression is
observed throughout the neocortex and ventral CA1.

5.3.4. Molecular signatures underlying the role of 5-HT4R in memory
Our electrophysiology and genome-wide TRAP-Seq data may provide
further evidence and candidate mechanism underlying the cellular and molecular
functions of 5-HT4R in memory. 5-HT4R may promote the formation of memory
by enhanced synaptic transmission as we found that 5-HT4R promotes the firing
of DG GCs. Indeed, optogenetic inhibition of dorsal DG GCs has shown to impair
contextual fear memories (Kheirbek et al., 2013). Our differential expression
analysis also support this hypothesis. We have found that many genes
dysregulated in the absence of 5-HT4R were involved in calcium-dependent
signaling, synaptic and vesicular transmission, cell adhesion and
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phosphorylation, all of which can affect the synaptic plasticity in these neurons. In
fact, gene set enrichment analysis (GSEA) in Chapter 4 also identified
significantly dysregulated genes that are expressed in GCs and correlated with
LTP and LTD, such as, Ppp2r1a, Plcb3, and Nos1 (data not shown).
Furthermore, our behavioral findings indicating a role for 5-HT4R in
positive regulation of memory may be correlated with our differential expression
data showing the dysregulation of ‘genes decreased in Alzheimer’s disease
patients’ (Figures 4.14 and 4.16). This may also be supported by the significant
changes in the expression of ‘genes enriched in astrocytes’ (Figure 4.14) since
astrocytes play a significant role in the processing of extracellular amyloid-beta
(Aβ) plaques (Frost and Li, 2017) linked to AD pathology. Furthermore, the
genes that are significantly dysregulated both in the dorsal and ventral DG upon
the loss of 5-HT4R (Figure 4.13E) include Apoe and Clu, two of the largest
known genetic risk factors for AD (Sadigh-Eteghad et al., 2012). Considering the
ameliorating actions of 5-HT4R agonists in animal models of AD, the analysis and
functional confirmation of our RNA-Seq results may bring more insights to the
field.

5.4.5. Conclusion
Our results demonstrated that 5-HT4R in hippocampal excitatory cells is a
prominent regulator of hippocampus-dependent memory processing. The
identification of cell type specific elements of 5-HT4R pathway via genome wide
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gene expression analyses has presented a powerful resource that will unravel
new cellular players for understanding the function of 5-HT4R in learning and
memory. Ultimately, this may provide novel molecular targets for the
development of new cognitive enhancers, which will be useful for treatments of
cognitive problems observed in many disease.
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CONCLUSIONS
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Since the discovery of first selective serotonin reuptake inhibitor,
fluoxetine, in 1974 (Wong et al., 1974), SSRIs still remain the most prescribed
antidepressant as the extensive search for more effective therapeutics continues.
Identification and targeting specific cell types and proteins underlying the
pathophysiology of the disease presents a powerful approach in this pursuit for
developing novel, more efficacious therapies with fewer side effects.
In this study, we generated the first Htr4 conditional knockout animals. We
successfully used this tool to study the role of 5-HT4R, one of the first putative
serotonergic targets for fast acting antidepressants, in different cell populations in
the hippocampus and neocortex. This tool will continue to help facilitate our
knowledge of the function of this receptor in cell type specific serotonergic
modulation in various biological processes.
We found that the loss of 5-HT4R from mature excitatory neurons of
hippocampus led to an extensive antidepressant-like behavioral response along
with increased innate anxiety levels. Moreover, these behavioral changes were
accompanied by antidepressant-like cellular and molecular changes in the
hippocampus; namely enhanced neurogenesis in the ventral dentate gyrus and
elevated neurotropic factors in the hippocampus. Slice electrophysiology
experiments revealed that the excitability of dentate gyrus granule cells was
decreased when 5-HT4R was absent, a regulation that is also observed in
response to SSRI treatments. Together, our results strongly indicate that 5-HT4R
in the hippocampus mediates anxiety and mood related behaviors differentially,
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and the ablation of functional 5-HT4R specifically in the hippocampus leads to
antidepressant-like actions.
The ventral dentate gyrus specific changes in neurogenesis as well as the
differential regulation of gene expression between ventral and dorsal dentate
gyrus in response to the loss of 5-HT4R provide further evidence that these
regions are under distinct control in modulating emotive behaviors. These results
support the hypothesis that 5-HT4R mediate anxiety and mood related behaviors
through ventral hippocampus.
Our results provide further insights in the circuit modulation underlying
antidepressant-like behavioral changes. The inhibition of dentate gyrus granule
cell activity seems to be a common and necessary factor in this process. Our
data and previous reports strongly suggest that antidepressant action may be
accomplished by increasing serotonergic inhibition directly on dentate gyrus
granule cells and recruiting GABAergic inhibition on the granule cells through
interneurons via increased number of young adult born neurons. As dentate
gyrus is the “main gate” to the hippocampus and mediates the neural
transmission to the rest of the region along the dorsoventral axis, an approach
targeting functionally distinct granule cell populations may be necessary. Teasing
apart the circuit elements that are sufficient to mediate emotive behavior may
lead to more specific anxiolytic and antidepressant targets.
Our TRAP-Seq approach identified excitatory cell specific 5-HT4R
regulations in the dentate gyrus. The analysis of gene set enrichment in
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dysregulated genes suggests that 5-HT4R is necessary for homeostasis of
intracellular calcium signaling which may be essential for the excitability of these
neurons and synaptic signaling. Further investigation and functional confirmation
of candidate genes identified in this study will unravel the exact intracellular
mechanisms of 5-HT4R signaling, especially that mediate granule cell excitability.
Further identification of ventral dentate gyrus specific genes in this pathway will
be especially valuable since it may lead to more specific targets for novel
therapeutics against anxiety and mood disorders.
Pharmacological activation of 5-HT4R shows fast acting anxiolytic and
antidepressant properties however the underlying mechanism of this action is
poorly understood. Our results showing that the ablation of 5-HT4R from the
hippocampus was sufficient to produce antidepressant-like responses support
the previously generated hypothesis that the desensitization of hippocampal 5HT4R may mediate the fast acting antidepressant effects of the 5-HT4R agonist
and the action of chronic SSRIs. On the other hand, it is also possible that the
agonist may achieve its fast actions via other brain regions such as the mPFC.
The administration of the 5-HT4R agonist in cell type specific or spatially
restricted Htr4 conditional knockout animals may point out a specific path of
action.
One of the questions regarding the function of 5-HT4R was whether it
mediates the SSRI responses in the neocortex. We tackled this question by
deleting 5-HT4R from all excitatory cells of pallial origin, and showed that 5-HT4R
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was not necessary for behavioral responses to chronic SSRIs in the neocortex.
This hypothesis was also tested with a more specific approach that directs the
conditional 5-HT4R targeting to the cortical cell population that mediates the
chronic SSRI actions. Although these cells had shown an increase in Htr4 mRNA
levels in response to chronic SSRI treatment, our results suggested that 5-HT4R
was not required for the behavioral antidepressant responses. However, what
would be the biological relevance of elevated 5-HT4R levels in these cells? It is
possible that neocortical 5-HT4R mediates the strength or side effects of the
SSRI action. Due to the limitations of behavioral tests in mice, the strength of the
SSRIs would be challenging to interpret. However, our results may support the
latter provocative hypothesis by indicating that pallial 5-HT4R was necessary for
some of the anxiogenic effects of SSRIs and its specific loss in corticostriatal
neurons may be anxiolytic. Regardless, these results suggest distinct functions
for 5-HT4R in the hippocampus and neocortex.
In addition to emotive behavior, hippocampal 5-HT4R was necessary for
maintaining some episodic memories involving hippocampal function, such as
contextual and cued fear memory and object memory. These results shed light
into the function of hippocampal 5-HT4R in mediating memory, as well as
differential regulation of innate anxiety and fear responses. Further
electrophysiological studies and the analysis of potential intracellular targets
identified by TRAP-Seq will elucidate its role in synaptic plasticity and may help
identify targets for cognitive enhancers.
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Furthermore, the differential regulation of anxiety, mood and memory
related behaviors by a single 5-HT receptor in the excitatory neurons of
hippocampus points out the importance of targeting functionally distinct circuit
elements to study emotive and cognitive processes. In this regard, our analysis
of multidimensional transcriptomics data that identified region and cell type
specific genes mediated by 5-HT4R will facilitate the discovery of such cell type
markers or direct molecular targets.
Overall, the behavioral and neural adaptations following hippocampal loss
of 5-HT4R were similar to the effects of SSRIs, considering our findings and
others showing SSRIs yield antidepressant-like responses while also elevating
anxiety levels in naïve animals of some mouse strains. Moreover, in patients,
chronic SSRIs achieve improved mood while acute SSRIs sometimes exacerbate
anxiety symptoms, resulting in poor therapeutic compliance. In this context, this
study will help elucidate the cellular and molecular mechanisms underlying 5HT4R function that may lead to novel targets for the treatment of anxiety and
mood disorders.

Closing remarks
As affective disorders show a change in the balance of the activity of
various limbic regions, teasing apart the distinct elements of the emotive circuitry
in the brain is essential to understand the disease. The source of the problem
may differ in each patient; however, the pathophysiology and symptoms show
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convergence to a great extent. Therefore, targeting a specific circuit component
could compensate for possible failures in other parts of the circuitry and recover
the emotive homeostasis. The circuit specific targeting may be achieved by the
identification of disturbances in the molecular profiles of specific cell types within.
The promise of the 5-HT4 receptor as a therapeutic target have led us to study its
function in distinct parts of the emotive circuit. This study identified specific roles
of this major neuromodulatory receptor in the limbic system, and provided strong
evidence in favor of the current hypothesis of hippocampal and serotonergic
modulation of emotive behavior. Furthermore, it provided new insights into the
divergent regulation of anxiety and mood as well as how a faster acting
antidepressant response may be achieved. Future investigation should focus on
confirming new targets in the hippocampus that is specific to a functional circuit
mediating a particular aspect of emotive behavior. This approach may lead to
more efficacious therapies and bring a balance to the extended circuitry. Discreet
targeting may also have a higher chance to challenge the behavioral and
physiological side effects of a more generalized therapy. While a discovery of an
effective and circuit specific target may not alleviate every symptom, it may
hopefully fix convergent problems. Further combinatorial pharmacological
approaches with the right dose adjustments based on a particular affective
disorder or even an individual patient will extend the scope of the therapeutics.
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MATERIALS AND METHODS
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M.1. Generation of Htr4-floxed mouse line

Targeting vector (TV) was designed by inGenious Targeting Laboratory
Inc., Ronkonkoma, NY. Annotated TV sequence (in full) can be found in the
Appendix. A 7.92 Kb region used to construct the targeting vector was first
subcloned from a positively identified C57BL/6 BAC clone (RP23:358G18). The
region was designed such that the short homology arm (SA) extends 2347 base
pairs (bp) 3’ to the Neo cassette. The long homology arm (LA) ends 5’ to the
target region, and is 4820 bp long. The loxP/FRT flanked Neo cassette is
inserted 252 bp downstream of exon 5. The single loxP site, containing
engineered MfeI and ApaI sites for southern blot analysis, is inserted 347 bp
upstream of exon 5. The target region is 752 bp and includes exon 5.
The targeting vector is confirmed by restriction analysis after each
modification step, and finally, by sequencing with the following primers. P6 (5’GAG TGC ACC ATA TGG ACA TAT TGT C -3’) and T73 (5’- TAA TGC AGG
TTA ACC TGG CTT ATC G -3’) primers anneal to the backbone vector sequence
and read into the 5’ and 3’ ends of the BAC sub-clone. N1 (5’- TGC GAG GCC
AGA GGC CAC TTG TGT AGC -3’) and N2 (5’- TGC GAG GCC AGA GGC CAC
TTG TGT AGC -3’) primers anneal to the 5’ and 3’ ends of the loxP/FRT flanked
Neo cassette and sequence the 5’ side of SA and 3’ side of the target region,
respectively.
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The BAC was sub cloned into a ~2.4kb backbone vector (pSP72,
Promega) containing an ampicillin selection cassette for retransformation of the
construct prior to electroporation. A pGK-gb2 loxP/FRT Neo cassette was
inserted into the gene as depicted in Figure 2.1 and Appendix. The targeting
construct was linearized using Notl prior to electroporation into ES cells. The total
size of the targeting construct (including vector backbone and Neo cassette) is
13.69 Kb.
Three lines of chimeric mice using C57BL/6 ES cells were generated at
the Janelia Research Campus Gene Targeting and Transgenic Facility; and one
of these lines, ROXY Htr4 1G12, showed germline transmission of the mutation.
We have established a colony of mice from the 1G12 line in our laboratory
referred as Htr4loxP/loxP or Htr4-floxed mice.

M.2. Animals

All procedures involving animals were approved by The Rockefeller
University Institutional Animal Care and Use Committee and were in accordance
with National Institutes of Health guidelines. Emx1-Cre mice were purchased
from The Jackson Laboratories (Stock #005628). Tlx3-Cre (Tlx3-Cre PL56) and
Drd3-Cre (Drd3-Cre KI198) mice were generated by the GENSAT Project (Gong
et al., 2007). Tlx3-Cre mice were maintained at The Rockefeller University and
Drd3-Cre were purchased from the Mutant Mouse Regional Resource Center

231

(MMRRC: 031741-UCD). Cre-dependent EGFP-L10a expressing mice,
Rosa26fsTRAP, were purchased from the Jackson Laboratories (Stock #022367).
All mice were bred on a C57BL/6J background, maintained on a 12-hour lightdark cycle (light cycle, 7 am to 7 pm) and given ad libitum access to food and
water. Animals used in the study were male and female.

M.3. Breeding and Genotyping

To generate enough number of age-matched littermates for behavior
cohorts, accelerated breeding by in vitro fertilization (IVF) was employed in
collaboration with Transgenic Services Laboratory in Comparative Bioscience
Center (CBC) at The Rockefeller University. For IVF, eggs from Htr4loxP/loxP
females and spermatozoa from Emx1/Tlx3/Drd3-Cre::Htr4 loxP/loxP male mice.
Animals for other lines and experiments were generated by duo (one male, one
female) or trio (one male, two females) breeding. Breeding for each specific
experiment was discussed in the corresponding Chapter.
For genotyping, at age 15-18 days, pups were marked with an ear punch
for identification and tail biopsies were performed. Each tail sample was lysed for
DNA extraction in 200 µl tail lysis buffer (100 mM Tris.HCl-pH8.8, 1 mM EDTA,
0.5% Tween20) at 56 °C for at least 24 hours. The tail DNA samples were
analyzed via PCR using 1-2 µl of lysis solution, GoTaq DNA Polymerase
(Promega) and corresponding primer pairs (Table M.1).
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Table M.1. Genotyping primers.
Expected
results (bp)

Primer*

Sequence

Htr4 loxP F
Htr4 loxP R
Cre F
Cre R
EGFP F
EGFP R
Rosa WT F
Rosa WT R

TCGAGGCATTCCTCGATTCA
TAACACCTGGCCGAAACGTT
CCGGGCTGCCACGACCAA
GGCGCGGCAACACCATTTTT
GCACGACTTCTTCAAGTCCGCCATGCC
GCGGATCTTGAAGTTCACCTTGATGCC
AAGGGAGCTGCAGTGGAGTA
GAGCGGGAGAAATGGATA G

WT: 172
loxP: 239
WT: n/a
Cre: 150
WT: n/a
EGFP: 265
WT: 297

*F: forward, R: reverse

M.4. Drug treatments and behavioral assays

Behavioral assays were performed on male mice starting from 8 weeks
and up to 4 months old. Mice were housed 2-3 per cage. Each experiment was
performed using only aged matched mice, and control groups always consisted
of littermates. All experiments, scoring and analysis were performed blinded to
the experimental groups. For every behavioral experiment, animals were brought
into the procedure room in their home cages and habituated to the room for one
hour. Assays were performed within the light cycle of the animals unless
otherwise is noted. The number of animals per group (n) and the statistical
analyses used for the result of each experiment were detailed in the
corresponding chapter. For behavioral analysis, data points outside 90%
confidence interval (conventionally, SD= ±1.644854) of the estimated Gaussian
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curve for each group were determined as “outliers” and excluded from analyses.
Statistical analyses were performed using GraphPad Prism 7 software, and
p<0.05 was considered significant.
For chronic fluoxetine (FLX) treatments, 8-week old mice were given
either 0.167 mg/ml FLX (Fluoxetine hydrochloride, Sigma F132, Sigma-Aldrich)
in vehicle (VEH, 1% saccharine in drinking water to mask the taste of FLX) or
only VEH for control. Drugs were administered by drinking via 50 ml canonical
tubes with sipper caps composed of 2.5 cm straight stainless steel sipper tubes
ball-point sipper tubes (Ancare), inserted into rubber stoppers. Behavioral assays
stared after 18 days of drug treatment. The treatment continued throughout the
behavior assessment period until mice were sacrificed. Every 2-3 days, fresh
FLX and VEH solutions were replaced.

M.4.1. Open field
Open field behavior was assayed in eight identical square arenas
(50x50x22.5 cm, acrylic) with white floor and clear walls, equipped with two rows
of infrared photocells placed 20 and 50 mm above the floor, spaced 31 mm
apart. The procedure room was brightly and homogenously lit with fluorescent
ceiling lamps and the arenas were placed on tables. Each animal was placed in
the open field arena for 60 min. Photocell beam interruptions were recorded on a
computer using the Superflex software (Accuscan Instruments). The floors and
the walls of the arenas were cleaned with Clidox sterilizer and water in between
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trials. The data was exported as time spent and distance traveled in total,
peripheral and center areas in 5 min bins. Thigmotaxis was calculated by dividing
time spend in the peripheral area by total time spent.

M.4.2. Elevated Plus Maze
The plus maze consisted of two opposite open arms without sidewalls
(35x5 cm) and two enclosed arms with 14 cm high sidewalls (35x5x14 cm). The
arms extended from a common central square (5 cm2) perpendicular to each
other, completing the shape of a plus sign. The entire plus-maze apparatus was
elevated to a height of 30 cm. The experimental area was isolated from the
experimenter with black curtains running down from the ceiling to the floor on
four-sides and homogenously lit by ceiling mounted LED lamps on four sides,
ensuring minimal shadows. The illumination at the middle of each open arm was
set to 30-lux. Testing began by placing an animal on the central platform of the
maze facing the same open arm. Trials were 5 min and recorded by a ceiling
mounted camera connected to a computer. EthoVision XT 7.0 software (Noldus)
was used to operate the camera, track the subject and record the total time spent
in each arm, total distance moved and velocity. The maze was wiped with 30%
Ethanol in between trials. Mice that fell off the open arms were excluded from the
analysis.
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M.4.3. Novelty Suppressed Feeding
Mice were food deprived for 24-hour before the test. The efficiency of food
deprivation was measured as the decrease in body weight (data is not reported
as none of the animals were excluded from the analysis by this measure).
Testing was performed in a brightly lit arena similar to the open field (50x50x22.5
cm) where a food pellet (1.8 cm length of 1.58x0.95 cm diameter oval pellets)
was placed in the middle on a circular filter paper (20 cm diameter, Fisherbrand).
A white noise source was active throughout the habituation and testing. Four
subjects were tested at the same time in adjacent arenas. The observer in the
room measured the latency to bite the food in 15 min trials. To record homecage
feeding, each animal was put in a clean cage similar to their home cage for 30
min with food ad libidum after each trial.

M.4.4. Tail suspension test
Mice were suspended by their tails using adhesive tape (1-2 cm from the
tip of the tail) to the end of a piece of flexible plastic tubing hanging from the top
center of one of the four compartments of the white acrylic box setup (101x55x26
cm). Four mice were tested at the same time in four adjacent compartments
separated by white acrylic walls. While suspending, mice were about 30 cm
above the floor of the box. Test sessions lasted 6 min and were videotaped. Mice
that held on to their bodies by their front limbs or started climbing up their tails
were gently repositioned using a long stick without distracting other subjects. The
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floors and the walls of the box were cleaned with Clidox sterilizer and water in
between trials. At a later date, the amount of time spent immobile in the last 4
min of the test was measured, which was estimated by scoring as mobile or
immobile in every 5 s. In case of body holding or climbing, scoring was not
applicable. If more than four time points were missed, mice were excluded from
the analysis.

M.4.5. Forced swim test
Mice were individually placed into the glass cylinders (15 cm diameter, 35
cm height) filled with tap water (23-25 °C) to a height of 15.7 cm. Four mice were
tested at the same time in separate cylinders placed as 2x2 adjacently. The
cylinders were visually separated by white acrylic sheets. To start a trial, mice
were gently placed into the cylinders keeping their head above the water surface.
Test sessions lasted 6 min and were videotaped from above. At a later date, the
amount of time spent immobile, defined as the absence of all motions except
floating and those required to keep a mouse’s head above the surface, was
measured, which was estimated by scoring as mobile or immobile in every 5 s.

M.4.6. Splash test
These experiments were performed in the dark cycle of the mice to
observe higher amount of activity. The procedure room was illuminated with red
light. Mice were squirted with 10% sucrose (in tap water) enough to soak the fur
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on their back by a small spray bottle (for results discussed in Chapter 2), or 200
µl per animal on their lower back by a 1 ml syringe with a needle tip attached (for
results discussed in Chapter 3). Immediately after, mice were placed in clean
small mouse cages (22.2x30.80x16.24 cm) with bedding and filter top (no wire
top). Four mice were tested at the same time in adjacent cages visually
separated by white acrylic sheets. Test sessions lasted 5 min and were
videotaped from the side. At a later date, grooming time was measured in total 5
min, which was estimated by scoring as grooming in every 5 s.

M.4.7. Sucrose preference test
Mice were water deprived for 24 h. Each mouse was then placed in a
clean cage with bedding, containing a 1% sucrose filled bottle and a tap water
filled bottle (50 ml canonical tubes with sipper caps composed of 2.5 cm straight
stainless steel sipper tubes ball-point sipper tubes (Ancare), inserted into rubber
stoppers). Sucrose and water consumption for 6 hours was measured by the
decrease in the weight of the bottles. At the 3-hour mark, bottles were switched
to avoid side preference. Sucrose preference was calculated as the ratio of the
amount of 1% sucrose consumed to the amount of total drinking.

M.4.8. Sucrose consumption test
Each mouse was placed in a clean cage with bedding and food,
containing a 1% sucrose filled bottle and a tap water filled bottle (as described in

238

sucrose preference test). Sucrose and water consumption for 72 h was
measured by the decrease in the weight of the bottles. At the each 12 h mark,
the bottles were weighted and switched to avoid side preference. At the end of
the test, animals were weighted. The amount of 1% sucrose or water consumed
(g or ml) was normalized per animal to the weight of the animals (g).

M.4.9. Marble burying
Equally spaced 12 black marbles (4x3) were placed on a deep woodchip
bedding (Sani-Chips) filled 3:4 of a small mouse cage (22.2 x 30.80 x 16.24 cm)
with open top. The number of marbles buried in 15 min was counted as a
measure of spontaneous digging. Marbles submerged at least 2:3 way into the
bedding was counted as buried.

M.4.10. Acoustic startle response and pre-pulse inhibition
Startle and PPI testing were performed in four identical startle response
systems (39×38×58 cm, SR-LAB system, San Diego Instruments), each
consisting of a non-restrictive clear Plexiglas cylinders (inner diameter 4 cm,
length 13 cm), resting on a white Plexiglas platform, placed in a ventilated,
sound-attenuated chamber. High frequency speakers mounted 33 cm above the
cylinders presented all acoustic stimuli, which were controlled by SR-LAB
software. Piezoelectric accelerometers mounted under the cylinders transduced
movements of the animals which were digitized and stored by an interface and
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computer assembly. A dynamic calibration system was used to ensure
comparable sensitivities across chambers.
The animal was placed into the startle chamber and allowed to acclimatize
for 5 min. The time between each trial was 7-23 s. The measurement was
performed in four blocks. All intensities were presented in a pseudo-random
order within a block. Beginning at startling stimulus onset, 65 consecutive 1-ms
readings were recorded to obtain the peak amplitude of the animal's startle
response (Vmax). 5 s after each stimulus, another 65 ms were measured which
constitutes the no-stimulus trials. Background noise was 65 dB.
In the first block (pre-test), mice were presented with 120 dB acoustic
stimuli (65 ms) for five trials. Maximum startle responses (Vmax) were recorded
per trial and averaged per subject.
In the second block (ASR), acoustic stimuli were presented in five different
intensities (120, 110, 100, 90 and 80 dB, 65 ms), each for four trials. Maximum
startle responses (Vmax) were recorded for each trial and averaged for each
stimulus intensity per subject.
In the third block (PPI), 120 dB acoustic stimuli (40 ms) preceded by four
different pre-pulse (PP) intensities (0, 3, 6, 12 dB, 20 ms) were presented, each
for ten trials. The time between the prepulse and the pulse were 100 ms.
Maximum startle responses (Vmax) were recorded for each trial and averaged
for each prepulse intensity per subject. PPI was calculated as the percent

240

decrease in startle response in PP3, PP6 and PP12 compared to PP0 per
subject.
Lastly, in the fourth block (post-test), 120 dB stimuli (65 ms) were
presented for five trials. Maximum startle responses (Vmax) were recorded per
trial, averaged per subject, and compared to the pre-test responses to assess the
habituation of ASR during the testing.

M.4.11. Fear Conditioning
Coulbourn Instruments Shuttle Cage for mouse (H10-11M-SC) was
converted into the operant conditioning chamber for fear conditioning
experiments as following: The Shuttle Cage was placed into a sound and light
proof isolation cubicle. Mice were only placed in the chamber on the right. A USB
camera (Coulbourn Instruments, ACT-VP-02) was mounted on the ceiling of the
right chamber to record the behavior of mice. The sound and shock generation,
control and delivery were accomplished by configuring the appropriate
accessories and modules (Coulbourn Instruments) with the chamber. The
FreezeFrame 3 Software (Coulbourn Instruments) was used to program the test,
operate the setup, record the videos and analyze the freezing behavior.
In day 1, mice were placed in the operant conditioning chamber for 300 s,
and an auditory tone (70 Db) was presented for 20 s preceding an electrical
footshock (0.75 mA, 1 s) for three times at 140, 200 and 260 s in a 300-s training
trial. In day 2 (24 h later), first, animals were returned to the operant chamber

241

(same context) for 300 s to induce contextual freezing behavior. After all animals
in a given cohort were tested for context, in the same day, animals were returned
to the operant chamber with altered context for 300 s: bottom and sides of the
camber was covered with colored and patterned plastic layering, and cotton balls
sprayed with 1% mint extract (in 30% ethanol) was placed in a separate
compartment at the bottom of chamber. Conditioned auditory tone was presented
in the same way as the training to induce cued freezing behavior. Percent
freezing was calculated by FreezeFrame 3 Software using the recorded videos
and the freezing detection threshold was set to 10 (default).

M.4.12. Novel object recognition
These experiments were performed in the dark cycle of the mice to
observe higher amount of activity. However, the fluorescent ceiling lamps in the
room were kept on, illuminating the room and arena similar to the light cycle.
Animals were habituated to the square arena (58x58x40 cm, clear acrylic) 24 h
before the test for 7 min. During the sampling phase (7 min), each subject was
placed in the arena containing two identical objects placed at 10 cm distances
from the two opposite corners of the same side. After 1 hour delay, each subject
was returned to the arena containing an identical object at one corner, and
another novel object at the other corner replacing the familiar object. This
recognition phase also lasted for 7 min. The arena was videotaped from above
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and the interactions with each object were manually scored by two stopwatches.
The sniffing behavior was considered as interaction.

M.4.13. Social interaction and recognition
Social behavior was measured using the three-chamber social interaction
setup. The arena is a rectangular box (58.5x43x22.7 cm) made of white acrylic,
two inner walls dividing it equally into three chambers. Each inner wall has an
open middle section with a removable sliding door, allowing free access between
the middle and the two side chambers when the doors are removed. The social
interaction test comprised two parts: a habituation session and a trial session.
During the habituation session, two empty wire cups were placed in the left and
right chambers. The test mouse was placed in the middle chamber and allowed
to explore all three chambers for 10 min. Next, the doors to the side chambers
were closed, the test mouse was placed in the middle chamber for the trial
session. A stranger mouse of the same sex/appearance and a novel LegoÒ
piece were placed inside the left and right wire cups in a random order to balance
for side preference. Doors between chambers were opened to allow the test
mouse to explore the three chambers freely for 10 min.
For social recognition, immediately following the social interaction test, the
doors were closed once again and the test mouse was placed in the middle
chamber. A novel stranger mouse of the same sex was replaced with the LegoÒ
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piece. Immediately, doors between chambers were opened to allow the test
mouse to explore the three chambers freely for 10 min.
During all sessions, the arena was videotaped from above. Stranger mice
were habituated to the wire cups for 10 min each day for three days before the
testing to minimize movement and stress responses such as defecation and
urination. The arena and the wire cups were thoroughly cleaned with Clidox
sterilizer and water between subjects. At a later date, the interaction time with
each cup were manually measured by two stopwatches on the recorded videos.
The sniffing behavior was considered as interaction.

M.4.14. Olfactory habituation/dishabituation
The procedure was performed as described previously (Yang and Crawley,
2001). Cotton swabs dipped into water (control), two nonsocial odors (almond
and mint extracts) and two social odors (bedding from two separate cages of
same sex) were presented as olfactory stimuli. Sniffing behavior was recorded by
stopwatches in real time.

M.5. shRNA construct generation and screening

Five shRNA sequences against Htr4 were designed by The RNAi
Consortium, Broad Institute (https://portals.broadinstitute.org/gpp/public). The
single-stranded DNA (ssDNA) oligonucleotides for shRNA (sense) and
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complementary (antisense) sequences were commercially synthesized and
purchased from e-oligos (Gene Link) (Table M.2). Overhang sequences were
added to allow for cloning (SapI: 5’- TTT -3’ for the sense, and XbaI: 3’- GATC -5’
to the antisense sequences). These oligonucleotides were annealed to generate
double-stranded DNA oligonucleotides with overhangs, and cloned into the
pGFP-shRNA vector (pAAV-CMV-EGFP-hGH-PA-mU6-shRNA-PA) as described
previously (Hommel et al., 2003). Briefly, ssDNA oligonucleotides were
resuspended at 0.25 nM/µl in water. Complementary ssDNA oligonucleotides
were annealed as following: 20 µl sense-oligo, 20 µl antisense-oligo, 5 µl water
and 5 µl 10X annealing buffer (10X = 1M NaCl, 100mM Tris pH7.4) for a total of
50 µl annealing reaction was mixed, rapidly heated to 95°C, and slowly cooled
down to room temperature in a PCR machine. Annealed templates were diluted
1:1000 in 0.5X annealing buffer. 1 µl of the dilution to 30-50 ng of the SapI/XbaI
restriction digested/gel purified pGFP-shRNA was used for each ligation reaction
in a total 10 µl volume. Sequencing primers, pGFP-shRNA-forward (5’- CAC
AGA CTT GTG GGA GAA GC -3’, 270 bp from hairpin) and pGFP-shRNAreverse (5’- CCC CTG AAC CTG AAA CAT AAA -3’, 190 bp from hairpin), were
used to select and confirm the positive clones.
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Table M.2. shRNA oligonucleotide sequences.
Name

Strand

Hairpin Sequence 5'-to-3'

shControl

sense

shControl

anti

sh249

sense

sh249

anti

sh261

sense

sh261

anti

sh270

sense

sh270

anti

sh284

sense

sh284

anti

sh304

sense

sh304

anti

TTTGGATCTTAGCCCCAAGGTACCGCAGGA
TTGCCCGTATAGGTGACGTCTCATATTTTT
CTAGAAAAATATGAGACGTCACCTATACGGG
CAATCCTGCGGTACCTTGGGGCTAAGATCC
TTTCCGGCCCTTCTTTGTCACCAATATTCTC
GAGAATATTGGTGACAAAGAAGGGTTTTT
CTAGAAAAACCCTTCTTTGTCACCAATATTCT
CGAGAATATTGGTGACAAAGAAGGGCCGG
TTTCCGGCCTTCCCATGTTTATATCTTTCTC
GAGAAAGATATAAACATGGGAAGGTTTTT
CTAGAAAAACCTTCCCATGTTTATATCTTTCT
CGAGAAAGATATAAACATGGGAAGGCCGG
TTTCCGGCCTCACAGCAACTTCTCCTTTCTC
GAGAAAGGAGAAGTTGCTGTGAGGTTTTT
CTAGAAAAACCTCACAGCAACTTCTCCTTTCT
CGAGAAAGGAGAAGTTGCTGTGAGGCCGG
TTTCCGGGCCTTTGGTTTATAGGAACAACTC
GAGTTGTTCCTATAAACCAAAGGCTTTTT
CTAGAAAAAGCCTTTGGTTTATAGGAACAAC
TCGAGTTGTTCCTATAAACCAAAGGCCCGG
TTTCCGGGCTGGCCTATTACCGAATCTACTC
GAGTAGATTCGGTAATAGGCCAGCTTTTT
CTAGAAAAAGCTGGCCTATTACCGAATCTAC
TCGAGTAGATTCGGTAATAGGCCAGCCCGG

TRC Clone ID

TRCN0000026249

TRCN0000026261

TRCN0000026270

TRCN0000026284

TRCN0000026304

For in vitro screening of the knockdown efficiency of shRNAs, HEK293T
cells (ATCC) cultured in 24-well plates (1.9 cm2 culture area, Corning) in
Dulbecco's Modified Eagle's Medium (DMEM) (Gibco) supplemented with 10%
fetal bovine serum (FBS) (Gibco) were cotransfected with pCMV6-Htr4-Myc-DDK
(Origene) and each of the pGFP-shRNA vectors via FuGENE 6 transfection
reagent (Promega). Four replicates per each shRNA construct were prepared. 48
hours after the transfection, total RNA samples were isolated using Qiagen
RNeasy Mini Kit with on-column DNase digestion. Total cDNA samples were
generated using qScript cDNA SuperMix (QuantaBio). qRT-PCR was employed
using the cDNA samples and TaqMan probes for Htr4 and Gapdh (Table M.3) to
measure relative Htr4 expression and calculate knockdown efficiency.
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M.6. Total RNA isolation and quantitative RT-PCR

Total RNA was isolated from cultured cells or dissected tissue using
Qiagen RNeasy Mini Kit for whole cortex and hippocampus, and RNeasy Micro
Kit for DG and CA fields. For tissue dissection, mice were sacrificed, followed by
rapid dissection of desired brain region with fine tip forceps in ice-cold HBSS
containing 2.5 mM HEPES-KOH (pH 7.4), 35 mM glucose, 4 mM NaHCO3. RNA
quantity was measured with a Nanodrop 1000 spectrophotometer (Thermo
Scientific). cDNA samples were generated from 300-1000 ng of total RNA using
qScript cDNA SuperMix (QuantaBio) (see Chapter 6.13 for polysome-bound RNA
isolation and cDNA amplification for TRAP-Seq).
All qRT-PCR experiments were performed on the LightCycler® 480
System (Roche), using TaqMan assays (Applied Biosystems) and LightCycler®
480 Probes Master mix (Roche). A list of Taqman assays used in this study was
given in Table 6.3. Default cycling conditions were followed (pre-incubation: one
cycle, 95°C, 5 min; amplification: 45 cycles, 95°C for 10 s, 60°C for 30 s, 72°C for
1 s; ramp rate: 4.4°C/s). 10-20 ng of cDNA were used for each qRT-PCR
reaction and three technical triplicates were run for every sample. The mean CT
for technical replicates was used for the quantification. Data were normalized to
Gapdh as the endogenous control by the comparative CT (2-ΔΔCT) method
(Schmittgen and Livak, 2008).
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Table M.3. TaqMan Gene Expression Assays used for qRT-PCR.
Gene Symbol
Htr4 (3-4)
Htr4 (4-5)
Htr4 (5-6)
Htr4 (6-7)
Gapdh
Htr1a
Htr1b
Htr1d
Htr1f
Htr2a
Htr2c
Htr3a
Htr5a
Htr5b
Htr6
Htr7
S100a10
Bdnf
Vegfa
Gad1
Tyro3
Lct
Dsp
Meis2
Trhr
Tdo2
EGFP
Colgalt2
Actb

Assay ID
Mm00434129_m1
Mm01258807_m1
Mm01258808_m1
Mm01258809_m1
Mm99999915_g1
Mm00434106_s1
Mm00439377_s1
Mm00434115_s1
Mm02619863_s1
Mm00555764_m1
Mm00434127_m1
Mm00442874_m1
Mm00434132_m1
Mm00439389_m1
Mm00445320_m1
Mm00434133_m1
Mm00501457_m1
Mm04230607_s1
Mm00437306_m1
Mm00725661_s1
Mm00444547_m1
Mm01285112_m1
Mm01351876_m1
Mm00487748_m1
Mm00443262_m1
Mm00451269_m1
Mr04097229_mr
Mm01290012_m1
Mm02619580_g1

Dye
FAM
FAM
FAM
FAM
FAM
FAM
FAM
FAM
FAM
FAM
FAM
FAM
FAM
FAM
FAM
FAM
FAM
FAM
FAM
FAM
FAM
FAM
FAM
FAM
FAM
FAM
FAM
FAM
FAM
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M.7. Generation of Htr4 cKO and WT expression vectors

Total RNA samples from the hippocampi of Emx1/Htr4 cKO mice or Htr4floxed (WT) littermates were isolated using Qiagen RNeasy Mini Kit with oncolumn DNase digestion. Htr4 cKO and WT cDNA was generated using qScript
cDNA SuperMix (QuantaBio). Htr4 cKO and WT cDNA coding sequences
(CDSs) (inserts) were cloned into pCMV6-Entry-Myc-DDK tagged mammalian
expression vector (OriGene) by homologous recombination-based In-fusion HD
cloning kit (Clontech). Specifically, the vector was linearized using AsiSI and MluI
restriction sites. The inserts were amplified from the cDNA samples by PCR
using CloneAmp HiFi PCR Premix (Clontech) and primers “Htr4 infusion forward”
(5’- AGA TCT GCC GCC GCG ATC GCC ATG GAC AAA CTT GAT GCT AAT
GTG -3’) and “Htr4 infusion reverse” (5’- GCG GCC GCG TAC GCG TAG TAT
CAC TGG GCT GAG CAG -3’). The primers were designed using “Online InFusion Tools” (https://bit.ly/1eFKzsP) to include 5’ and 3’ homologous sequences
to the ends of the linearized vector for In-Fusion HD cloning, and the Htr4 CDS
start codon, yet exclude the stop codon to allow for the expression of the MycDDK tag sequences and following stop codon and polyA tail in the backbone.
The resulted expression vectors were called Htr4 cKO and WT plasmids.
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M.8. cAMP induction assay

HEK293T cells (ATCC) cultured in 24-well plates (1.9 cm2 culture area,
Corning) in Dulbecco's Modified Eagle's Medium (DMEM) (Gibco) supplemented
with 10% fetal bovine serum (FBS) (Gibco) were transfected with the Htr4 cKO
and WT plasmids via FuGENE 6 transfection reagent (Promega). 48 hours after
the transfection, all cells were incubated in stimulation buffer (DMEM + 0.5mM
IBMX (Sigma Aldrich)) for 30 min. For cAMP induction, cells were incubated in
either stimulation buffer (Basal) or 100µM Zacopride (Tocris Bioscience) in
stimulation buffer (Zacopride) for 45 min. The cells were lysed with lysis buffer
(0.1 M HCl, 0.1%Triton-X) for 20 min, and the lysates were centrifuged for 10 min
at 21,500 x g. cAMP levels in the supernatants were measured by monoclonal
anti-cAMP antibody based direct cAMP ELISA kit (Non-acetylated version,
NewEast Biosciences). Four biological replicates and two technical replicates
were performed for each experimental group. The cAMP level of each biological
replicate was normalized to its protein concentration measured by Qubit protein
assay kit (Invitrogen) and Qubit 3.0 Fluorometer (Invitrogen). Statistical analysis
of normalized cAMP levels was performed in GraphPad Prism 7 by two-way
ANOVA followed by Fisher’s LSD.
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M.9. Generation of AAV-DIO-Htr4-Myc

The mouse Htr4-Myc-DDK transgene was PCR amplified from pCMV6Htr4-Myc-DDK (Origene) using Phusion High-Fidelity DNA Polymerase (New
England Biolabs) and primers Htr4-inverted-AscI-forward (5’- GGC GCG CCC
TAT TAA ACC TTA TCG TCG TCA TCC T -3’) and Htr4-inverted-NheI-reverse
(5’- GCT AGC CAC CAT GGA CAA ACT TGA TGC TAA TGT -3’), adding 5’ AscI
and 3’ NheI restriction sites to the inverted Htr4-Myc-DDK sequence (insert). For
the vector backbone, pAAV-EF1a-DIO-EYFP (Addgene, plasmid #27056) was
linearized using AscI and NheI restriction sites removing the inverted EYFP
sequence. The insert was then cloned into the backbone in reverse orientation by
Quick Ligation Kit (New England Biolabs), to generate pAAV-DIO-Htr4-Myc. For
the confirmation of the Cre-dependent expression of the plasmid in HEK cells in
vitro (detailed in Chapter 3), AAV-Cre-GFP (AAV-CMV-Cre-GFP, Stereotype:2)
were purchased from University of North Carolina (UNC) Vector Core. Following
the confirmation of expression in vivo, the plasmids were packaged into AAV2.9
stereotype viral vectors at the University of Pennsylvania Vector Core at the titer
4.782 x1013 gc/ml (gc: genome copy).
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M.10. Stereotactic surgeries

Mice were anesthetized with a mixture of ketamine (100 mg/kg) and
xylazine (10 mg/kg) in 0.9% sterile saline solution by intraperitoneal injection.
Once deeply anesthetized, mice were immobilized in a Kopf stereotactic
apparatus using intra-aural positioning studs and a tooth bar to immobilize the
skull. Bilateral holes were drilled on the surface of the skull at the injection sites.
Each AAV injections was performed using a glass needle (thinly pulled glass
capillary) attached to a Hamilton Microliter syringe (5 µl syringe with 0.05 µl
increments). The syringe was held and controlled by a Kopf Microinjection Unit
(Modell 5000) for a precise volume delivery (0.05 µl every 5 min). If an injection
was performed at multiple point on the same dorsoventral (DV) axis, it was
completed with a single needle insertion, starting at the most ventral coordinate
and retracting to the following dorsal point of injection. After an injection was
completed at a coordinate, the needle was left in place for an additional 5 min
before slowly being retracted. The injection coordinates and volumes for different
brain regions were as follows: dorsal DG (A-P: -1.58, M-L: 0.8, D-V: 1.87 [0.1 µl];
and A-P: -2.06, M-L: 1.13, D-V: 1.75 [0.1 µl]), ventral DG (A-P: -3.52, M-L: 2.50,
D-V: 3.25 [0.05 µl], 2.25 [0.05 µl]; and A-P: -3.80, M-L: 2.50, D-V: 3.50 [0.05 µl],
2.88 [0.1 µl], 2.25 [0.05 µl]). A-P and M-L are distances (mm) from bregma, D-V
is from dura.
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After the needle removal, the incision sites were closed by surgical
sutures or wound staples. Antibiotic powder (Neo-Predef with Tetracaine,
Pharmacia and Upjohn) was placed on the wounds, and 0.5 ml sterile 0.9%
saline solution was administered subcutaneously to prevent dehydration.
Animals were allowed to recover in a clean cage set on a heating blanket 37°C
until achieving ambulatory recovery. Ibuprofen (0.1 mg/ml) was administered in
the drinking water for 2-7 days following surgery, and all surgical sutures or
wound staples were removed after 7-10 days.

M.11. Electrophysiological recordings

Mice of 8 weeks of age were euthanized with CO2. After decapitation and
removal of the brains, transversal slices (400 μm thickness) were cut using a
Vibratome 1000 Plus (Leica Microsystems) at 2 °C in a NMDG-containing cutting
solution (in mM): 105 NMDG (N-Methyl-D-glucamine), 105 HCl, 2.5 KCl, 1.2
NaH2PO4, 26 NaHCO3, 25 Glucose, 10 MgSO4, 0.5 CaCl2, 5 L-Ascorbic Acid, 3
Sodium Pyruvate, 2 Thiourea (pH was around 7.4, with osmolarity of 295–305
mOsm). After cutting, slices were left to recover for 15 min in the same cutting
solution at 35 °C and for 1 h at room temperature (RT) in recording solution (see
below). Whole-cell patch-clamp recordings were performed with a Multiclamp
700B/Digidata1550A system (Molecular Devices). Dentate gyrus granule neurons
were selected for recording based on their size, shape and position in the granular
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layer using an upright Olympus BX51WI microscope. The extracellular solution
used for recordings contained (in mM): 125 NaCl, 25 NaHCO3, 2.5 KCl, 1.25
NaH2PO4, 2 CaCl2, 1 MgCl2 and 25 glucose (bubbled with 95% O2 and 5% CO2).
The slice was placed in a recording chamber (RC-27L, Warner Instruments) and
constantly perfused with oxygenated aCSF at 24 °C (TC-324B, Warner
Instruments) at a rate of 1.5–2.0 ml/min. Whole-cell patch-clamp recordings were
obtained from granule neurons using recording pipettes (King Precision Glass, Inc,
Glass type 8250) pulled in a horizontal pipette puller (Narishige) to a resistance of
3–4 MΩ, filled with an internal solution containing (in mM): 126 K-gluconate, 4
NaCl, 1 MgSO4, 0.02 CaCl2, 0.1 BAPTA, 15 glucose, 5 HEPES, 3 ATP, 0.1 GTP
(pH 7.3). For whole-cell recordings in the voltage clamp configuration, BIMU-8 (10
mM, Tocris Bioscience) was added to the bath for 1 minute and subsequently
washed. Tetradotoxin (TTX, 1 mM, Tocris Bioscience) was added previously to the
bath to avoid activation of neighboring neurons by BIMU-8. To measure the firing
of the DG granule neurons, steps of 10 pA current were injected from a set starting
membrane potential of -80mV.
Data were acquired at a sampling frequency of 50 kHz and filtered at 1 kHz
and analyzed offline using pClamp10 software (Molecular Devices). All
electrophysiological data are expressed as means ± SEM. Statistical analysis was
performed using the two-tailed unpaired Student’s t-test in GraphPad Prism 7
software. p<0.05 was considered significant.
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M.12. Histology

For fixed brain serial slice preparations, mice were deeply anesthetized by
ketamine/xylazine intraperitoneal (IP) injections and transcardially perfused with
10 ml of phosphate buffered saline (PBS) followed by 30 ml of 4%
paraformaldehyde (PFA) in PBS. Brains were post-fixed in 4% PFA overnight at
4°C and cryoprotected by 30% sucrose in PBS. Coronal sections (40 µm) were
acquired by a freezing microtome (Leica SM2010 R Sliding Microtome). The
sections were then transferred to PBS, or cryoprotection buffer (25% glycerol and
25% ethylene glycol in PBS, pH 7.4) for long term storage at -20°C.
For both 3,3′-Diaminobenzidine (DAB) immunohistochemistry (IHC) and
all immunofluorescence (IFC) procedures, serial sections were blocked for 60
min in PBS containing 3-5% normal donkey serum (NDS, Jackson
ImmunoResearch) or normal goat serum (NGS, Vector Laboratories) and 0.1%
Triton X-100 or 0.1% Saponin; and then incubated in the same blocking buffer
overnight at 4°C with primary antibodies on Table M.4 at listed dilutions. On the
next day, the sections were washed 3 times with PBS for 5 min, and then
incubated for 2 h at room temperature with the appropriate Alexa dye-conjugated
(for IFC) or horseradish peroxidase (HRP)- conjugated (for DAB IHC) secondary
antibodies (Invitrogen) diluted 1:500 in the blocking buffer. The sections were
then washed 3 times with PBS, and counterstained with DAPI for nuclear staining
at 1:10,000 dilution (for IFC). For DAB IHC, the staining was developed using
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SIGMAFAST™ DAB tablets (Sigma-Aldrich) following the manufacturers’
protocol. The sections were mounted on the Superfrost slides (VWR) and sealed
with Prolong Gold mounting reagent (Invitrogen). The slides were imaged on a
Zeiss LSM700 confocal microscope or a Zeiss Axiosko2 microscope. Brightness
and contrast adjustments were made on ImageJ post-acquisition.
Table M.4. Primary antibodies used in this study.
Antibody Name

Source

Catalog #

Dilution

rbxHtr4_C'

Abcam

ab101910

1:500

rbxHtr4_N'

Millipore

SAB4501480

1:500

rbxHtr4_Ala361

Cell Signaling

#13690

1:1000

rbxHtr4_3rdCYTloop

Sigma

S0195

1:150

rbxHtr4_31-70

Abcam

ab60359

1:500

rbxHtr4_presige

Sigma

HPA040591

1:200

SR-4 (C-18)

Santa Cruz

sc-32566

1:50

SR-4 (K-19)

Santa Cruz

sc-19155

1:50

SR-4 (N-18)

Santa Cruz

sc-32564

1:50

SR-4 (N-16)

Santa Cruz

sc-19154

1:50

SR-4 (G-3)

Santa Cruz

sc-376158

1:50

rbxHtr4_C'_NL

Novus Bio

NLS656

1:500

DDK, clone 4C5

OriGene

TA50011

1:1000

GAD67, clone 1G10.2

Millipore

MAB5406

1:500

GFP

Abcam

ab13970

1:1000

Myc tag, clone 9E10

Sigma

SAB4700447

1:500

NeuN, clone A60

Millipore

MAB377

1:1000

Calbindin-D-28K

Sigma

C7354

1:500

Calretinin

Swant

6B3

1:500

ChAT

Millipore

AB144P

1:500

Parvalbumin

SWANT

McAB325

1:500

Doublecortin (C-18)

Santa Cruz

sc-8066

1:200
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M.13. Translating ribosome affinity purification and RNA isolation

Affinity purification of EGFP-tagged polysomes was performed as
previously described (Heiman et al., 2014), with minor modifications. Three
biological replicates consisting of brain tissue pooled from one male and one
female mice were used for each condition (except for KO1 replicate which was
pooled from two females). Mice were sacrificed, followed by rapid
microdissection of dorsal and ventral dentate gyrus with fine tip forceps in icecold HBSS containing 2.5 mM HEPES-KOH (pH 7.4), 35 mM glucose, 4 mM
NaHCO3, and 100 μg/ml cycloheximide. Each pooled dentate gyrus tissue
sample was then homogenized in 1 ml extraction buffer containing 10 mM
HEPES-KOH (pH 7.4), 150 mM KCl, 5 mM MgCl2, 0.5 mM DTT, 100 μg/ml
cycloheximide, RNasin (Promega) and SUPERas-In

TM

(Life Technologies)

RNase inhibitors, and Complete-EDTA-free protease inhibitors (Roche), and then
cleared by centrifugation at 2000 x g at 4 °C. IGEPAL CA-630 (NP-40, Sigma)
and DHPC (Avanti Polar Lipids) were both added to the S2 supernatant to a final
concentration of 1% for each, followed by centrifugation at 20,000 x g.
Polysomes were immunoprecipitated from the S20 supernatant using 100 μg
monoclonal anti-EGFP antibodies (50 μg each of clones 19C8 and 19F7; see
(Heiman et al., 2008)) bound to biotinylated-Protein L (Pierce, Thermo Scientific)
coated streptavidin-conjugated magnetic beads (Life Technologies), and washed
in high salt buffer containing 10 mM HEPES-KOH (pH7.4), 350 mM KCl, 5 mM
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MgCl2, 1% IGEPAL CA-630, 0.5 mM DTT, 100 μg/ml cycloheximide, and RNasin
RNase inhibitors (Promega). IPs were carried out overnight at 4°C. Bound RNA
was purified using the RNeasy Micro Kit (Qiagen) with on-column DNase
digestion. RNA was also purified from a fraction of the pre-IP S20 supernatant to
serve as whole-tissue “input” samples. RNA quantity was determined using the
Qubit RNA HS Assay kit (Invitrogen) and RNA quality was determined using
Agilent 2100 Bioanalyzer with RNA 6000 Pico chips. Only samples with RNA
integrity values >7.0 were used for RNA-seq.

M.14. RNA sequencing (RNA-Seq)

For each sample, 15 ng of purified RNA was converted to cDNA and
amplified using the Ovation RNA-Seq System V2 Kit (NuGEN). cDNA was
fragmented to an average size of 250 bp using a Covaris C2 sonicator with the
following parameters: intensity 5, duty cycle 10%, cycles per burst 200, treatment
time 120 seconds. RNA-Seq libraries were prepared from 10 μg amplified RNA
using the TruSeq RNA Sample Preparation Kit v2 (Illumina) following
manufacturer’s protocols. The quality of the libraries was assessed using the
Agilent 2200 TapeStation system with D1000 High Sensitivity ScreenTapes.
Libraries were sequenced at The Rockefeller University Genomics Resource
Center on the Illumina NextSeq 500 platform to obtain 75 bp paired-end reads.
12 samples were multiplexed per sequencing lane (Table M.5).
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Table M.5. Overview of RNA-Seq datasets.¥

Sample*

FastQ Name

RNA- Truseq
Seq Adapter
Pool
Index

dDG_WT_IP_1

2128_Drd3_dDG_WT_IP Rep1

A

AR002

dDG_WT_IP_2

2129_Drd3_dDG_WT_IP Rep2

A

AR005

dDG_WT_IP_3

2130_Drd3_dDG_WT_IP Rep3

A

AR007

vDG_WT_IP_1

2131_Drd3_vDG_WT_IP Rep1

A

AR004

vDG_WT_IP_2

2132_Drd3_vDG_WT_IP Rep2

A

AR006

vDG_WT_IP_3

2133_Drd3_vDG_WT_IP Rep3

A

AR012

dDG_KO_IP_1

2134_Drd3_dDG_Htr4_KO_IP Rep1

A

AR013

dDG_KO_IP_2

2135_Drd3_dDG_Htr4_KO_IP Rep2

A

AR015

dDG_KO_IP_3

2136_Drd3_dDG_Htr4_KO_IP Rep3

A

AR018

vDG_KO_IP_1

2137_Drd3_vDG_Htr4_KO_IP Rep1

A

AR014

vDG_KO_IP_2

2138_Drd3_vDG_Htr4_KO_IP Rep2

A

AR016

vDG_KO_IP_3

2139_Drd3_vDG_Htr4_KO_IP Rep3

A

AR019

dDG_WT_Input_1

2140_Drd3_dDG_WT_input Rep1

B

AR002

dDG_WT_Input_2

2141_Drd3_dDG_WT_input Rep2

B

AR005

dDG_WT_Input_3

2142_Drd3_dDG_WT_input Rep3

B

AR007

vDG_WT_Input_1

2143_Drd3_vDG_WT_input Rep1

B

AR004

vDG_WT_Input_2

2144_Drd3_vDG_WT_input Rep2

B

AR006

vDG_WT_Input_3

2145_Drd3_vDG_WT_input Rep3

B

AR012

dDG_KO_Input_1

2146_Drd3_dDG_Htr4_KO_input Rep1

B

AR013

dDG_KO_Input_2

2147_Drd3_dDG_Htr4_KO_input Rep2

B

AR015

dDG_KO_Input_3

2148_Drd3_dDG_Htr4_KO_input Rep3

B

AR018

vDG_KO_Input_1

2149_Drd3_vDG_Htr4_KO_input Rep1

B

AR014

vDG_KO_Input_2

2150_Drd3_vDG_Htr4_KO_input Rep2

B

AR016

vDG_KO_Input_3

2151_Drd3_vDG_Htr4_KO_input Rep3

B

AR019

* brain region_genotype_RNA source_replicate
¥

All data sets have been deposited in NCBI’s Gene Expression Omnibus (GEO) (Barrett

et al., 2013): accession-numbers-pending.
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M.15. RNA-Seq read mapping, analysis, and visualization

RNA-Seq read quality was assessed by FastQC (0.11.4). Sequences
were trimmed for trailing adaptors from the Illumina sequencing process by Trim
Galor (0.4.1). The trimmed reads were then aligned to annotated exons using
the mm10 mouse reference genome (UCSC) with STAR (2.4.2a) (Dobin et al.,
2013) using default settings. SAMtools (v0.1.19-444) was used for indexing and
removal of duplicates. The numbers of raw and mapped reads (bases), and the
percentage of mapping for each sample were calculated via Picard (1.123) using
the CollectRNASeqMetrics program (Table M.6).
The quantification of aligned, sorted and indexed reads was done using
the htseq-count module of the HTSeq framework (0.6.0) (Anders et al., 2015),
using the “union” mode with default settings to generate raw counts for each
sample. Aligned bam files were converted to tdf format using igvtools (2.3.61) for
Integrative Genomics Viewer (IGV) visualization. Differential expression was
calculated by DESeq2 (Love et al., 2014), R-package version 1.4.5. Significant p
values were corrected to control the false discovery rate (FDR) of multiple testing
at 0.05 threshold. Fold change cutoff ± 1.25 (|log2| fold change >0.3219) was
applied unless otherwise noted. For scatter plots and heatmap visualizations, raw
counts normalized to sample size for each sample (“normalized counts”) were
used as calculated by DESeq2. Morpheus software (Broad Institute) was used to
generate the heatmaps. Significant differentially expressed genes were split into
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up- and down-regulated for Gene set enrichment analysis (GSEA) and gene
ontology (GO) analysis. GSEA was performed using Molecular Signature
Database (MSigDB, Broad Institute) (FDR<0.05). GO network and visualization
was generated using BiNGO (A Biological Network Gene Ontology tool, 3.0.3)
(Maere et al., 2005) as a Cytoscape (3.6.0) plugin.

Table M.6. Quality control of RNA-Seq alignments.
Raw
Reads

Mapped
Reads

Ribosomal %

Coding
%

UTR
%

Intronic %

Intergenic %

dDG_WT_IP_1

5389296447

5287301402

15.10

33.07

37.00

7.52

7.95

70.07

dDG_WT_IP_2

5211282117

5115099172

15.04

34.80

39.34

4.30

7.20

74.13

dDG_WT_IP_3

4532219275

4440093124

19.30

35.14

36.49

2.95

6.96

71.64

vDG_WT_IP_1

5055676715

4963214738

15.25

35.93

39.45

3.22

6.83

75.37

vDG_WT_IP_2

5200875692

5096531166

18.77

34.24

37.98

2.97

6.88

72.22

vDG_WT_IP_3

5176647321

5088146609

11.74

39.38

38.93

3.07

7.41

78.31

dDG_KO_IP_1

5097724216

5010604143

10.87

28.77

28.77

23.42

8.65

57.54

dDG_KO_IP_2

4873024410

4780034112

15.55

34.78

37.09

5.73

7.53

71.87

dDG_KO_IP_3

4279892247

4200940083

12.57

37.37

37.59

5.45

7.58

74.96

vDG_KO_IP_1

4386834142

4294720920

18.98

33.93

37.81

3.40

6.72

71.74

vDG_KO_IP_2

5041820503

4938661168

18.97

34.77

37.26

3.27

6.56

72.04

vDG_KO_IP_3

4351693105

4268363380

15.35

36.19

37.92

3.98

7.24

74.11

dDG_WT_input_1

4976974951

4898777541

11.00

26.15

34.18

11.65

17.48

60.33

dDG_WT_input_2

4114194145

4048376030

9.60

28.97

36.85

9.12

15.87

65.82

dDG_WT_input_3

6348807839

6241867530

13.52

30.73

36.91

7.14

12.29

67.64

vDG_WT_input_1

5274266386

5200347558

7.32

29.76

37.30

9.69

16.25

67.07

vDG_WT_input_2

5908160994

5817160131

8.02

31.64

36.97

8.64

15.09

68.61

vDG_WT_input_3

5200024888

5110416182

12.45

30.12

36.81

7.70

13.47

66.93

dDG_KO_input_1

5030052258

4951122004

8.97

19.82

25.71

6.90

38.97

45.54

dDG_KO_input_2

5318465410

5237452256

9.40

29.55

37.17

8.97

15.33

66.72

dDG_KO_input_3

4494618359

4433172922

7.08

30.48

37.47

8.40

16.89

67.95

vDG_KO_input_1

5390357255

5295752262

11.57

27.52

35.93

8.45

17.04

63.45

vDG_KO_input_2

5347253361

5264487834

10.03

29.78

38.46

8.79

13.38

68.24

vDG_KO_input_3

4711433994

4633197615

12.18

29.09

36.28

8.18

14.81

65.37

Sample

* mRNA is the percentage of total bases mapping to Coding + UTR.
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mRNA*
%

M.16. Statistical Analysis

All data analysis was performed in GraphPad Prism 7, Microsoft Excel or
R (R Core Team, 2013). Statistical parameters including the exact value of n,
precision measures (mean ± SEM) and statistical significance are reported within
the corresponding Chapter in the text, the figures and/or the figure legends. Data
were judged to be statistically significant when p<0.05 by two-way ANOVA
(regular or repeated measures-RM) followed by post hoc Fisher’s LSD test, or
two-tailed unpaired t-test. ‘¥’ symbol indicates significance by Two-way ANOVA,
and asterisk indicates significance by Fisher’s LSD test or two-tailed t-test.
For RNA-Seq analysis, Pearson correlation coefficients were calculated
with GraphPad Prism 7 using normalized expression values and statistical
significance was based upon the assumption that values exhibit a Gaussian
distribution. Differential expression was calculated by DESeq2 (Love et al.,
2014), R-package version 1.4.5. DESeq2 corrected the p values to control the
false discovery rate (FDR) of multiple testing, generating adjusted p values (padj). p-adj<0.05 was considered significant. For GSEA, FDR<0.05 was used. For
BiNGO, hypergeometric statistical test with Benjamini & Hochberg FDR
correction was applied with a significance level 0.01 using Cytoscape.
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APPENDIX
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Construction of Conditional Targeting Vector for Htr4-floxed

1. Vector Design Outline

N1

Lox1
5’

3’

P6

T73
Vector Seq.

Vector Seq.
N2
LA

SA

Target
Region

Ex5: Htr4 exon 5
LA: Long arm
SA: Short arm
Neo: Neomycin resistance cassette
Black triangles: LoxP sites
White semicircles: FRT sites

2. Sequencing Data Analysis
PCR primers used for sequencing:
Primer
Primer
Primer
Primer
Primer

P6: 5’T73: 5’N1: 5’N2: 5’lox1:5’-

GAG
TAA
TGC
TTC
GGA

TGC
TGC
GAG
CTC
CAG

ACC
AGG
GCC
GTG
CAA

ATA
TTA
AGA
CTT
TCT

TGG
ACC
GGC
TAC
AAG

ACA
TGG
CAC
GGT
GAG
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TAT
CTT
TTG
ATC
CAC

TGT C
ATC G
TGT AGC
G
AG

-3’
-3’
-3’
-3’
-3’

3. Assembled ROXY Htr4 targeting vector
1. Vector backbone: Blue text (e.g., ATCG)
2. LA (4820 bp): Bold and italic text (e.g., ATCG)
3. Distal loxP (67 bp): Lightgray text, highlighted in yellow (e.g., ATCG)
4. MA (752 bp): Green text (e.g., ATCG)
5. Neo (1713 bp): Red text (e.g., ATCG)
6. SA (2347 bp): Underlined text (e.g., ATCG)
7. LoxP: Red text, highlighted in yellow (e.g., ATCG)
8. FRT: Red and underlined text, highlighted in gray (e.g., ATCG)
9. Exon: Highlighted in pink (e.g., ATCG)
10. Genotyping forward primer – Htr4 loxP F (TCGAGGCATTCCTCGATTCA)
11. Genotyping reverse primer – Htr4 loxP R (TAACACCTGGCCGAAACGTT,
reverse transposed)
3’end of BAC subclone joins here.
CGATGATATCAGATCTGCCGGTCTCCCTATAGTGAGTCGTATTAATTTCGATAAGCCAGGTTAACCTGCAT
TAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGCGTATTGGGCGCTCTTCCGCTTCCTCGCTCACTGA
CTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCA
CAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAG
GCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCA
GAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTC
CTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCAT
AGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCC
CGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTAT
CGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTG
AAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTAC
CTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTT
GCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGAC
GCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGAT
CCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACC
AATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCCC
GTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCC
ACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTG
CAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAAT
AGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATT
CAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCT
TCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCAT
AATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTG
AGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCA
GAACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTG
AGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTTC
TGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATAC
TCATACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTT
GAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTGACGTCTA
AGAAACCATTATTATCATGACATTAACCTATAAAAATAGGCGTATCACGAGGCCCTTTCGTCTCGCGCGTT
TCGGTGATGACGGTGAAAACCTCTGACACATGCAGCTCCCGGAGACGGTCACAGCTTGTCTGTAAGCGGAT
GCCGGGAGCAGACAAGCCCGTCAGGGCGCGTCAGCGGGTGTTGGCGGGTGTCGGGGCTGGCTTAACTATGC
GGCATCAGAGCAGATTGTACTGAGAGTGCACCATATGGACATATTGTCGTTAGAACGCGGCTACAATTAAT
ACATAACCTTATGTATCATACACATACGATTTAGGTGACACTATACCTGCAGGCGCGCCATTTAAATGCGG
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CCGCTTAATTAACTCGACAAAAGCTGTTGGGATATGCCACTCCCCATGACAGGGAGGGTCTTCAGAGGGTA
AGACTAAAACTAAGCCCTGAATCATTAATTATGAACTAATGCATTTCAGCCTTTGATTTTCATTGTATATG
TTTTGTGTCTGTGTGGACCATTCATTACCTATAAGCATGGTAGCTCATCTTGGTCTGTTTTTTGGCCAGTT
TCTCCCTAATTAAGAATGCCAAAAGAACCAATCTGACCTCATCAACTTTGTGCTCTTGCTACAGACAAACA
AAGGAGCTGTCCCATACGTGTTTACATGAACATAGGCTGCTCTGAGATGTGCCTTGTTTTTTTATTACAAT
TTTGGTGTTAATTTTTCTTCTCTTCTGATAAATTTGACATAAGAAAAAAATGGGTAAGAGTGTGGCCTGGG
GTATTAGACTGCCTAGGTGCATTCTCACTTGAACAAATATGAGTTTCATCATCTTGAAAAAGCTACTTGAA
TTTTCTGGAGCTCACCTAGTTTGTAGAATTATGTTAATGACAGAAGCTTTCTCTGAGAGACTAAGGGAGTG
ACATAAATGAAGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGATGTATAAGCAGGTGCC
GCATACCTAATTCATCTCACTGATTTTAACCATTTGCCTTGGGAATTTTCCAAATACAAAGTGGCTTCTGC
AGGTGACTTCCTCGGCCTGACTCTTCAGCCTGATGAGCATCTGTTGTTGGAGAGTTAAGAGATTTCTCAGC
CTTGTGTGAAGCCTCCCCTTCCTTTGAAGAACTTACTTATCTGGTGGCTCACTTGAACCTTTCTTTTTGTT
CTCTCAGTTTACTTCTAGGCTCCAAGGTCCTCTCTCTATCTGTCTCTTATGAGGAGTACCTTCAGCATCTT
TCCTTTTCTCTCAAACCCAATAGGTTCAAAGTGGAAAATGTCCATCATACCTTAATAATCTTTTCTAGTTG
TTACATCAAAGGATTCCAAGTGTTGCCTTGTAGTTGCAGACATTGATACAAAATAGGACTTGCTTCTTGCC
ACAAAAGGTACTTCAATTAGCATGTGGCATATGCTGTAGATAATTGAAGTATCAGAGAAGAAAGCAGCAAT
TACAATGTAGTTGGAGAAACACCATGGAAACAGCAATGATACAGTGTGCTGAAGTGGGAAGCACATCCTTG
ATCTGGAGAGAAGGACACATTCAGAGAGCTGACCTAAAATATGGCTACTCCACAGCCTGGAGGAAGGGCTA
CTTCACTGCCCAGCTACACACACACACACACACACACACACACACACACACACACAAATGTATAGGTAAAG
ATATAGGTATTGATATAGATGATATCTCTGTTTATCCTGTTGTAATTATGTGTGAGTATGGAAATTGACCC
CAAAATGTGTAAGCAATAGTATCTATTACATCTTATATGCAATGAACTCCATCATTCGCAGCCATTTACCT
AGAGGGAACAGCTTATTTGACGTTTTGTGTCTTAGACTCTCTAAGTACTAGGAGAGATGCTGATCCAGGCA
TTTTCATATGATGTATGTGCCAGGATCTTCCTATGTTTTCAACATATTATCTCATCTGTTCTCACAGCAAG
TGCATGGCGTAGCATCATTATCCCACTTTACAACTGAAGAAACTGTCTCGAAGAGGGTCAATAGCTAGCTC
TAAGTCTAGAGGGTATAAGAGTAAGGTAAAGGAAGTCAGTGGCCAACTGTGAGGGCACATGAGGTTGACTG
CTAGGTCTGCTAATTGTGAAAATCCAGGATTCCTGGTTGGTCTGGATGCTTCTCCTTTACCTATGGTTAGA
GAGCAGGGAATGAAAAGGTAAAATTTTCCTTAATGGCAGGAGTGGTGAAGACATTAGCTTGGGGCTTAAAA
TATACTGCTCTCTTCTAAGACTTGTCAAAGTAAATTGTGTCCCTGGAGACATTTAAAAGCAATTATGTCCC
TCATTTGCATGTGGCTGTGGTTGGAGAAGCTGCAGGTTGTCTACCAAAGGGGACTTTTATGGAGTTTTGTG
AGCAAACTTTGAAATGTTCAAAATAAGAACTTACTTTGTAAATTCCTTTGCTACATTCTAGCTAATCCTGG
CCATCTGGAACCAAATTTGCCATTACATTTATTGATTCATTTTGTAAAAGTATTTTTGCTTAACTAGAAAA
TGTCCTAGGAATGTCTAAAGAACAGAACTTATATAGTAGTATACTCCCAAGATAAACCACAGTTCTGTTTG
CTAAACAGCATCCTCTAGCCTGAGAATCAACAGCCCTCCTCTTTATTGGTTGTAATCCTCTCTGTTAGAAG
GGCATGCTGCAGGATTGACCTAGATGGGCATGTTCAAGTTCTGTGACCTCTTCTACATTAATAAACTCTTT
TAGAAGAATTACACCACTCCTTCTTTTCCTGCCTTGCATCTTTAGTTTTTGAGATGAGACTACCTTGAAAC
AGATGTCCTGGTCCTCTGGCTCTTACAATCTTTCTGGTGTCTCTTCCCCTGTGTCCCCTGAGCCTTAGATA
CAGGAATTGTGTTGTAGACCTATCCACTGGGGCTGGCACCCATGGCCAGCTCTTCTCTACAGTTTGAGCAG
TTGTTGTTTTGTGTTGGTCTCTATCTACTGAAAAAATGAAGCTCCTTCGATTCAGGGCAAAAACTACTCTT
ATCTGTAGGTGTAGGAACAGTACTTAGAATGCAGTTAGAAACCACACTGCTTTGAGAATGTGACAGTAAAT
TCTATGTCCCATGGCCTCGCCAGTTCTTATTTTTTCATCTTGAGACAGATACATGTGTGTATTTTGCCTTT
TAAAAAACTCAGGAGGGGCTGCTAGAAAGATATTCCAGTCACTAAAGTGACATGTTGTGCTCGTACAAGGA
CTTAAGTTCAAGCTTTAGAACTCATGTGAAAAGCTGGGCATTGTGGCACACACCTGTAATCTCAGGGTTGG
TGTTGGGTGTGGGGGTGGGAAGTGAGTAGACACAGGCAGGCCCCAGGGCTTGCCAGCCAGCCAGCTGAGAA
TATTTGATGAGTTCCTTTCCCATGAAAGACTCCTTTTCAAAAAAAAAAAAAAAAACAGGTGAATGGCAATC
AAGATTGACCTCTGGCCGCCTCTGCACACATATAAACACAGGCTTGCCTACAAAACACACACACACACACA
CACACACACACACACACACTAGTTATGAGTGTTGTATATTCTAAGTACAGCCTTTAGTAAGGAAATCAGTG
GTAACGGTTACAATCAACTCTGTCAGTATATGTTAGGTGATCTCAGAACACTTGCCAATTTGACTTGCAAC
TTCTCACTAATGATGCTACCGTGCATATTTTAGAGGAAGGTCACAATACCATAAGGAAATTTTCTTAAAAA
CAAAACATACACAAAAAAACGTTTCTAGAATTTTTGCTTGAAATTGAAGATTTTATGATATGAGGAAAGGT
ACTCAAAACACATAGGTGGCTTTTTGAGAGTTCTGCCTTGAGAATACCAAAATCCTCAAAAGGAACCTTCA
GCATTTATGTCAATGTTGTGAGTTTTAGCTAAGAATCTCATATTTTGCCAGGCAGTGAGGCCAGTTTGGTC
TATAGACTGAATTTCAAGGCTACACAGAAAAACCCTGCCTTGAAATACAAAATACACAAACAAAAGCAAAA
ACCCTAATATTCTTTGTCCCATGCTACCAGTTAAAAATATTGTTATGTTTATTGTAGAATAAAGACAGAAT
TTAAGTCAAATATGAATCTGGGCATAATCACATATTTTCATTATATCTAAGCTAATCTAGCACTCCGGGTT
TCACCAACCTAGTTTAAAATTAAATAAAATAATCTCCTCCTCTTTTCTATTGCTAATGTTTTAAAGATGAG
GAAGAATTTTCCTATCTTCCTTAATAATTCATGTCTATGCAAGTTCAAATGTCCATAATTGTCTATACAGT
GGGCATCCCTGCCTCCCACACTAGCCCCTGACAACATCTTCAGTTACCCATTCCCCAGGATACTGACTGTA
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TCCAGAATATTTCCATTTGTTTCTCTGAATCAGCATCCTATACTAGTCTAGAGCAGTACCAATCAAGGCAT
AGAACATCTGGATAGACTGGAATAACATGGAGGATCACGTCTGGGAGTTGGAACTGAGGCCATTTGTGGAG
GAACAAGAAATTTAATACTTCAGGCAGAATATAAGAGGGTGAACAGTAAATTCCAAGAAAGGCTCCTATCA
CAGCAAATAAGGGAAGAGTACTTTCAACAAGCTGGCAAAATAACTAAGAGTAAGATGTTGGCAATTTTATA
TTCTTAGCTTTAGAGAAACAATTAAGCAATCACTGTCAGAAACAATGTATGTGAATTCTACTTGCCACATT
TCAGCTTGAGCATCTCATGTGCATGTACCCCTAGCCGGGAAATAAATAAGTGGTACTTCCTGGAGGTAGTG
TTGACTCAGGGGTGGACATGTACAGTCCAGGTGGCTGCCCGGCAAGCCGTGATACAGAAGACCCTCAGAAT
CTATGCTCTTCTCAGCTAAGTCTGTTGAGGGAGAAGAGAGGAGAAAGGGTAAGCCGGGACAGCAATCTAAG
GAGCACAGAAGTACACACAACATCTCAGCACCACCCTCAAGAAGAAGAGGACAAATCTGTGATAGTTCAAA
TTATCGTCACAGAAGCTAAAGGTGCCTGTGTGTAAGGGTCTGGAGAGCTCGAGGCATTCCTCGATTCACAG
AAAATGGGACTGTGTCCGAGGCAGAGTAGACCTTCATGCTACTTAAGACTTTGGGAATGAAGAGGGAAGTG
GAGCCAATTGTATCACGCGTATAACTTCGTATAGCATACATTATACGAAGTTATGCCACTAGAGGATCCCC
GGGCCCGAGGCAATGTCCTTCACATGCACTATAAACGTATTTTATATAGTAACAAACGTTTCGGCCAGGTG
TTAATGTTTTTATTGTATAATTGCCTTTATTATTCTCTCTGTTCTCTGCCCTCATCCCCTTCCTTTTCATT
TCCCTCCTCTGCCATCTCCTTCCCCACTTATTCCCAATTTTGTTTTCCCATTTTACTCTCCTCCTCTGATT
CTCCTTTTCTCAATATTTCCTCCTTCTTTCCATTTTTTTTTTACTCTTCTTGTCCTTCTCTCCCTTGTCCA
CTGTGGTCTTTCCCCTCTCCTTCTCATGTCCCCCTGCCTGTGGCCCCACCCTTAATTGTCTCTCCAGGTAT
TACGCCATCTGCTGCCAGCCTTTGGTTTATAGGAACAAGATGACCCCTCTACGCATCGCATTAATGTTGGG
AGGCTGCTGGGTCCTTCCCATGTTTATATCTTTTCTCCCCATAATGCAAGGCTGGAACAACATCGGCATAG
TTGATGTGGTAAGTATGCATACAAAGCCATGGGATTATTATCCACTCGGTTTTGTTAGGCATTTTAGATAA
GCAGACACTCTTAGCTAGGTAGCTATTTTAATAGATATTATAATAGTGGTCTGAGCAACATATTTAAATGT
CCTATTGATGCCTTGGTCAAATGTTAGTCAAGATCCTCTGAATTATCTTCCCAATGAGAACTTGTGTTCTT
AGAGTTCATTTATTTATTATTTGAAAATCTCATGCATAAGTGCAATCGTACGCCGGCTTAAGTGTACACGC
GTACTAGTCTAGCGAAGTTCCTATACTTTCTAGAGAATAGGAACTTCCCGCGGATAACTTCGTATAGCATA
CATTATACGAAGTTATGTAGATCTGATATCAGGGAGCTCTCAGACGTCGCTTGGTCGGTCTTTATTCGAAC
CCCAGAGTCCCGCTCAGAAGAACTCGTCAAGAAGGCGATAGAAGGCGATGCGCTGCGAATCGGGAGCGGCG
ATACCGTAAAGCACGAGGAAGCGGTCAGCCCATTCGCCGCCAAGCTCTTCAGCAATATCACGGGTAGCCAA
CGCTATGTCCTGATAGCGGTCCGCCACACCCAGCCGGCCACAGTCGATGAATCCAGAAAAGCGGCCATTTT
CCACCATGATATTCGGCAAGCAGGCATCGCCATGGGTCACGACGAGATCCTCGCCGTCGGGCATGCGCGCC
TTGAGCCTGGCGAACAGTTCGGCTGGCGCGAGCCCCTGATGCTCTTCGTCCAGATCATCCTGATCGACAAG
ACCGGCTTCCATCCGAGTACGTGCTCGCTCGATGCGATGTTTCGCTTGGTGGTCGAATGGGCAGGTAGCCG
GATCAAGCGTATGCAGCCGCCGCATTGCATCAGCCATGATGGATACTTTCTCGGCAGGAGCAAGGTGAGAT
GACAGGAGATCCTGCCCCGGCACTTCGCCCAATAGCAGCCAGTCCCTTCCCGCTTCAGTGACAACGTCGAG
CACAGCTGCGCAAGGAACGCCCGTCGTGGCCAGCCACGATAGCCGCGCTGCCTCGTCCTGCAGTTCATTCA
GGGCACCGGACAGGTCGGTCTTGACAAAAAGAACCGGGCGCCCCTGCGCTGACAGCCGGAACACGGCGGCA
TCAGAGCAGCCGATCGTCTGTTGTGCCCAGTCATAGCCGAATAGCCTCTCCACCCAAGCGGCCGGAGAACC
TGCGTGCAATCCATCTTGTTCAATGGCCGATCCCATGGTTTAGTTCCTCACCTTGTCGTATTATACTATGC
CGATATACTATGCCGATGATTAATTGTCAACACGTGCTGCTGCAGGTCGAAAGGCTCGGAGATGAGGAAGA
GGAGAACAGCGCGGCAGACGTGCGCTTTTGAAGCGTGCAGAATGCCGGGCCTCCGGAGGACCTTCGGGCGC
CCGCCCCGCCCCTGAGCCCGCCCCTGAGCCCGCCCCCGGACCCACCCCTTCCCAGCCTCTGAGCCCAGAAA
GCGAAGGAGCAAAGCTGCTATTGGCCGCTGCCCCAAAGGCCTACCCGCTTCCATTGCTCAGCGGTGCTGTC
CATCTGCACGAGACTAGTGAGACGTGCTACTTCCATTTGTCACGTCCTGCACGACGCGAGCTGCGGGGCGG
GGGGGAACTTCCTGACTAGGGGAGGAGTGGAAGGTGGCGCGAAGGGGCCACCAAAGAACGGAGCCGGTTGG
CGCCTACCGGTGGATGTGGAATGTGTGCGAGGCCAGAGGCCACTTGTGTAGCGCCAAGTGCCCAGCGGGGC
TGCTAAAGCGCATGCTCCAGACTGCCTTGGGAAAAGCGCCTCCCCTACCCGGTAGAATGAAGTTCCTATAC
TTTCTAGAGAATAGGAACTTCGTTCGAACATAACTTCGTATAGCATACATTATACGAAGTTATGGTACCTG
CAGAATTCATGCATAAGCTTGGATCCGTTCTTCGGACGCCTCGTCAACACCGTACGAATGTATTTAGATCA
CATGAAACCCTAAACAAGAAGTTACATTTCTGTGTCTGTCTTAGATTCTTTTCCTGTGCAATAATAAAATG
CCCTGACAGAAACAACTTAAGGGAGAAATGGCTTATTTTAGCTCACAGTTTAAGATATCCATCATGGCAGA
GATGTCAAGAGAGCAGGGACCTGCAGCAGTGAGTCCCTTAATGTCCATAGTCAGAAGACAATTAAACTGCT
CAGTTTGGGGTTTGTTTGTTTGTTTGTTTGTTTTGGGTTTGTTTGTTTTGGCTTCTACATTCTAGAACCCC
GTGTTAGGGTAAGGTCCTACCCACAACTAAGATGGATCTTCCCACACCAATTACCATACACAAGATAATCT
TCCCCGCTATACCCAGTGGCACTTCTTGTAGGTGATTCAGACTCTGTCAAGTTGACAATTCCCTCTAACCA
ACACAATGTCCAACTTTGCATTGCTCAGTTTCAGCAAGGATGCTGATGAGTCGGTTTATCTTGAATCCCCC
AGGACCAGGCACTTCATCCTTCACCTTTCCCATGAGATGTCTGATTGCCCTGGCTTGTCTTCAGCAAGAAT
CCTGCTAAGTTGACTTTCCCACTTTCTCTTCCCATTTACTCTGAATAGTTTTCTGTTCACTGACCCTCATC
CATCAATTCCTTGGCTATACATTCCCCACCACCACCACCACCTTTTTTTCCCTTTGGTGTTTTAGAGTTGA
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ATCTAATCTCTTTGTGAAAAAAATCACAGTATTTTCTCTTATGAAAATAATGTGAAATATGTGGAATAAAG
GCTCCTTAGCAGGTGTTTCAAATATTTTTTTAACATTACAGTGAATCAGACATTACAATAAGGAATGACAT
TACAATAAGGAATTATACTTTTGGAAAGAGTATAATTATGGCAGTTTAAAGATGTGCAGGTTAATTTGCAC
TTCCCATGACACATAGTTTTCCTATAAAAAGAGTTTTAATTTCATTTATTTTATATATTTATTAAATATTT
ATTGATATTTATAAATCAGTTTCCAGAACTTGAGGCATATCATGTCCCAAGAAGTCTTCGTTATATTTCAT
ATTGAGTCTATAAGGATTACAGTGCCTATGGAAAGGCATACCAAGTAAATGGACAATGCCAAGGAATATGA
AAATCCTGGGCCAGAAGTCAGGAACTAAGCTGTGAGCCCAGCTCTGCTAATGCCCAACTTCCTGAAGAACT
GTATTAAGAAGGGAAGTTGGTGCTGAGTGAAAAATTGTCTAGTGTGAGTCTAAGGGGACCCATGCCACATA
GGCCATACATTGTCCAAACTCTGGATATTGTTTTCCAGAGACATAGAACTAATAGGATGTTTGTGTGCATA
TGTTCATCTATCTGTCTATCCATCTATATGTCTATCCACCTATCTGTCCATGAATCTATCTGTCATCTATC
TGTCTGTCTGTCTAACCATCTATCTACTATCTATTATCTATCTAACTATCTATCTGTCTGTCTGTCTGTCT
AACCAACCATCTATCTACTATCTATTATCTATATATCTACATTTCTATTTATCTTCTAATCTATCTAATCT
ATCTATCTATCTATCTATCTATCTATCTATCTATCTATCTATCATCTTTTCCTTGTCATGTATCTCTTTAT
CTATTTACCTATACACTTAGAAAAAGAAAAAGAGAAACAGAGGCAGACATATAGACATATTGTAACTGGTC
CTCCTGGTTGTGGAAGTTGATAATTCTCAGCAAACTAGAGACTGAGGAAAGGCAATATTTCAACTCAAGTC
CAAATATAGGAAAAAACTGATGGCCTTCATTAAGTCAATAGAGCAGTTCCCTCTTATTCGGTTATTTTGTT
CTATTTGGGCCTTTAATAGAGTTAGATGCAGTGCTAAATCGGAAGAGAAAATGGATTTATACAATCTGCCA
GTACAGAGCTTAATCTCAATCCCAAATGTTGTCGTACACAAAATTGGGTTTTACCAATTATCTGGATACCT
ATGACTTGGTTACACTGGCACATAACATTAACCATCTTGCTGTCAAAATCATCTACTCTGGCACACCAAAT
TATAATGATGATTAAAACTGATAGTCCAGATTCATTGTCAGGGCTATACATTTCTAAAGGAATATGGCATG
CAGTCACTTATAGCCAGTCCTAAGATCTTGCTAGATGTGGAGAAGGGGGCAGAAAGAAGAGGTTGAGAATG
AAGAATGAGTTCTGACCCAAGTGGATCAGAAAAAAAGAGAATTTGCCTTCTTTTCTGCACACCTAAGGACT
TTAATTTTATTTTCAAATGAGTCCCATGGCCAGGACATTTCTGAGTA
5’ end of BAC subclone joins here.
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